

AUTHOR INDEX

- Aalinkel, R., 200
 Abad, L.W., 288
 Abbasi, F., 594, 795, 819
 Ackermans, M.T., 1030
 Adler, A., 1294
 Afandi, B., 1113
 Agarwal, S., 1197
 Aguilar-Salinas, C.A., 311, 729
 Ahrén, B., 325
 Aigner, R., 681, 1220, 1323
 Akiyama, Y., 1213
 Al Banchaabouchi, M., 1418
 Alemzadeh, R., 1457
 Alford, F.P., 512
 Al-Haddad, W., 548
 Ali, S.S., 607
 Aljada, A., 548
 Allen, R.H., 1275
 Allum, A.R., 319
 Alonso, A., 157
 Alton, K.B., 1234
 Altura, B.M., 1409
 Altura, B.T., 1409
 Amaral, M.E.C., 530
 Ambrosch, A., 640
 Ament, M.E., 53
 Amini, S.B., 1197
 An, P., 916, 1315
 Andersen, O., 1123, 1130
 Anderson, E.J., 265
 Andersson, P.-E., 1078
 Andrade, A., 1117
 Aparicio, M., 335
 Arciero, P.J., 1429
 Ardehali, H., 602
 Arisaka, O., 377
 Aristegui, R., 447
 Aronne, L.J., 889
 Ascaso, J.F., 651
 Ascensão, J.L., 99
 Ashley, M., 380
 Aso, Y., 568
 Atasever, T., 1336
 Autran, D., 1330
 Averbukh, Z., 270
 Avery, N.G., 1351
 Aw, T.Y., 259
 Awata, T., 3
- Babaya, N., 1282
 Babazono, T., 789
 Bach-Ngohou, K., 277
 Bachelard, H., 65
 Badawi, A.F., 1001
 Bahouth, S.W., 921
 Bailey, C.J., 1402
 Baillet, L., 335
 Bakker, S.J.L., 387
 Ball, M.J., 505
 Barakat, H.A., 783
 Baraldi, L., 253
 Bard, J.M., 277, 635
- Baron, M., 767
 Barreau, P., 463
 Barthe, N., 335
 Barton, J., 512
 Baše, J., 1472
 Bast, A., 1484
 Batta, A.K., 708, 1106
 Battistini, B., 194, 306
 Baumann, G., 184
 Baur, L.A., 380
 Beamer, W.G., 436
 Beaufort-Krol, G.C.M., 399
 Becker, U., 1340
 Bedair, E.-S.M.A., 905
 Behnam, K., 436
 Belfiore, F., 573
 Bellanné-Chantelot, C., 366
 Bennetts, J.B., 657
 Berenson, G.S., 299, 370, 696, 894, 1441
 Bergeron, J., 246
 Bergerone, S., 30
 Berman, S., 270
 Bernhart, S., 594
 Bernstein, M., 720
 Berthold, H.K., 1275
 Berti, J.A., 530
 Bianchi, A., 382
 Bianchi, G., 253
 Bilakovics, J.M., 963
 Bilchinsky, R., 270
 Biolo, G., 19
 Biselli, R., 1270
 Bisschop, P.H., 1030
 Bjørnland, K., 1389
 Björntorp, P., 1059
 Blåbjaerg, O., 1409
 Blachère, J.-C., 945
 Blackwell, S.J., 771
 Bode, A., 151
 Boeing, H., 640
 Boerwinkle, E., 894
 Bogardus, C., 223
 Bokemark, L., 120
 Bonadonna, S., 107
 Bond, A., 407
 Bond, G., 1095
 Bonilla, S., 1161
 Bonné, A.C.M., 458
 Bonner-Weir, S., 1369
 Boobis, L.H., 756
 Boozer, C.N., 889
 Borch-Johnsen, K., 882
 Borecki, I.B., 1315
 Borkenstein, M.H., 681, 1220, 1323
 Boschero, A.C., 530
 Bossios, A., 1091
 Boston, R.C., 512
 Bouchard, C., 246, 841, 916, 1059, 1255, 1315
 Bowen, R.F., 1489
 Bowman, B.A., 370
 Bray, G.A., 86, 425
- Brito, M.N., 1208, 1493
 Brito, S.M.R.C., 1208, 1493
 Brito-Zurita, O.R., 178
 Brizi, M., 253
 Brochu, M., 835
 Brooks-Worrell, B.M., 1008
 Brown, A.T., 1014
 Brown, M.D., 1102
 Brownsey, R.W., 674
 Brufsky, A., 1242
 Brun, J.-F., 349, 418
 Brunani, A., 107
 Buckley, A., 380
 Buffington, C., 921
 Bukowiecki, L.J., 945
 Bukowska, H., 131
 Bureau, I., 558
 Burge, M.R., 171
 Burrier, R.E., 1234
 Buse, M.G., 1063
 Bush, E., 1294
 Byun, D.-W., 473
 Byun, Y., 1356
- Cabré, M., 997
 Caldefie-Chézet, F., 1054
 Callis, A., 349
 Calpona, P.R., 60, 739
 Cam, M.C., 674
 Cameron, N.E., 868
 Campbell, W.W., 849
 Camps, J., 997
 Camuto, M., 573
 Canudas, J., 447
 Caponetti, A., 60, 739
 Capristo, E., 876, 1004
 Cardoso-Saldaña, G., 178
 Carmena, R., 651
 Carmena-Ramón, R., 651
 Carter, L., 830
 Caruso, D., 1426
 Casagrande, M., 1270
 Casamitjana, R., 1479
 Cascorbi, I., 184
 Cassader, M., 30
 Castelo-Branco, C., 995
 Castilho, L.N., 530
 Castracane, V.D., 488
 Caumo, A., 107
 Cavagnini, F., 107
 Cavaleri, A., 573
 Cavalleri, E.L., 1001
 Cavallo-Perin, P., 30
 Cedars, A.M., 1083
 Cenarro, A., 447
 Cha, M.C., 889
 Chagnon, M., 1059
 Chai, Z., 1168
 Champagne, C.M., 86
 Chan, A., 657
 Chan, A.Y.W., 1393
 Chan, J.C.N., 135

- Chan, T.Y.K., 135
 Chandramouli, V., 47
 Chang, R.-L., 1447
 Charbonnel, B., 635
 Chen, C.-L., 1203
 Chen, S.-Y., 1203
 Chen, W., 1441
 Chen, Y.-T., 355, 1447
 Chen, Z., 36
 Choi, Y., 1356
 Chow, C.C., 1393
 Chung, D.J., 74
 Chung, M.Y., 74
 Chvojková, Š., 1472
 Ciardaldi, T.P., 830
 Cinarli, B., 1336
 Cincotta, A.H., 1377
 Civeira, F., 447
 Clifford, G.M., 1264
 Cline, G.W., 598
 Cockram, C.S., 135, 1393
 Codner, E., 830
 Cohen, M.P., 1435
 Cohn, J.S., 112
 Collazo, R., 207
 Comune, M., 30
 Connelly, P.W., 494
 Coolen, S.A.J., 1484
 Cordeman, T.P., 1369
 Corella, D., 936
 Corey, P., 494
 Correa, L.R., 325
 Corssmit, E.P.M., 742
 Cortina, S., 936
 Cotter, M.A., 868
 Coulston, A., 594
 Cowan, G.S.M., Jr., 921
 Craven, P.A., 1043
 Critchley, J.A.J.H., 135
 Crombie, D.L., 963
 Cucinotta, D., 60, 739
 Cunningham, I., 715
 Cusi, K.J., 602
 Cynober, L., 1054
 Cyr-Campbell, D., 849

 Daimon, M., 955
 Dana, S.L., 963
 Dandona, P., 548
 D'Angelo, L., 1457
 Danne, T., 657
 Darmaun, D., 293
 Darnell, B., 594
 Dashti, N., 594
 Davies, J.E., 237
 Davignon, J., 112
 Davis, H.R., Jr., 1234
 De Angelis, C., 1270
 De Deyn, P.P., 1418
 Deeg, M.A., 1489
 DeFronzo, R.A., 602
 DeGaetano, A., 1004
 De Jong, S.A., 319
 DeJonge, L., 425

 De la Bretonne, J., 425
 De la Fuente, J., 1117
 DeLany, J.P., 86
 Delongchamp, R.R., 1014
 De Luca, G., 60, 739
 De Marinis, L., 382
 Denkins, Y.M., 86
 DeRubertis, F.R., 1043
 Després, J.-P., 246
 Devaraj, S., 207
 Dhanjil, S., 825
 D'Hooge, R., 1418
 Diaz, C., 447
 Di Benedetto, A., 60, 739
 Dierkes, J., 640
 Di Giorgio, R.M., 60, 739
 Dimopoulou, I., 1397
 Dimsdale, J.E., 1452
 Dinc, M., 1336
 Dinc, S., 1336
 Ding, W., 1168
 Djurhuus, M.S., 1409
 Doenst, T., 1083
 Dohm, G.L., 553
 Doi, K., 477
 Donaghue, K., 657
 Donker, A.J.M., 387
 Donthireddy, V., 151
 Downie, P.F., 237
 Drakatos, A., 1091
 Drezner, M.K., 912
 Drouin, P., 1019
 Duarte, M.E., 436
 Dubini, A., 107
 Dubois-Laforgue, D., 366
 Dumon, H., 293
 Duriez, P., 1019
 Durlach, V., 1330
 Dyky, M.A., 1242
 Dziewanowski, K., 131

 Ebeling, P., 283
 Ebenbichler, C.F., 723
 Efendic, S., 47
 Egusa, G., 443
 Ehnholm, C., 696
 Eide, I., 1175
 Ekberg, K., 47
 Elkasabany, A., 696, 894, 1441
 Elkeles, R.S., 825
 Elliott, T., 306
 Ellis, P.N., 407
 Emblem, R., 1389
 Emoto, M., 805
 Emptoz-Bonneton, A., 1248
 Endert, E., 1030
 Endo, A., 646
 Ercilla, M.B., 325
 Erwa, W., 1220
 Essén, P., 1308
 Evans, A.A.L., 1402
 Evans, W.J., 849
 Eydoux, N., 418

 Fagerberg, B., 120
 Fagone, S., 573
 Fain, J.N., 921
 Fanghänel-Salmón, G., 729
 Farrace, S., 1270
 Feiglin, D., 976
 Feng, W., 1168
 Fernández-Real, J.-M., 1248, 1479
 Ferrando, A.A., 771
 Ferré, N., 997
 Ferrell, R.E., 1102, 1391
 Fields, M., 558
 Finegood, D.T., 715
 Fink, L.M., 1014
 Fisker, S., 1340
 Fletcher, J.M., 161
 Floras, J.S., 194, 306
 Fluiters, E., 1117
 Folch, J., 936
 Fonseca, V.A., 1014
 Fontaine, R.N., 360, 856
 Ford, I., 868
 Forlani, G., 253
 Fossum, E., 1175
 Frandsen, H., 1123
 Franklin, D.M., 407
 Fredenrich, A., 112
 Freedman, D.S., 370
 Frénais, R., 635
 Frohlich, J.J., 24, 708
 Fruchart, J.-C., 1019
 Fujii, S., 1136
 Fujikawa, R., 443
 Fujimoto, K., 259
 Fujita, T., 631
 Fujiwara, K., 631
 Fukunaga, A., 477
 Fukushima, M., 477
 Furumoto, E.J., 494
 Fusco, A., 382

 Gachon, F., 1054
 Gagnon, J., 841, 916, 1255, 1315
 Gagnor, A., 30
 Galli, C., 1426
 Galli, G., 1426
 Gallistl, S., 681, 1220, 1323
 Gannon, M.C., 93
 Gans, R.O.B., 387
 Garcia, N., 171
 García-Lozano, R., 157
 García-Mayor, R.V., 1117
 García-Otín, A.L., 447
 Garlick, P.J., 1308
 Gasbarrini, G., 1004
 Gašparović, J., 24
 Gaudreault, N., 65
 Geiss, H.C., 983
 Gentile, C.L., 1429
 Gentilella, R., 382
 Gerard, D.P., 598
 Gerding, A.M., 399
 Ghanim, H., 548
 Giampietro, A., 382

- Gibson, A.StC., 1286
 Gilkison, C.R., 771
 Gimble, J.M., 407
 Gimpel, T., 488
 Gin, H., 335
 Girard-Globa, A., 1330
 Giraud, F., 277
 Giunti, S., 30
 Glueck, C.J., 360, 856
 Gniuli, D., 876
 Go, V.L.W., 53
 Goedecke, J.H., 1286
 Golub, M.S., 53
 Gómez, A.L., 1351
 Gómez Pérez, F.J., 729
 González, J.I., 936
 Gonzalez-Huix, F., 1479
 González-Valdez, H., 729
 Goodwin, G.W., 1083
 Goto, S-i., 3
 Gotoda, T., 36
 Gourgiotis, D., 1091
 Granner, D.K., 602
 Greaves, M., 868
 Greco, A.V., 876, 1004
 Green, J.S., 1255
 Greenbaum, C.J., 1008
 Greene, E.L., 1063
 Greenway, F., 425
 Grigoriu, A.C., 767
 Grisanti, M.S., 436
 Grobler, L., 1286
 Groubet, R., 1161
 Grundy, S., 207
 Guarnieri, G., 19
 Guerci, B., 1019, 1330
 Guillén, M., 936
 Gullías-Herrero, A., 729
 Guzmán, C.B., 151
 Gyllenborg, J., 882
- Haase, U., 1141
 Haave, N.C., 12
 Habito, R.C., 505
 Hada, T., 241, 393, 952, 1230
 Hadeed, V., 1242
 Haenni, A., 1147
 Hagberg, J.M., 1102, 1391
 Hales, C.N., 562, 1070
 Hall, J.E., 265
 Hallman, D.M., 894
 Halvorsen, Y.-D.C., 407
 Hamada, T., 646, 1361
 Hamada, Y., 1282
 Hamadeh, M.Z., 767
 Hamagishi, M., 631
 Hamaguchi, K., 703
 Hamed, J., 1429
 Hamouda, W., 548
 Han, I.S., 1356
 Hanabusa, T., 863
 Hannibal, N.S., III., 1429
 Hansen, K.T., 1123
 Hara, M., 1193
- Harada, A., 1
 Harada, K., 36
 Harada, L.M., 530
 Harding, A.-H., 1186
 Hardman, A.E., 756
 Hargreaves, M., 481
 Harker, L., 715
 Harris, D.M., 53
 Hashimoto, N., 812
 Hashimoto, T., 613
 Hata, S., 414
 Haug, E., 1389
 Hauner, H., 184
 Hayashi, K., 1301
 Hayashi, T., 801
 Hedman, A., 1078
 Heitmann, B.L., 882
 Hennings, S.H.J., 1186
 Henriksen, J.E., 1409
 Henriksen, J.H., 1340
 Henry, R.R., 830
 Herbert, B.M., 972
 Herd, S.L., 756
 Hermansen, K., 451
 Hernández, G., 447
 Hernández-Ono, A., 178
 Heymsfield, S.B., 1004
 Hietaniemi, K., 1036
 Higashi, K., 1462
 Higuere, P., 1161
 Himeno, Y., 631
 Hino, K., 801
 Hirano, T., 801
 Hirata, A., 955
 Hirose, H., 1301
 Hirose, M., 216
 Hirsch, I.B., 1008
 Hisatome, I., 646
 Hisatomi, A., 259
 Hoener, P.A., 963
 Hoffer, L.J., 767
 Høiegg, A., 1175
 Hokari, S., 3
 Hollingdal, M., 41
 Holshouser, S., 1457
 Homma, M., 801
 Honami, Y., 646
 Hong, S., 53
 Hong, Y., 916
 Hoshi, M., 377, 1136
 Houmard, J.A., 783
 Howlett, K.F., 481
 Huang, Y., 99
 Hubbard, J.L., 265
 Huerta, M.G., 537
 Hulthe, J., 120
 Humbert, B., 293
 Huschke, B., 929
 Husebye, E., 1389
 Hwang, I., 53
- Iannello, S., 573
 Ibebunjo, C., 216
 Ichikawa, Y., 231
- Igarashi, M., 955
 Igawa, O., 646
 Iizuka, Y., 36
 Ikeda, I., 1361
 Ikeda, T., 763
 Ikegami, H., 1282
 Ikemoto, S., 414
 Ilias, I., 1397
 Illig, E., 856
 Illingworth, D.R., 494
 Imaizumi, K., 1361
 Imamura, S., 631
 Imataka, M., 377
 Innis, S.M., 12
 Inoue, I., 3
 Inoue, Y., 414
 Inukai, T., 568
 Irtun, Ø., 189
 Ishibashi, S., 36
 Ishii, T., 1136, 1301
 Islam, K.N., 207
 Itani, S.I., 553
 Ito, M., 1181
 Ito, T., 1462
 Itoh, M., 631
 Iwakiri, R., 259
 Iwamoto, Y., 789
 Iwanaga, T., 1213
 Iwata, K., 763
- Jackson, R.A., 1369
 Jacober, S.J., 151
 Jahoor, F., 720
 James, R.W., 657
 Januszkiewicz, A., 1308
 Jaynes, E.B., 976
 Jeckel, A., 640
 Jeng, C.-Y., 355
 Jenkins, D.J.A., 494
 Jetton, T.L., 1377
 Jialal, I., 207
 Jiang, J., 771
 Jirasakuldech, B., 1113
 Jodka, C., 583
 Johnson, L.G., 488
 Jones, P.K., 47
 Jones, P.J.H., 494
 Jones, S.D., 319
 Joven, J., 997
 Juhl, C.B., 41
 Juneja, R., 1008
 Juul, A., 882
- Kajimura, N., 1213
 Kakizawa, H., 631
 Kalhan, R., 1197
 Kalhan, S.C., 1197
 Kamatani, N., 1203
 Kamimoto, M., 627
 Kanaley, J.A., 976
 Kanatsuka, A., 812
 Kanazawa, M., 801
 Kanazawa, S., 377
 Kaneki, M., 216

- Kang, D.G., 74
 Kaňková, K., 1152
 Kanno, S., 377
 Kano, K., 377
 Kao, Y.L., 657
 Kaplan, L.N., 767
 Karbowska, J., 734
 Karpathios, T., 1091
 Kaser, S., 723
 Katayama, S., 3
 Kato, M., 646
 Kato, T., 631
 Kato, T., 955
 Kato, Y., 703
 Katoh, S., 414
 Katzmarzyk, P.T., 841
 Kauffman, R.F., 963
 Kavazarakis, E., 1091
 Kawaguchi, Y., 1282
 Kawai, T., 1301
 Kawamura, T., 443
 Kawasaki, K., 1136
 Kawashita, N.H., 1208, 1493
 Kay, J.P., 1457
 Kazdová, L., 1472
 Keller, E., 1141
 Kemp, A., 380
 Kendall, C.W.C., 494
 Kennedy, J.A., 463
 Kettelhut, I.C., 1208, 1493
 Khan, M.A., 93
 Kiens, B., 756
 Kiess, W., 1141
 Kim, C., 1356
 Kim, C.-H., 473
 Kim, D.-J., 590
 Kim, H.-S., 594, 795, 819
 Kim, K.-W., 590
 Kim, S.H., 1356
 Kim, S.Y., 1356
 Kinugawa, T., 646
 Kirwan, J.P., 849
 Kishimoto, H., 477
 Kitatani, N., 477
 Kiviluoto, T., 1036
 Kjeldsen, S.E., 1175
 Klein, R.L., 99
 Klein, S., 720
 Klink, M., 131
 Klitgaard, N.A.H., 1409
 Klötting, I., 458
 Knights, P., 1402
 Knüpfer, M., 1141
 Kobayashi, T., 631
 Kochan, Z., 734
 Kohzuki, M., 627
 Koide, H., 1193
 Koistinen, H.A., 283
 Koivisto, V.A., 283
 Koivula, T., 1095
 Komoda, T., 3
 Kopf, D., 929
 Kordonouri, O., 657
 Korytkowski, M.T., 1102
 Koshimura, K., 703
 Koutras, D.A., 1397
 Kovács, P., 458
 Koval, J., 602
 Kraemer, F.B., 1264
 Kraemer, G.R., 488
 Kraemer, R.R., 488
 Kraemer, W.J., 1351
 Kramer, D., 1294
 Kratzsch, J., 1141
 Krempf, M., 277, 635
 Kröning, G., 929
 Kuipers, J.R.G., 399
 Kulkarni, K., 594
 Kuribayashi, T., 377
 Kuroda, Y., 1181
 Kurokohchi, K., 231
 Kurose, T., 79
 Kusunoki, S., 342
 Lambert, E.V., 1286
 Lamendola, C., 594, 795, 819
 Landaker, E., 1369
 Landau, B.R., 47
 Lang, J.E., 360, 856
 Langley, G., 1457
 Laule, M., 184
 Lautenslager, G.T., 1435
 Lavoie, H.B., 265
 Laychock, S.G., 200
 Le, D.T., 1452
 Lea-Currie, Y.R., 407
 Le Bacquer, O., 293
 Lee, B., 200
 Lee, D.H., 74
 Lee, J.U., 74
 Lee, K.-S., 1356
 Lee, K.-U., 473
 Lee, M.-K., 590
 Lee, M.-S., 590
 Lee, S.C., 1356
 Lee, W.-J., 355, 1447
 Lee, Y.-J., 1346
 Lee, Z.S.K., 135
 Lefevre, M., 86
 Leffler, C.W., 921
 Lehnert, H., 929
 Lehtimäki, T., 1095
 Leibel, R.L., 889
 Leon, A.S., 841, 916, 1255, 1315
 Lerman-Garber, I., 311
 Levitt, N.S., 1286
 Lewis, C.G., 558
 Lewis, R.M., 562
 Liachenko, J., 1043
 Liang, Y., 1377
 Lin, L.-Y., 1447
 Lin, S.-Y., 355
 Lindgärde, F., 325
 Lindsay, R.S., 223
 Lindström, P., 144
 Lithell, H., 1147
 Lithell, H.O., 1078
 Liu, R.H., 79
 Liverani, E., 876
 Loimaala, A., 1095
 Loizou, C.L., 1070
 Look, M.P., 1275
 Lopes-Virella, M.F., 99
 Love, D.M., 1351
 Love, R.J., 889
 Lovejoy, J.C., 86, 425
 Loviscach, M., 830
 Lührmann, P.M., 972
 Luley, C., 640
 Lundgren, N., 288
 Lupattelli, G., 330
 Macaione, V., 739
 McCole, S.D., 1102, 1391
 McCullough, P., 856
 MacDonald, K.G., 553
 McDonald, L., 207
 McLaughlin, T., 594, 795, 819
 MacLean, P.S., 783
 McManus, R.M., 715
 McNeill, J.H., 667, 674
 McNurlan, M.A., 1308
 Magnusson, I., 598
 Magot, T., 635
 Mahmood, F., 151
 Mäkimattila, S., 1036
 Makino, M., 631
 Malin, R., 1095
 Mamputu, J.-C., 688
 Mancini, A., 382
 Mandarino, L.J., 602
 Manetta, J., 349
 Mannarino, E., 330
 Manning, P.J., 319
 Mantzos, E., 1397
 Marchesi, S., 330
 Marchesini, G., 253
 Marcoux, C., 112
 Marescau, B., 1418
 Marette, A., 65
 Marino, B., 1270
 Marino, S., 1004
 Márová, I., 1152
 Márquez, M.G., 1025
 Martensz, N.D., 1070
 Martinez, A., 1161
 Martinez, C.L., 311
 Martini, W.Z., 189
 Martyn, J.A.J., 216
 Maruyama, H., 1301
 Maruyama, K., 1213
 Masramon, X., 447
 Mastorakos, G., 1397
 Matsukura, S., 79
 Matsunaga, T., 3
 Matsuo, M., 125
 Matsuo, T., 125
 Matsushima, M., 414
 Matsura, T., 477
 Maugeais, C., 635
 Medhus, A.W., 1389
 Mehling, C.C., 494

- Meijer, E.P., 1484
 Meisel, C., 184
 Melchionda, N., 253
 Melhem, M.F., 1043
 Meneilly, G.S., 194, 306
 Mensink, R.P., 520
 Mercier, J., 349, 418
 Mercuri, M., 1095
 Meyer, R.A., 976
 Meza, E., 729
 Michl, J., 1113
 Migliorini, R.H., 1208, 1493
 Milardi, D., 382
 Minet-Quinard, R., 1054
 Mingrone, G., 876, 1004
 Minkenberg, R., 166
 Miranda, M.L., 157
 Mironova, M., 99
 Mitchell, J., 1186
 Miwa, T., 801
 Miyamoto, M., 1136
 Mizuno, M., 1
 Modai, D., 270
 Moghadasian, M.H., 708
 Mohanty, P., 548
 Moinard, C., 1054
 Molenkamp, M.C., 399
 Möller, R., 681
 Möller, S., 1340
 Monterrubio-Flores, E.A., 729
 Montes, J., 729
 Montilla, C., 157
 Moore, G.E., 1102, 1391
 Mori, T., 703
 Moriwaki, K., 342
 Moriwaki, Y., 241, 393, 952, 1230
 Mortensen, J., 1130
 Moulin, P., 1330
 Moura, M.A.F., 1208, 1493
 Moustaki, M., 1091
 Mudaliar, S., 830
 Mühlen, I., 929
 Mukherjee, R., 963
 Muñoz-Grijalvo, O., 157
 Murakami, Y., 703
 Murray, E.J.B., 436
 Murray, S.S., 436
 Mužik, J., 1152
 Myers, L., 299

 Nadeau, A., 65
 Nagamani, M., 771
 Nagasaka, A., 631
 Nagasaka, S., 477
 Nagasaki, K., 1213
 Nagata, I., 477
 Naik, R.G., 1008
 Naito, E., 1181
 Nájera, G., 651
 Nakagiri, H., 1361
 Nakai, A., 631
 Nakai, Y., 477
 Nakaishi, S., 477
 Nakajima, D., 377
 Nakajima, K., 1462
 Nakajima, T., 3
 Nakamura, H., 1462
 Nakamura, K., 621
 Nakamura, T., 1193
 Nakanishi, N., 621
 Nakano, Y., 863
 Nanjo, K., 863
 Nara-ashizawa, N., 1213
 Naruszewicz, M., 131
 Natale, S., 253
 Nawata, H., 613
 Negishi, M., 377
 Nelesen, R.A., 1452
 Nelson, B.A., 1063
 Nenonen, A., 1095
 Neuhäuser-Berthold, M., 972
 Ng, L.L., 237, 778
 Nguyen, L.B., 708, 1106, 1224
 Nguyen, P., 293
 Nicolaides, A.N., 825
 Niitsuma, T., 801
 Nijpels, G., 1030
 Nindl, B.C., 1429
 Nishi, M., 863
 Nishikura, K., 377
 Nishioka, M., 231
 Nishizawa, Y., 805
 Nitta, A., 377
 Nitta, K., 789
 Noakes, T.D., 1286
 Noda, T., 259
 Noël-Suberville, C., 1161
 Nojima, K., 1282
 Nonaka, M., 1361
 Notoya, Y., 801
 Numata, M., 377
 Nunes, V.S., 530
 Nuttall, F.Q., 93

 O'Byrne, D., 207
 Ochi, H., 763
 Oda, N., 631
 Ogihara, T., 1282
 Ogilvie, K.M., 963
 Ogino, K., 646
 Ohara, S., 1361
 Ohashi, K., 36
 Ohnuma, H., 955
 Öhrvall, M., 1147
 Ohsuzu, F., 1462
 Oja, P., 1095
 Oka, K., 801
 Okai, K., 863
 Oki, C., 863
 Okubo, M., 443
 Okumura, T., 477
 Oliveira, H.C.F., 530
 Olmos, S., 1025
 Olson, L.K., 1489
 Olsson, T., 325
 Orban, T., 1369
 Ordovás, J.M., 651, 936
 Ørskov, L., 451

 Osada, S., 1193
 Osaki, S., 646
 Osterlund, L., 594
 Osuga, J.-i., 36
 Otto, C., 166, 983
 Otvos, J.D., 370
 Ouguerram, K., 635
 Oz, M., 1336
 Ozanne, S.E., 562, 1070
 Ozkan, O., 189

 Pacini, G., 30
 Paek, Y.W., 74
 Pagano, G., 30
 Palmer, J.P., 1008
 Palumbo, B., 330
 Pamies, E., 157
 Panini, R., 1466
 Pannitteri, G., 1270
 Pappu, A.S., 494
 Páramo, C., 1117
 Parhofer, K.G., 983
 Parkes, D.G., 583
 Pasanen, M., 1095
 Pasqualinotto, L., 107
 Patel, M.S., 200
 Patelli, R., 1426
 Paterniti, J.R., Jr., 963
 Patsch, J.R., 723
 Patti, M.-E., 1369
 Paul, A., 997
 Paul, J.-L., 1330
 Payerl, D., 681, 1323
 Pcolinsky, M., 1106
 Pedersen, K.K., 1409
 Pei, D., 355
 Pelikánová, T., 1472
 Pereira Arias, A.M., 1030
 Perelli, P., 1270
 Pérez, F.J.G., 311
 Pérez, J., 311
 Perez-Martin, A., 418
 Perrelli, M., 382
 Perrey, S., 36
 Pérusse, F., 945
 Pérusse, L., 246
 Petersen, K.F., 598
 Petry, C.J., 562, 1070
 Phillips, S.L., 1043
 Pile, K., 463
 Pincelli, A.I., 107
 Pincus, S.M., 41
 Pirro, M., 330
 Pitre, M., 65
 Pitt, J.J., 161
 Pittner, R., 583
 Plat, J., 520
 Ploutz-Snyder, L.L., 976
 Pocová, M., 447
 Poehlman, E.T., 835
 Poirier, L.A., 1014
 Popovich, D.G., 494
 Pories, W.J., 553
 Pørksen, N., 41

- Portolés, O., 936
 Posadas-Romero, C., 178
 Pouncey, L., 921
 Pratipanawatr, T., 602
 Pratley, R.E., 223
 Préfaut, C., 349, 418
 Printz, R., 602
 Pugeat, M., 1248
 Pula, K.K., 1234
 Pulzer, F., 1141
 Puthawala, K., 1197
 Py, G., 418

 Qian, Q., 1168
 Qualls, C.R., 171
 Quilliot, D., 1019
 Quinn, P.A., 778

 Racini, M., 494
 Raikwar, N.S., 1489
 Ramadan, M.A.F., 905
 Randolph, C.J., 1014
 Rankinen, T., 841, 1255, 1315
 Ransom, T.P.P., 494
 Rao, A.V., 494
 Rao, D.C., 246, 841, 916, 1255, 1315
 Rašlová, K., 24
 Rasmussen, B.M., 451
 Rasmussen, S.L., 882
 Rassoul, F., 1141
 Raynaud, E., 418
 Real, J.T., 651
 Reaven, G.M., 594, 795, 819
 Reddy, V., 151
 Redonnet, A., 1161
 Reed, M.J., 1049
 Rehman, N., 830
 Reims, H.M., 1175
 Reinoso, M.F.G., 1025
 Reneland, R., 1078
 Renier, G., 688
 Ricart, W., 1248, 1479
 Rice, T., 916, 1315
 Richter, V., 1141
 Richter, W.O., 166
 Riezler, R., 1275
 Rigalleau, V., 335
 Ringdén, O., 1308
 Ritsch, A., 723
 Ritter, M.M., 166
 Rizk, M.M., 905
 Robinson, K.A., 1063
 Robledo, L.M.G., 311
 Rockstroh, J.K., 1275
 Rodrigues, B., 674
 Roemmich, J.N., 537
 Rogan, E.G., 1001
 Rogol, A.D., 537
 Romano, G., 60
 Romijn, J.A., 742, 1030
 Rondinone, C.M., 1294
 Rood, J.C., 86
 Rooth, P., 144
 Roots, I., 184

 Roscini, A.R., 330
 Rosenberg-Zand, R., 494
 Rosenthal, M.J., 53
 Rosmond, R., 1059, 1315
 Rostrup, M., 1175
 Rothman, D.L., 598
 Roubenoff, R., 288
 Roussos, C., 1397
 Roux, M.E., 1025
 Ruan, Z., 1369
 Ruiz, F., 1224
 Ryan, D., 425

 Sabater, A., 936
 Saeki, N., 342
 Sagendorf, K.S., 976
 Saiki, S., 627
 Saito, I., 1301
 Saito, Y., 812
 Sáiz, C., 936
 Sakai, M., 477
 Sakata, H., 259
 Sako, Y., 613
 Sakurai, K.-i., 812
 Salbe, A.D., 223
 Salen, G., 708, 1106, 1224
 Salvio, G., 1466
 Sames, C., 976
 Sánchez, L., 729
 Sandhofer, A., 723
 Sanke, T., 863
 Santuré, M., 65
 Saruta, T., 1301
 Sasaki, H., 863
 Sato, T., 627, 1136
 Satomura, S., 1181
 Sauerbruch, T., 1275
 Sauerwein, H.P., 742, 1030
 Sawai, Y., 631
 Scacchi, M., 107
 Scarpetta, G., 1466
 Schaaf, P., 795
 Schade, D.S., 171
 Schaff, P., 594
 Scheiber, J., 849
 Schillaci, G., 330
 Schliefer, K., 1275
 Schmitz, O., 41, 451
 Schumann, W.C., 47
 Schussler, G.C., 1113
 Schwandt, P., 166, 983
 Segrest, J., 594
 Sen, A., 407
 Sendzik, I., 929
 Serné, E.H., 387
 Shapiro, R., 1294
 Sharman, M.J., 1351
 Sharp, P., 825
 Sharpless, J.L., 265
 Shearman, C.W., 1435
 Shefer, S., 708, 1106, 1224
 Shen, M.-L., 1203
 Sherif, A., 905
 Sheu, W.H.-H., 355, 1447

 Shibata, M., 1282
 Shigemasa, C., 646
 Shimada, N., 1193
 Shinde, R., 1393
 Shionoiri, F., 36
 Shiroyama, K., 342
 Shoji, T., 805
 Shuldiner, A.R., 1102, 1391
 Shulman, G.I., 598
 Siepi, D., 330
 Sieve-Smith, L., 360, 856
 Silink, M., 657
 Sims, E.A.H., 1499
 Sites, C.K., 835
 Skakkebaek, N.E., 882
 Skinner, J.S., 841, 916, 1255, 1315
 Smith, M.E., 1402
 Smith, P., 1457
 Smith, P., 583
 Smith, S.R., 86, 425
 Smolková, B., 24
 Söderberg, S., 325
 Sol, J.M., 447
 Soliman, A.T., 905
 Song, M.K., 53
 Sørensen, H., 1123
 Sørensen, J.N., 1123
 Sowers, J.R., 151, 607
 Spriet, L.L., 481
 Squire, I.B., 237
 Srinivasan, M., 200
 Srinivasan, S.R., 299, 370, 696, 894, 1441
 Stabler, S.P., 1275
 Stanforth, P.R., 1255
 Stangl, K., 184
 Stangl, V., 184
 Staniewicz, A., 131
 Stanzl, U., 723
 Stejskalová, A., 1152
 Stepkowski, S., 1083
 Steppan, C.M., 976
 Stiefel, P., 157
 Story, J.A., 494
 Strauss, C.C., 265
 Streicher, P., 856
 Stuart, C.A., 771
 Subbiah, M.T.R., 856
 Sudí, K.M., 681, 1220, 1323
 Sugano, M., 1361
 Sugita, H., 216
 Suh, K.-I., 473
 Sujkowski, D., 407
 Sundaresan, S.M., 537
 Sutherland, W.H.F., 319
 Suzuki, K., 621
 Swaminathan, R., 1393
 Swick, A.G., 976
 Swiercznski, J., 734
 Swisher, S.L., 976
 Synovitz, L.B., 488

 Tacchino, R.M., 382
 Taegtmeier, H., 1083
 Tafeit, E., 681

- Taguchi, N., 125
 Tahara, H., 805
 Tajima, N., 414
 Tajiri, Y., 613
 Takahashi, S., 241, 393, 952, 1230
 Takamura, H., 801
 Takanashi, K., 568
 Takeda, M., 789
 Takemura, M., 1
 Takemura, Y., 568
 Takens, J., 399
 Takeuchi, H., 125
 Talwar, S., 237
 Tanaka, A., 801
 Tanaka, S., 1136
 Tang, T., 1049
 Taniguchi, A., 477
 Tanner, C.J., 783
 Tariq, N., 494
 Tataara, K., 621, 1181
 Tataranni, P.A., 223
 Tayama, K., 568
 Tchernof, A., 835
 Tchugunova, Y., 1336
 Teppo, A.-M., 283
 Ter Maaten, J.C., 387
 Thomas, G.N., 135
 Thompson, C., 380
 Thrybom, T., 144
 Tibaldi, A., 107
 Timonen, T., 1036
 Timsit, J., 366
 Tint, G.S., 1106, 1224
 Toigo, G., 19
 Tokuyama, K., 477
 Tokuyama, Y., 812
 Tominaga, M., 955
 Tomlinson, B., 135
 Townsend, C.M., Jr., 720
 Townsend, R.R., 468
 Tozawa, R., 36
 Tracy, T.M., 856
 Tremblay, M., 112
 Trezza, R., 1270
 Tröbinger, M., 1323
 True, B.S., 463
 Trump, D.L., 1242
 Tsai, J.C.R., 1346
 Tsuchiya, H., 955
 Tsui, J.K.C., 661
 Tsukada, T., 1213
 Tsutsumi, Z., 241, 393, 952, 1230
 Tunnicliffe, G., 1402
 Turner, J.R., 151
 Turrubiatez, L.C., 311

 Ueda, H., 1282
 Ukkola, O., 246, 1315
 Umeda, F., 613
 Ushiyama, C., 1193
 Utsumi, H., 259

 Vácha, J., 1152
 Valabhji, J., 825

 Valle, D., 382
 Van den Brandt, J., 458
 Van Eps, W.S., 387
 Vang, O., 1123, 1130
 Van Lith, H.A., 458
 Van Marck, E., 1418
 Vanrell, J.A., 995
 Van Zutphen, L.F.M., 458
 Vasson, M.-P., 1054
 Vayreda, M., 1479
 Veldhuis, J.D., 41
 Velho, G., 366
 Ventura, P., 1466
 Vergés, B., 1330
 Verlato, C., 1466
 Vernon, R.G., 1264
 Vicente, J.J., 995
 Vidgen, E., 494
 Villa, A.R., 311
 Villar, J., 157
 Visioli, F., 1426
 Vohnout, B., 24
 Volafova, J., 425
 Volek, J.S., 1351
 Von Känel, R., 1452
 Vukovich, M.D., 1429
 Vuksan, V., 494
 Vuori, I., 1095

 Wajngot, A., 47
 Walsh, M.F., 151, 607
 Walters, E., 1019
 Walters, J.M., 512
 Wang, C.-L., 1070
 Wang, J., 667
 Wang, M., 1083
 Wang, P., 360, 856
 Ward, G.M., 512
 Ward, J., 380
 Wareham, N.J., 1186
 Watkins, R.W., 1234
 Watson, A., 715
 Weber, K., 856
 Weber, T.J., 912
 Weinstock, R.S., 976
 Weisnagel, S.J., 246
 Weiss, E.P., 1102
 Weissfeld, J., 1242
 Weissgarten, J., 270
 Weitgasser, R., 1369
 Wellby, M.L., 463
 Wen, G., 771
 Wernecke, K.-D., 184
 Wernerman, J., 1308
 Westerp, K.R., 1484
 Westphal, S., 640
 Weyer, C., 223
 Wikstrand, J., 120
 Wilkison, W.O., 407
 Williams, D.E.M., 1186
 Williams, S.M., 319
 Williamson, M.E., 771
 Wilmore, J.H., 841, 916, 1255, 1315
 Winters, S.J., 1242

 Wise, C.K., 1014
 Wolf, H.J., 723
 Wolfe, R.R., 189
 Wong, B., 311
 Wong, N.L.M., 661

 Xatzidimoula, A., 1091
 Xu, G., 1106

 Yagui, K., 812
 Yagyu, H., 36
 Yahagi, N., 36
 Yamada, A., 805
 Yamada, K., 1282
 Yamada, N., 36
 Yamada, Y., 1
 Yamagami, K., 1136
 Yamaguchi, H., 955
 Yamaguchi, K., 1213
 Yamakita, J.-i., 393
 Yamakita, T., 1136
 Yamamoto, K., 631
 Yamamoto, T., 241, 393, 952, 1136, 1230
 Yamamoto-Kimura, L., 178
 Yamashita, Y., 477
 Yamato, E., 1282
 Yano, K., 1
 Yap, M.G., 1113
 Yasuhara, S., 216
 Ye, W.-Z., 366
 Yeaman, S.J., 1264
 Yip, I., 53
 Yki-Järvinen, H., 1036
 Yokota, I., 1181
 Yokoyama, J., 414
 Yonemura, A., 1462
 Yoneyama, H., 231
 Yoo, M.-H., 473
 Yoshida, H., 621
 Yoshida, T., 259
 Yoshikawa, H., 613
 Yoshioka, K., 1136
 Yosida, T., 627
 Young, A., 583
 Young, R.P., 135
 Youssef, A.A., 1441
 Yuen, V.G., 667
 Yuge, O., 342
 Yun, S.-K., 473

 Zaccheroni, V., 253
 Záhajský, J., 1152
 Zaïr, Y., 635
 Zamora-González, J., 178
 Zeis, P.M., 1091
 Ziegler, M.G., 1452
 Ziegler, O., 1019
 Ziemer, S., 184
 Zijlstra, W.G., 399
 Zirkind, R., 1113
 Zmuda, J.M., 1102, 1391
 Znojil, V., 1152

SUBJECT INDEX

- AAs, *see* Amino acids
- Ab(s) (antibodies) to pancreatic islet cells and to glutamic acid decarboxylase in identification of type 1½ diabetes in patients presenting with NIDDM, 1008-1013
- Abdominal adipose tissue (AT)
- in premenopausal and postmenopausal women, 976-982
 - visceral, GH therapy effects on, in GH-deficient prepubertal children, 543
 - see also* Subcutaneous adipose tissue, and metabolic complications of obesity
- ABI (ankle brachial index), and prostacyclin-induced skin BF changes in NIDDM, 568-572
- ACAC (acetoacetate) in fasting MCAD-deficient children, 162-165
- Acanthosis nigricans with severe IR, altered *GLUT1* and *GLUT3* gene expression and subcellular redistribution of *GLUT4* in, 771-777
- Acarbose, exercise effects on efficacy of, 1049-1053
- Acclimation, effects of cold, on BAT FA synthesis in subjects on high-protein, CHO-free diet and, 1493-1498
- ACE gene insertion/deletion (I/D) associated with ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
- ACE (angiotensin-converting enzyme) inhibitor therapy, cough related to, in Chinese NIDDM women, insertion/deletion of ACE gene and, 1346-1350
- Acetoacetate (ACAC) in fasting MCAD-deficient children, 162-165
- α (alpha)-1-Acid glycoprotein (A1GP) in NIDDM, 285
- Acipimox, effects of, on plasma FFAs mimicking CL-316243 effects in obese DM subjects, 945-951
- Acquired immunodeficiency syndrome (AIDS)
- N-methylglycine and N,N-dimethylglycine in, during short-term HAART of, 1275-1281
 - protein metabolic response to acute exercise in, effects of protein wasting on, 288-292
- Acromegaly, serum IGFBP-3 with serum leptin and/or plasma IGF-1 for, compared, 1117-1121
- β (beta)-Actin mRNA (messenger ribonucleic acid) in cancer cachexia, 1214-1215
- Acute arthritis in gout
- HTGL and LPL activity in, 953
 - VAT accumulation and IR risk in, 394
- Acute exercise, effects of protein wasting on protein metabolic response to, in AIDS, 288-292
- Acute hypoglycemia in NIDDM, alcohol and glucose counterregulation during, 451-457
- Acute intermittent porphyria (AIP) attacks, triptorelin with tobolone in prevention of, 995-996
- Acylation-stimulating protein, C-reactive protein-related concentration of, in NIDDM, 283-287
- Acyl-coenzyme A (CoA) dehydrogenase, fasting medium-chain, ketone production by children deficient in, 161-165
- Adenosine in hepatic glucose production, 744, 747
- Adenosine triphosphatase (ATPase), platelet Na^+/K^+ , as marker in hyperthyroidism, 1393-1396
- Adenosine triphosphate (ATP), intracellular, in KCN- and IAA-exposed hepatocytes, 344
- S-Adenosylmethionine, blood, lymphocyte MTHFR activity and concentrations of, in DM and diabetic nephropathy, 1014-1018
- Adipocytes, *see* Adipocytes, TZDs and; 3T3-L1 adipocytes
- Adipocytes, TZDs and
- glucocorticoids and TZDs inducing differentiation of preadipocyte stromal cells and adipocytes, 407-413
- Adipocytes, TZDs and (Continued)
- PPAR γ* mRNA downregulated by TZDs and TNF- α in 3T3-L1 adipocytes, 36-40, 407
- Adipose tissue (AT; body fat)
- action of BRL-49653 in, through glucose transporter regulation, 1294-1300
 - brown, *see* Brown adipose tissue
 - as CV risk factor in men, 884-885
 - exercise effects on, *see* Adipose tissue, exercise effects on
 - and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
 - glycolytic flux and glucose uptake in, with high-protein, CHO-free diet, 1208-1212
 - in obesity, leptin release stimulated by arachidonic acid and PGE_2 in, 921-928; *see also* Obesity
 - and pancreatic polypeptide secretion, 224
 - in PM women, short-term HRT effects on, 267
 - and protein wasting in AIDS, 290
 - serum DHEA relationship to gender and, 488-493
 - and thermic effect of SMLCTs and LCTs, 126
 - total, *see* Total adipose tissue
 - vanadium effects on, 669, 670
 - white, *see* White adipose tissue
 - see also* Adipocytes, TZDs and; Adipose tissue distribution; Fat mass; 3T3-L1 adipocytes
- Adipose tissue (AT; body fat), exercise effects on
- aerobic exercise effects on blood lipids and changes in AT, 841-848
 - exercise-induced oxidative stress in older subjects, 1485
 - fasting RER and, 1288
 - in NIDDM, *see* Adipose tissue, exercise effects on, in NIDDM
- Adipose tissue (AT; body fat), exercise effects on, in NIDDM
- with cardiovascular disease, 1258, 1260, 1261
 - on serum leptin levels, 1137
- Adipose tissue (AT; body fat) distribution
- in children, *see* Adipose tissue distribution in children
 - in elderly subjects, effects of FM and, on RMR, 972-975
 - relationship between insulin sensitivity, HRT and, in obese PM women, 835-840
 - see also* Abdominal adipose tissue; Subcutaneous adipose tissue, and metabolic complications of obesity; Visceral adipose tissue; Waist-to-hip ratio
- Adipose tissue (AT; body fat) distribution in children
- obese children, relationship between AT and, hemostatic abnormalities and, 681-687
 - in prepubertal GH-deficient children during GH therapy, 537-547
- Adolescents
- having been SGA neonates, serum leptin relationship to gender, puberty, body composition, insulin sensitivity, creatinine, and serum uric acid in, 1141-1146
 - race of, *see* Race and ethnicity of adolescents
 - weight loss by, *see* Adolescents, weight loss by
 - see also* Adolescents, obese; Puberty
- Adolescents, obese
- nondiabetic morbidly obese, metformin effects in, 1457-1461
 - see also* Adolescents, obese, weight loss by
- Adolescents, obese, weight loss by
- by obese adolescents, Hcy in, 1220-1223
 - DMD, paradoxical weight loss with extra EE at BAT by, 1181-1185

- β (β)₂-*ADR* gene Gln27Glu mutation
interactions between polymorphism of glucocorticoid receptor gene, LPL gene and, plasma insulin and lipid levels and, 246-252
see also: β ₂-*ADR* gene Gln27Glu mutation, obesity and
- β (β)₂-*ADR* gene Gln27Glu mutation, obesity and endurance exercise and, 1391-1392
mutation relationship to obesity, IGT, and DM in Japanese subjects, 443-446
- β (β)₃-*ADR* gene polymorphism
interactions between Gln27Glu mutation of β ₂-*ADR* gene, glucocorticoid receptor gene polymorphism, and LPL gene, plasma insulin and lipid levels and, 246-252
see also Trp64Arg polymorphism of β ₃-*ADR* gene
- Adrenaline, *see* Epinephrine
- Adrenergic receptor genes, *see*: β ₂-*ADR* gene Gln27Glu mutation; β ₃-*ADR* gene polymorphism
- Adult(s), *see* Adulthood; Young adults and specific conditions
- Adulthood, Lp variables from childhood to, in CHD parents offspring, 1441-1446
- AECs, *see* Aortic endothelial cells
- Aerobic capacity, *see* $\dot{V}O_2$ during exercise; $\dot{V}O_{2max}$ during exercise
- Aerobic exercise, changes in blood lipids due to, related to AT and aerobic fitness, 841-848
- African-Americans, *see* Race and ethnicity
- Ag (antigen), tissue-type plasminogen activator-, in obese children, 681-687
- AGA (appropriate-for-gestational age) neonates, Lp profile and CETP in, 724-725
- Age
of acromegaly subjects, 1119
of AIDS subjects, protein wasting and, 290
and angiotensin II effects on lipolysis, 470
of anorexic subjects, 877
of CAD subjects, *see* Age of CAD subjects
of carotid artery atherosclerosis subjects, 1097
of children, *see* Age of children
circulating GM-CSF, serum FA composition and, 1480
of COPD subjects, 1337, 1398
of CRF subjects, 208, 271, 272
and CT-1 stability, 238
and CV risk factors in men, 884-886
and DHEA levels, 1316
DHEAS and, 918
of diabetic nephropathy subjects, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity and, 1015
of DM subjects, *see* Age of DM subjects
of DMD subjects, 1182
and exercise, *see* Age, exercise and
gene polymorphism and, *see* Age, gene polymorphism and
gestational, *see* Gestational age
and glucose effects on plasma von Willebrand factor, 1453
of gout subjects, *see* Age of gout subjects
of HIV-infected subjects, 1278
of hyperhomocysteinemic elder subjects, 1467
of hyperlipidemic subjects, *see* Age of hyperlipidemic subjects
of hypertensive subjects, *see* Age of hypertensive subjects
of hyperthyroidic subjects, 1394
and hyperuricemia development, 623-625
of idiopathic osteoporotic men, 913
and insulin resistance, *see* Age of insulin-resistant subjects
and Lp distribution of apo C-III, 113
and myosin light-chain phosphorylation in resting platelets, 153
- Age (Continued)
of NIDDM subjects, *ACE* gene I/D and, 1348; *see also* Age, gene polymorphism; Age of NIDDM subjects
of nondiabetic subjects, *see* Age of nondiabetic subjects
of normolipidemic subjects, serum-promoted C efflux and, 1332
of obese subjects, *see* Age of obese subjects
of pancreatic cancer subjects, 1037
and pancreatic polypeptide secretion, 224
of PM women, *see* Age of PM women
of premenopausal women, abdominal AT, 976-982
of pycnodysostosis subjects, 907, 911
and risk of NIDDM in French subjects, 367
T, SHBG, body composition and, 1243
and tHcy levels differences between men and women, 643
and thermic effect of SMLCTs versus LCTs, 126
variation in serum HDL-C and, 896, 897
see also Aging; Older subjects and entries beginning with terms: Middle-aged, Young
- Age, Ala54Threo polymorphism of *FABP2* gene and polymorphism effects of, 474
with Trp64Arg polymorphism of β ₃-*ADR* gene, 1303-1305
- Age, exercise and
exercise effects on dietary fat intake/IR association, 1188, 1189
exercise effects on HKII mRNA, 603
exercise-induced oxidative stress in older subjects and, 1485
insulin sensitivity, fasting RER and, 1288
see also Age of exercising men
- Age, gene polymorphism and
influence of age on *APOE* gene polymorphism effects on plasma lipid concentrations, 938, 939
see also Age, Ala54Threo polymorphism of *FABP2* gene and
- Age of CAD subjects
 β ₃-*ADR* gene mutation and, 186
with DM, RLP-C in, 1442
- Age of children
of fasting MCAD-deficient children, 162, 163
GH-deficient prepubertal, 538
of NIDDM parents, autonomic balance and, 1271
obese children, *see* Age of obese children with metabolic complications
relation of serum leptin to lipid profile and, 1093
of South Asian immigrants, lipid profile, leptin, insulin, and anthropometry of, 1199
- Age of diabetic women
on HRT, 314
of lactating women with GDM history, 716
- Age of DM subjects
with CAD, RLP-C in, 1463, 1464
with CRF, systemic 11 β -HSD and, 802, 803
obese DM subjects with IGT, Gln27Glu mutation of β ₂-*ADR* gene and, 444, 445
see also Age of diabetic women; Age of IDDM subjects; Age of NIDDM subjects
- Age of exercising men
and effects of high and moderate glycemic index meals on performance, 850
 S_g , S_i and, 350
- Age of FH subjects
and association between TaqIB polymorphism in *CETP* gene locus and plasma Lp levels in FH, 653
of heterozygous FH subjects, 636
- Age of gout subjects
familial gout, 1205, 1206
HTGL and LPL activity and, 953

- Age of gout subjects (*Continued*)
 VAT accumulation, IR risk and, 394, 396
- Age of hyperlipidemic subjects
 with mixed hyperlipidemias, 731
 with NIDDM, simvastatin effects on, 356
 urban and rural Mexican subjects, 314
see also Age of FH subjects; Age of hyperlipidemic women
- Age of hyperlipidemic women
 ATCVD and, 362
 PM women, 331
- Age of hypertensive subjects
 with *APOE* gene polymorphism, 159
 and their normotensive offspring, insulin sensitivity and Na excretion in, 931, 932
- Age of IDDM subjects
 apo A-IV concentrations and, 1020
 carotid distensibility, serum VEGF and, 827
 with DKA, 172
 and Mg effects on IMGU and serum lipids, 1410
- Age of insulin-resistant obese women, weight loss and
 by obese women, IR, risk of CAD and, 796
 with sibutramine, metabolic changes and, 820
- Age of insulin-resistant subjects
 with acanthosis nigricans, 772
 dietary fat and, *see* Age of insulin-resistant subjects, dietary fat and
 and
 with HTN, 1449, 1450
 LDL particle size, IR, and proinsulin in older men, 120-124
 MI prior to age 40 associated with IR, 30-35
 with NIDDM, insulin secretory dysfunction and, 591
 plasma CETP and, 785
see also Age of insulin-resistant women
- Age of insulin-resistant subjects, dietary fat and
 and dietary fat relation to markers of IR, 88
 exercise effects on dietary fat intake/IR association, 1188, 1189
- Age of insulin-resistant women
 of PM women, 595, 596
see also Age of insulin-resistant obese women, weight loss and
- Age of NIDDM subjects
 with *ACE* gene I/D, 1348
 acylation-stimulating protein-CRP relation and, 284
 aminophylline effects on insulin secretion and, 1031
 with hyperlipidemia, simvastatin effects and, 356
 with insulin gene polymorphism, 631
 insulin secretory dysfunction, IR and, 591
 IVGTT modeling and, 513
 normoalbuminuric and macroalbuminuric subjects, 569
 platelet taurine fluxes and, 61
 serum PL FA composition and insulin action in NIDDM and, 1473
 SM protein kinase C theta content and, 554
 and troglitazone effects on VAT and sulfonylurea-associated fatty liver, 415
- Age of nondiabetic subjects
 carotid distensibility, serum VEGF and, 827
 serum PON arylesterase activity and, 806, 808, 809
- Age of obese children with metabolic complications
 and hemostatic complications, 682, 685
 short-term weight loss and, 1324
- Age of obese men
 effects of obesity on Lp(a) with and without hyperinsulinemia, 180
see also Age of obese subjects
- Age of obese subjects
 with DM and IGT, Gln27Glu mutation of β_2 -*ADR* and, 444, 445
 and effects of changes in glucose, insulin, and IGF-1 level on serum CBG, 1249
 with metabolic complications, *see* Age of obese subjects with metabolic complications
 with metabolic syndrome, 137-141
 morbidly obese adolescents, 1458
 and risk of CVD, 300, 302
 with upper body obesity, 20
see also Age of obese men; Age of obese women
- Age of obese subjects with metabolic complications
 total AT, abdominal SAT, and VAT contributions to metabolic complications, 430
see also Age of obese children with metabolic complications
- Age of obese women
 on HRT, relationship between AT distribution, insulin sensitivity and, 837, 838
 serum leptin, blood pressure and, 326
see also Age of insulin-resistant obese women, weight loss and; Age of obese subjects
- Age of PM women
 and abdominal AT distribution, 976-982
 of diabetic women, 314
 on HRT, *see* Age of PM women on HRT
 hyperlipidemic, PP lipemia and, 331
 IR and, 595, 596
- Age of PM women on HRT
 diabetic women, 314
 obese, relationship between AT distribution, insulin sensitivity and, 837, 838
- Aging
 effects of, on mitochondrial gene mRNA level in beta cells, 200-206
see also Older subjects
- A1GP (α -1-acid glycoprotein) in NIDDM, 285
- AIDS, *see* Acquired immunodeficiency syndrome
- AIP (acute intermittent porphyria) attacks, triptorelin with tobolone in prevention of cyclic, 995-996
- ALA, *see* α -Lipoic acid
- Alanine (Ala)
 in IDDM and NIDDM platelets, 740
see also Alanine aminotransferase; Ala54Threo polymorphism of *FABP2* gene
- Alanine aminotransferase (ALT)
 in DM with CRF, systemic 11β -HSD and, 803
 gemfibrozil and/or ciprofibrate effects on, in mixed hyperlipidemias, 731
 in sulfonylurea-induced fatty liver in NIDDM, troglitazone effects on, 415, 416
- Ala54Threo polymorphism of *FABP2* gene
 effects of β_2 -*ADR* gene Trp64Arg polymorphism and, on insulin resistance and FPG in young and older Japanese men, 1301-1307
 in hyperinsulinemic men associated with increased dietary fat oxidation and hyperinsulinemia but not with FA absorption, 473-476
 insulin sensitivity in older women and, 1102-1105
- Albumin
 plasma, in hyperhomocysteinemic elder subjects, 1467, 1469
see also Albuminuria; Serum albumin
- Albuminuria
 in metabolic syndrome, 137-140

- Albuminuria (*Continued*)
 see also Macroalbuminuria; Microalbuminuria; Normoalbuminuric non-insulin-dependent diabetes mellitus
- Alcohol consumption
 and APOE gene polymorphism effects on plasma lipid concentrations, 936-944
 glucose counterregulation and, during acute hypoglycemia in NIDDM, 451-457
 in gout, see Alcohol consumption, gout and
 by IDDM subjects, apo A-IV concentrations and, 1020
 by men, see Alcohol consumption by men
 physical activity effects on IR association with, 1188, 1189
- Alcohol consumption, gout and
 familial gout, 1206
 HTGL and LPL activity and, 953
 VAT accumulation and, 395, 397
- Alcohol consumption by men
 and atherosclerosis in MI survivors and their spouses, 25
 as CV risk factor, 886
 and hyperuricemia development in middle-aged men, 623-625
- Aldosterone, plasma, see Plasma aldosterone
- Alendronate, effects of, on BMD in male idiopathic osteoporosis, 912-915
- Alkaline phosphatase (ALP)
 in cirrhosis, 1342
 in COPD, 1397
 in idiopathic osteoporotic men, 913
 plasma, in Tg subjects, CETP activity and, 532
- Allele and allele frequency
 APOE gene polymorphism, 27, 158, 938
 Arg, in carriers and/or non-carriers of β_2 -ADR gene polymorphism, 186
 of TNF- α -238 and -308 polymorphisms, 1449
 of 2184A/G and 1704G/T RAGE gene polymorphism in NIDDM and nondiabetic subjects, 1154
 of vitamin D-binding protein gene variants, 367
- ALP, see Alkaline phosphatase
- Alpha (α)-1-acid glycoprotein (A1GP) in NIDDM, 285
- Alpha 1-amino-nitrogen, see α -Amino nitrogen
- Alpha (α) cells (pancreatic alpha cells), NO-induced secretion of glucagon from, cGMP and, 703-707
- Alpha-lipoic acid, see α -Lipoic acid
- Alpha-lipoprotein, see High-density lipoprotein(s)
- Alpha (α)-tocopherol in NIDDM and nondiabetic subjects, antioxidant status and, 1155-1158
- ALT, see Alanine aminotransferase
- Amino acids (AAs)
 glucose, lipid kinetics and, following palliative resection in glucanoma syndrome, 720-722
 in hepatic glucose production regulation, 744, 745
 platelet, see Platelet amino acids
 see also specific amino acids
- α (alpha)-Amino nitrogen
 and glucose rate of appearance following galactose ingestion, 96
 hepatic, PGE₂ and conversion of, to urea nitrogen in poorly controlled NIDDM, 253-258
- Aminophylline, effects of, on insulin secretion in NIDDM, 1030-1035
- Aminotransferase, see Alanine aminotransferase; Aspartate aminotransferase
- Amylase, serum amyloid, in NIDDM, 285
- Amylin
 effects of insulin, proinsulin and, on renin release, 763-766
- Amylin (*Continued*)
 glucose-stimulated secretion of, in nondiabetic subjects with pancreatic cancer, 1036-1042
- Amyloid amylase, serum, in NIDDM, 285
- Anatomical differences between IR-obese and metabolically normal obese subjects, 1501
- Androgen
 effects of, on bone maturation and BMD in children with CAH and/or CPP, 377-379
 see also Free androgen index
- Ang, see Angiotensin; Angiotensin II
- Angiotensin (Ang), ET_B receptor regulated by, in IMCD, 661-666
- Angiotensin II (AngII)
 effects of, on lipolysis, 468-472
 plasma, furosemide effects on, 242, 243
- Angiotensin-converting enzyme (ACE) inhibitor therapy, cough related to, in Chinese NIDDM women, insertion/deletion of ACE gene and, 1346-1350
- Animal fat and meat meal, sex hormone concentrations in men following, 505-511
- Ankle brachial index (ABI), and prostacyclin-induced skin BF changes in NIDDM, 568-572
- Anorexia nervosa
 glucose metabolism in, 876-881
 long-lasting hyperleptinemia and, induced by dexamethasone in older subjects, 1054-1058
- ANPs (atrial natriuretic peptides) in hypertensive subjects and their normotensive offspring, insulin sensitivity, Na excretion and, 932, 934
- Anthropometry
 of South Asian immigrants' offspring, lipid profile, leptin, insulin, and anthropometry of, 1197-1202
 see also specific anthropometric data
- Antibodies (Abs) to pancreatic islet cells and to glutamic acid decarboxylase in identification of type 1½ diabetes in patients presenting with NIDDM, 1008-1013
- Antidiabetic activities
 of zinc, cyclo (his-pro), and arachidonic acid in STZ-DM, 53-59
 see also specific antidiabetic agents
- Antigen (Ag), tissue-type plasminogen activator-, in obese children, 681-687
- Antioxidant(s)
 aspirin as, 558-561
 fat-soluble, effects of plant stanol FA ester mixtures on concentrations of plasma ubiquinol-10 and, 520-529
 see also specific antioxidants
- Antioxidant enzymes, glucosinolate effects on activities of, 1130-1135
- Antioxidant status, 2184A/G and 1704G/T RAGE gene polymorphisms associated with, 1152-1160
- Antipyrine, oxidation of, exercise-induced oxidative stress in older subjects and, 1484-1488
- Antiretroviral therapy, short-term highly active HIV infection, N-methylglycine and N,N-dimethylglycine during, 1275-1281
- Antitrypsin in NIDDM, 285
- Aortic compliance, and CV risk factors in men, 882-888
- Aortic endothelial cells (AECs)
 cytokine effects on LDL metabolism by, 99-106
 PPAR γ and PPAR α effects on CuZn-SOD and p22^{phox} message gene expression in HUVECs and HAECs, 3-11
- Aortopulmonary shunts, and metabolic responses to moderate exercise, 399-406
- Apo(s), see specific apolipoproteins
- APOE gene polymorphism

- APOE gene polymorphism** (*Continued*)
 environmental factors modulating effects of, on plasma lipid concentrations, 936-944
 genotypes of, in MI survivors and their spouses, 27
 modulation of association between obesity and dyslipidemia by, in young adults, 696-702
 related to metabolic abnormalities, effects of, on erythrocyte membrane lipid composition or sodium-lithium countertransport in essential hypertension, 157-160
- Apolipoprotein(s) (apo)**
 plasma, levels of, as risk factor for atherosclerosis in MI survivors and their spouses, 26-27
see also specific apolipoproteins
- Apolipoprotein A (apo A) in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on**, 415, 416
- Apolipoprotein A-I (apo A-I)**
 and atherosclerosis in MI survivors and their spouses, 27
 in CAD, 186
 diet effects on, *see* Apolipoprotein A-I, diet effects on
 in FH, *see* Apolipoprotein A-I in FH
 in IDDM, apo A-IV concentrations and, 1020
 IR and, *see* Apolipoprotein A-I in IR
 Lp distribution of, 113
 plasma, in heterozygous FH, 636
 in PM women, *see* Apolipoprotein A-I in PM women
- Apolipoprotein A-I (apo A-I), diet effects on**
 dietary cholesterol effects in insulin-resistant PM women, 595, 596
 very-high-fiber, vegetable, fruit, nut diet effects, 497
- Apolipoprotein A-I (apo A-I) in FH**
 LDL effects on kinetics of, in heterozygous FH, 635-639
 TaqIB polymorphism in *CETP* gene locus and, 653, 654
- Apolipoprotein A-I (apo A-I) in IR**
 in insulin-resistant PM women, dietary cholesterol effects on, 595, 596
 LDL particle size, proinsulin and, 122
 and MI prior to age 40 associated with IR, 31
- Apolipoprotein A-I (apo A-I) in PM women**
 in diabetic PM women on HRT, serum PON arylesterase effects on, 321
 insulin-resistant, dietary cholesterol and, 595, 596
- Apolipoprotein A-II (apo A-II)**
 in IDDM, apo A-IV concentrations and, 1020
 in insulin-resistant PM women, dietary cholesterol and, 595, 596
- Apolipoprotein A-IV (apo A-IV) in IDDM secondary to chronic pancreatitis, effects of chronic hyperglycemia, inflammation, or dietary fat malabsorption on concentration of**, 1019-1024
- Apolipoprotein B (apo B)**
 and atherosclerosis in MI survivors and their spouses, 27
 in CAD, *see* Apolipoprotein B in CAD
 in carotid artery atherosclerosis subjects, 1097
 diet effects on, *see* Apolipoprotein B, diet effects on
 in FH, TaqIB polymorphism in *CETP* gene locus and, 653, 654
 in IDDM, apo A-IV concentrations and, 1021
 IR and, *see* Apolipoprotein B in IR
 and Lp distribution of, 113
 in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731
 in moderate exercise, 759
 in NIDDM, *see* Apolipoprotein B in NIDDM
 in PM women, *see* Apolipoprotein B in PM women
- Apolipoprotein B (apo B), diet effects on**
 dietary cholesterol effects in insulin-resistant PM women, 595, 596
- Apolipoprotein B (apo B), diet effects on** (*Continued*)
 very-high-fiber, vegetable, fruit, nut diet effects, 497
- Apolipoprotein B (apo B) in CAD**
 and β_2 -*ADR* gene polymorphism, 186
 lipids and, as risk factors for CAD in older urban and rural Mexican subjects, 311-318
- Apolipoprotein B (apo B) in IR**
 dietary cholesterol and, in PM women, 595, 596
 LDL particle size, IR, proinsulin and, 122
 MI prior to age 40 associated with IR, 31
- Apolipoprotein B (apo B) in NIDDM**
 with cardiovascular disease, changes in disease and $\dot{V}O_{2max}$ changes in, 1258, 1260, 1261
 with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
- Apolipoprotein B (apo B) in PM women**
 in diabetic PM women on HRT, serum PON arylesterase effects on, 321
 insulin-resistant, dietary cholesterol and, 595, 596
- Apolipoprotein C-III (apo C-III)**
 in IDDM, apo A-IV concentrations and, 1020
 in insulin-resistant PM women, dietary cholesterol and, 595, 596
 Lp distribution of, and its relationship to plasma TG-rich remnant Lps, 112-119
- Apolipoprotein E (apo E)**
 effects of deficiency of, on bile acid and hepatic cholesterol synthesis, LDL receptor function, and plasma and fecal sterol levels, probucol and/or phytosterol therapy of, 708-714
 in IDDM, apo A-IV concentrations and, 1020
 in insulin-resistant PM women, dietary cholesterol and, 595, 596
see also: APOE gene polymorphism; Apolipoprotein E-containing lipoprotein(a)
- Apolipoprotein E (apo E)-containing lipoprotein(a) [Lp(a)] in normotriglyceridemia and hypertriglyceridemia**, 277-282
- Apoptosis**
 effects of suppressed intestinal, on small intestinal mucosa thickness in STZ-DM, 259-264
 pancreatic islet cell, systemic bromocriptine/SKF38393 effects on, in obesity, 1379-1380
- Appendicular bone, DR effects on**, 436-442
- Appetite, vanadium effects on**, 667-673
- Appropriate-for-gestational age (AGA) neonates, Lp profile and CETP in**, 724-725
- Arachidonic acid**
 antidiabetic activities of zinc, cyclo (his-pro) and, in STZ-DM, 53-59
 leptin release stimulated by PGE₂ and, in AT of obese subjects, 921-928
- Arg, *see* L-Arginine; Trp64Arg polymorphism of β_2 -*ADR* gene L-Arginine (Arg)**
 in IDDM and NIDDM platelets, 740
 N(G)monomethyl-, effects of, on insulin-mediated SM blood flow and glucose disposal in older subjects, 194-199
 urinary insulin response to, in MIS, 865
- Arterial blood gases in COPD**, 1398
- Arterial pH**
 in COPD, 1399
 in moderate exercise, 402
- Arthritis**
 acute, *see* Acute arthritis in gout
 osteoarthritis of knee, relationship between OPG/OCIF concentrations in synovial fluid and severity of, 1-2
 rheumatoid, serum IL-6 and thyroid hormones in, 463-467
 Arylesterase, *see* Paraoxonase arylesterase

- Ascites in cirrhosis, 1342
- Asparagine (Asp) in IDDM and NIDDM platelets, 740
- Aspartate aminotransferase (AST)
in AIDS, 290
in cirrhosis, 1342
in DM with CRF, systemic 11β -HSD and, 803
gemfibrozil and/or ciprofibrate effects on, in mixed hyperlipidemias, 731
and troglitazone effects on VAT and sulfonyleurea-induced fatty liver in NIDDM, 415
- Aspartic acid (Asp) in IDDM and NIDDM platelets, 740
- Aspirin, effects of, on blood cholesterol in copper deficiency, 558-561
- AST, *see* Aspartate aminotransferase
- AT, *see* Adipose tissue
- Atherosclerosis
carotid artery, relation between HDL *PON1* gene M/L55 polymorphism and, in smoking and nonsmoking men, 1095-1101
see also Risk factors for atherosclerosis
- Atherothrombotic cardiovascular (CV) disease, interaction between ERT and thrombophilic 20210 G/A thrombophilic prothrombin gene mutation for, in hyperlipidemia, 360-365
- Athletes, *see* Exercise
- Atorvastatin
in combined hyperlipidemia, effects of, on serum chitotriosidase genotype, 447-450
effects of, on LDL subtypes in hyperlipoproteinemia, 983-988
- ATP (adenosine phosphate), intracellular, in KCN- and IAA-exposed hepatocytes, 344
- ATPase (adenosine triphosphatase), platelet Na^+/K^+ , as marker in hyperthyroidism, 1393-1396
- atRA (A11-*trans*-retinoic acid) metabolism, effects of farnesol derivatives on, 1356-1360
- Atrial natriuretic peptides (ANPs) in hypertensive subjects and their normotensive offspring, insulin sensitivity, Na excretion and, 932, 934
- Autoantibodies to oxidized LDLs, LDL-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules and, in CRF subjects on HD, 207-215
- Autonomic balance of NIDDM subjects' offspring, 1270-1274
- Autonomic nervous system in hepatic glucose production, 744, 748-749
- Backflow, hepatic vein, 189-903
- Balloon-injured vascular smooth muscle cell (VSMC) proliferation, pioglitazone effects on, 955-962
- Basal metabolic rate (BMR) in DMD, 1183
- Basal serum-promoted cholesterol (C) efflux, PP and, in normolipidemia, 1330-1335
- BAT, *see* Brown adipose tissue
- Beclomethasone dipropionate, effects of long-term inhaled, on osteocalcin levels in COPD, 1336-1339
- Beta (α)-actin mRNA (messenger ribonucleic acid) in cancer cachexia, 1214-1215
- Beta-adrenergic receptor genes, *see*: β_2 -ADR gene Gln27Glu mutation; β_1 -ADR gene polymorphism
- Beta (β) cells (pancreatic β cells), 1369-1384
FFA effects on functions of, PPAR α receptor and pancreatic/duodenal homeobox involvement in, 613-618
GPI-PLD mRNA in, regulated by glucose and insulin, 1489-1492
high-fructose diet and preservation of mass of, and diabetes prevention in non-obese subjects, 1369-1376
hyperplastic, in obesity, systemic bromocriptine/SKF38393 effects on GLUT2, glucokinase, *irf* levels and, 1377-1384
- Beta (β) cells (pancreatic β cells) (*Continued*)
mitochondrial gene regulating, 200-206
visceral AT and function of, in lactating women with GDM history, 715-719
- 17 β estradiol, *see* 17 β -Estradiol
- Beta-hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone
- Beta-lipoprotein, *see* Low-density lipoprotein
- Bezafibrate
in combined hyperlipidemia, effects of, on serum chitotriosidase genotype, 447-450
effects of, on insulin sensitivity and insulin secretion in non-obese Japanese NIDDM subjects, 477-480
- BF, *see* Blood flow
- Bicarbonate, *see* HCO_3
- Bile acids, effects of apo E deficiency on LDL receptor function, plasma and fecal sterol levels, and synthesis of hepatic cholesterol, probucol and/or phytosterol therapy for, 708-714
- Biliopancreatic diversion (BPD), opioid dysregulation after, and naloxone effects on GHRH-induced PP and preprandial GH release after BPD-induced weight loss, 382-386
- Bilirubin, serum, in cirrhosis, 1342
- Binding protein, *see* Ala54Threo polymorphism of *FABP2* gene; Growth hormone-binding protein; Insulin-like growth factor-binding protein-1; Vitamin D-binding protein gene
- Biological parameters, long-term effects of partial nephrectomy on renal histology, guanidino compounds and, 1418-1425
- Birth weight
Lp profile, CETP and, 723-728
see also Small-for-gestational age neonates
- Black Americans, *see* Race and ethnicity
- Blood
whole, stability of CT-1 in, 237-240
see also entries beginning with term: Blood element: Hem- and terms ending with suffix: -emia
- Blood acetoacetate (ACAC) in fasting MCAD-deficient children, 162, 163
- Blood S-adenosylmethionine, lymphocyte MTHFR activity and concentrations of, in DM and diabetic nephropathy, 1014-1018
- Blood cholesterol (C), aspirin effects on, in copper deficiency, 558-561
- Blood flow (BF)
ALA or evening primrose oil effects on, in STZ-DM, 868-875
caval backflow of hepatic vein, 189-193
and CV risk factors in men, 884
exercise effects on, *see* Blood flow, exercise effects on
hepatic, in cirrhosis, 1342
limb, *see* Limb blood flow
skeletal muscle, in older subjects, L-NMMA effects on, 195-199, 306-310
skin, NIDDM and prostacyclin-induced changes in, ABI, plasma TM and, 568-572
see also Glucose, insulin effects on BF and uptake of glucose, *see* Glucose, insulin effects on BF and uptake of
- Blood flow, exercise effects on
creatine and endurance exercise effects on limb blood flow, 1429-1434
moderate exercise, 402
- Blood free fatty acids (FFAs), S_1 of blood glucose versus S_1 of, in normal, obese, and obese diabetic subjects, 573-582
- Blood gases, arterial, in COPD, 1398
- Blood glucose
in DM, *see* Blood glucose in DM
in fasting MCAD-deficient children, 162, 163

Blood glucose (*Continued*)

- high-fat, high-cholesterol diet effects on, 460
- hyperinsulinemia in suppression of insulin secretion and, 108, 109
- LDL particle size, IR, proinsulin and, 122
- in obesity, *see* Blood glucose in obesity
- regional, insulin effects on, 69
- S_1 of blood FFAs versus S_1 of, in normal subjects, 573-582

Blood glucose in DM

- S_1 of blood FFAs versus S_1 of, in obese diabetic subjects, 573-582
- in STZ-DM subjects, muscle SV lactate transport and, 420
- in young IDDM subjects, serum PON arylesterase activity and concentration modulated by, 657-660

Blood glucose in obesity

- oral nicotine effects on, 80-81
- S_1 of blood FFAs versus S_1 of, in obese and obese diabetic subjects, 573-582

Blood 3-hydroxybutyrate (3-OHB) in fasting MCAD-deficient children, 163

Blood lactate, and hypoxanthine response to cardiopulmonary exercise by HTN subjects, 647-648

Blood lipids, aerobic exercise and changes in, related to AT and aerobic fitness, 841-848

Blood pressure (BP)

- in carotid artery atherosclerosis subjects, 1097
- as CV risk factor in men, 884, 885
- in DM, *see* Blood pressure in DM
- exercise and, *see* Blood pressure, exercise and
- gene polymorphism and, *see* Blood pressure, gene polymorphism and
- and glucose effects on plasma von Willebrand factor, 1453, 1455
- in gout, *see* Blood pressure in gout
- in hyperlipidemic older subjects, coronary risk factors and, 314, 315
- and hyperuricemia development in middle-aged men, 623-625
- and insulin effects on regional blood flow, 67
- and IR, *see* Blood pressure in IR
- NE effects on, 1231, 1232
- of NIDDM subjects' offspring, autonomic balance and, 1271
- in nondiabetic subjects, carotid distensibility, serum VEGF and, 827
- in obesity, *see* Blood pressure in obesity
- in older subjects, *see* Blood pressure in older subjects
- restricted maternal Fe effects on glucose tolerance, serum lipids and, in 3-month-old offspring, 562-567
- in SCD, 389
- very-high-fiber vegetable, fruit, nut diet effects on, 496-498
- see also* Hypertension

Blood pressure (BP), Ala54Threo polymorphism of *FABP2* gene and effects of *FABP2* gene polymorphism, 474

and Trp64Threo polymorphism of β_3 -*ADR* gene, 1303-1305

Blood pressure (BP), exercise and

- in moderate exercise, 401
- in NIDDM subjects with cardiovascular disease, changes in disease and in $\dot{V}O_{2max}$ and, 1258, 1260, 1261

Blood pressure (BP), gene polymorphism and

- of *CRH* gene regulatory region in obesity, 1060
- in FH, association between TaqIB polymorphism in *CETP* gene locus and plasma Lp levels and, 653
- see also* Blood pressure, Ala54Threo polymorphism of *FABP2* gene and

Blood pressure (BP) in DM

- and CRF, systemic 11β -HSD and, 802, 803
- in IDDM, carotid distensibility, serum VEGF and, 827
- in lactating women with GDM history, 716

Blood pressure (BP) in DM (*Continued*)

see also Blood pressure in NIDDM

Blood pressure (BP) in gout

- HTGL and LPL activity and, 953
- VAT accumulation and, 394, 396

Blood pressure (BP) in IR

- in hyperinsulinemic NIDDM with insulin secretory dysfunction, 591

LDL particle size, proinsulin and, 122

MI prior to age 40 associated with, 31

- in obese women, relationship between IR, weight loss, and coronary heart disease and, 795-800

Blood pressure (BP) in NIDDM

- with *ACE* gene I/D, 1348
- with cardiovascular disease, changes in disease and in $\dot{V}O_{2max}$ and, 1258, 1260, 1261
- with hyperinsulinemia, insulin secretory dysfunction, IR and, 591
- with macroalbuminuria, 1184
- prostacyclin-induced skin BF changes and, 569
- with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416

Blood pressure (BP) in obesity

- with and without hyperinsulinemia, 180
- and metabolic complications, 430, 431
- in obese women, relationship between IR, weight loss, coronary heart disease and, 795-800
- polymorphism of *CRH* gene regulatory region and, 1060
- risk of CVD and, 300, 301
- serum leptin and low, in obese Peruvian Indian and Caucasian women, 325-329
- upper body obesity, 20, 21

Blood pressure (BP) of older subjects

- effects of L-arginine on, 195, 196
- hyperlipidemic older subjects, coronary risk factors and, 314, 315
- L-NMMA effects on, 307
- older men, changes in leg BF and capillary density in SM of, 1080

Blood urea nitrogen, *see* BUNBMD, *see* Bone mineral densityBMI, *see* Body mass and body mass index

BMR (basal metabolic rate) in DMD, 1183

Body composition

- energy balance and, of PM women, short-term HRT effects on, 265-269
 - in obesity, sibutramine and low-dose leptin effects on, 891
 - of prepubertal GH-deficient children, alterations in AT distribution and, during GH therapy, 537-547
 - serum leptin relationship to, in adolescents having been SGA neonates, 1141-1146
 - T, SHBG and, in young adult men, race and, 1242-1247
 - see also* Adipose tissue; Fat mass; Fat-free mass
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)
- of adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 - of AIDS subjects, protein wasting and, 290
 - and angiotensin II effects on lipolysis, 470
 - of anorexic subjects, 877
 - aspirin effects on, 559
 - atherosclerosis and, *see* Body mass and body mass index, atherosclerosis and
 - of CAD subjects, 186
 - of children, *see* Body mass and body mass index of children
 - circulating GM-CSF, serum FA composition and, 1480

- Body mass and body mass index (BMI) (*Continued*)
 of cirrhotic subjects, 1342
 of COPD subjects, 1337, 1398
 of CRF subjects, 208
 as CV risk factor in men, 884, 886
 DHEAS and, 918
 of diabetic subjects, *see* Body mass and body mass index of diabetic subjects
 and differences in tHcy levels between men and women, 641
 of DMD subjects, 1182
 DR effects on, 437-438
 and exercise, *see* Body mass and body mass index, exercise and
 gene polymorphism and, *see* Body mass and body mass index, gene polymorphism and
 and Gln27Glu mutation of β_2 -ADR gene, 444, 445
 of gout subjects, *see* Body mass and body mass index of gout subjects
 of heterozygous FH subjects, 636
 of hyperhomocysteinemic elder subjects, 1467
 of hyperlipidemic subjects, *see* Body mass and body mass index of hyperlipidemic subjects
 of hypertensive subjects, *see* Body mass and body mass index of hypertensive subjects
 and hyperuricemia development in middle-aged men, 623-625
 IR and, *see* Body mass and body mass index of insulin-resistant subjects
 and Lp distribution of apo C-III, 113
 of NIDDM subjects' offspring, autonomic balance and, 1271
 of nondiabetic subjects, *see* Body mass and body mass index of nondiabetic subjects
 of normolipidemic subjects, serum-promoted C efflux and, 1332, 1333
 of obese subjects, *see* Body mass and body mass index of obese subjects
 of older subjects, *see* Body mass and body mass index of older subjects
 of pancreatic cancer subjects, 1037
 and pancreatic polypeptide secretion, 224
 of PM women, *see* Body mass and body mass index of PM women
 of premenopausal women, *see* Body mass and body mass index of premenopausal women
 of pycnodysostosis patients, 907
 as risk factor for atherosclerosis in MI survivors and their spouses, 25
 T, SHBG, and body composition and, race and, 1243
 and thermic effect of SMLCTs versus LCTs, 126
 and variations in serum HDL-C, 897, 898
 variations in vitamin D-binding protein gene and risk of NIDDM and, 367
 Body mass and body mass index (BMI), Ala54Threo polymorphism of *FABP2* gene and
 hyperinsulinemia and, 474
 and Trp64Arg β_2 -ADR gene polymorphism, 1303-1305
 Body mass and body mass index (BMI), atherosclerosis and
 BMI as risk factor for atherosclerosis in MI survivors and their spouses, 25
 carotid artery atherosclerosis, 1097
 Body mass and body mass index (BMI), exercise and
 creatine and endurance exercise effects on REE and LBF and, 1431
 dietary fat intake/IR association and, 1183
 exercise effects on HKII mRNA and, 603
 Body mass and body mass index (BMI), exercise and (*Continued*)
 by NIDDM subjects, *see* Body mass and body mass index, exercise and, in NIDDM
 oxidative stress in older subjects induced by exercise, 1485
 by young and middle-aged men, S_{α} , S_1 and, 350
 Body mass and body mass index (BMI), exercise and, in NIDDM
 with cardiovascular disease, changes in disease and $\dot{V}O_{2\max}$ changes in, 1258, 1260, 1261
 exercise effects on serum leptin levels, 1137
 Body mass and body mass index (BMI), gene polymorphism and
 APOE gene polymorphism effects on plasma lipid concentrations and, 938, 939
see also Body mass and body mass index, Ala54Threo polymorphism of *FABP2* gene and
 Body mass and body mass index (BMI) of children
 of GH-deficient prepubertal children, 538
 of obese children, *see* Body mass and body mass index of obese children
 and relationship of serum leptin to lipid profile of children, 1092, 1093
 of South Asian immigrants, 1199, 1200
 Body mass and body mass index (BMI) of diabetic subjects
 with CRF, systemic 11β -HSD and, 803
 of diabetic premenopausal women, myosin light-chain phosphorylation in resting platelets and, 153
 of lactating women with GDM history, 716
see also Body mass and body mass index of IDDM subjects;
 Body mass and body mass index of NIDDM subjects
 Body mass and body mass index (BMI) of gout subjects
 familial gout, 1206
 HTGL and LPL activity and, 953
 VAT accumulation, IR risk factor and, 394, 396
 Body mass and body mass index (BMI) of hyperlipidemic subjects
 with NIDDM, 311, 314, 315, 356
 in PP women, 331
 Body mass and body mass index (BMI) of hypertensive subjects
 effects of, on APOE gene polymorphism effects on plasma lipids, 159
 and their normotensive offspring, insulin sensitivity, Na excretion and, 931, 932
 Body mass and body mass index (BMI) of IDDM subjects
 apo A-IV concentrations and, 1020
 carotid distensibility, serum VEGF and, 827
 with DKA, 172
 and Mg effects on IMGU and serum lipids, 1410
 Body mass and body mass index (BMI) of insulin-resistant obese women
 PM women, 595, 596
see also Body mass and body mass index of insulin-resistant obese women, weight loss and
 Body mass and body mass index (BMI) of insulin-resistant obese women, weight loss and
 and relationship between IR, weight loss, and risk of CAD, 796
 with sibutramine and low-dose leptin, metabolic changes and, 820
 Body mass and body mass index (BMI) of insulin-resistant subjects
 with acanthosis nigricans, 772
 and glucose effects on plasma von Willebrand factor, 1453
 with HTN, 1449, 1450
 LDL particle size, IR, proinsulin and, 122
 and MI prior to age 40, 31
 and physical effects on dietary fat intake/IR association, 1188, 1189
 PL FAs and, 88
 and plasma CETP activity, 785

- Body mass and body mass index (BMI) of insulin-resistant subjects
(*Continued*)
see also Body mass and body mass index of insulin-resistant obese women
- Body mass and body mass index (BMI) of Japanese NIDDM subjects
lean subjects, and bezafibrate effects on NIDDM, 478
polymorphisms of insulin gene and, 631
- Body mass and body mass index (BMI) of NIDDM subjects
with ACE gene I/D, 1348
acylation-stimulation protein-CRP relation and, 284
aminophylline effects on insulin secretion and, 1031
on gemfibrozil or simvastatin therapy, 1149
hyperlipidemic subjects, 311, 314, 315, 356
IVGTT modeling and, 513
Japanese subjects, *see* Body mass and body mass index of Japanese NIDDM subjects
Korean NIDDM subjects, 591
platelet taurine fluxes and, 61
prostacyclin-induced skin BF changes and, 569
serum PL FA composition and insulin action in NIDDM and, 1473
SM protein kinase C theta content and, 554
troglitazone effects on VAT and sulfonylurea-associated fatty liver and, 415, 416
- Body mass and body mass index (BMI) of nondiabetic subjects
carotid distensibility, serum VEGF and, 827
and RXR expression in skeletal muscle, 833
serum paraoxonase activity and, 808, 809
- Body mass and body mass index (BMI) of obese children
effects of changes in BMI on metabolic risk in obesity after short-term weight loss, 1323-1329
Hcy and, 1221
- Body mass and body mass index (BMI) of obese men
with and without hyperinsulinemia, Lp(a) and, 180
see also Body mass and body mass index of obese subjects
- Body mass and body mass index (BMI) of obese subjects
and effects of changes in glucose, insulin, and IGF-I level on serum CBG, 1249
greater than 30 in nondiabetic morbidly obese subjects, metformin reducing BW, centripetal obesity, leptin, and LDL-C in, 856-861
with metabolic syndrome, 137-140
morbidly obese adolescents, 1458
with NIDDM, RXR expression in skeletal muscle of, 833
obese adolescents, Hcy and, 1221
and risk of CVD, 300, 301
with upper body obesity, 20, 21
see also Body mass and body mass index of obese children; Body mass and body mass index of obese men; Body mass and body mass index of obese women; Obesity
- Body mass and body mass index (BMI) of obese women
serum leptin, blood pressure and, 325, 326
see also Body mass and body mass index of insulin-resistant obese women; Body mass and body mass index of obese subjects
- Body mass and body mass index (BMI) of older subjects
and effects of L-NMMA on glucose disposal and IMGU in, 195, 307
of older men, and changes in leg BF and capillary density in SM, 1080
as risk factor for CAD, 314, 315
RMR and, 973, 974
- Body mass and body mass index (BMI) of PM women
abdominal AT distribution and, 978
estrogen effects on serum DHEA and, 489
hyperlipidemic women, PP lipemia and, 331
insulin-resistant women, 595, 596
see also Body mass and body mass index of PM women on HRT
- Body mass and body mass index (BMI) of PM women on HRT
diabetic women, 321
obese, relationship between AT distribution, insulin sensitivity and, 837
on short-term HRT, 267
- Body mass and body mass index (BMI) of premenopausal women
abdominal AT distribution and, 978
of diabetic premenopausal women, myosin light-chain phosphorylation in resting platelets and, 153
- Body weight (BW)
of acanthosis nigricans subjects with severe IR, 772
of adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
at birth, Lp profile, CETP and, 723-728
BRL-49653 effects on, 1295-1296
of children, *see* Body weight of children
of cirrhotic subjects, 1342
of COPD subjects, 1398
of CRF subjects, KSVLPD effects on, 337
and CV risk factors in men, 884
diet effects on, *see* Body weight, diet effects on
of DMD subjects, 1182
exercise and, *see* Body weight, exercise and
and fructose-induced hypertension, 76
of hyperlipidemic subjects, 731
of idiopathic osteoporotic men, 913
LDL particle size, IR, proinsulin and, 122
of metabolic syndrome subjects, 137, 140
of NIDDM subjects, IVGTT modeling and, 513
of older subjects, RMR and, 973
and pancreatic polypeptide secretion, 224
and pioglitazone effects on balloon-injured VSCM proliferation, 957
of PM women, *see* Body weight of PM women
of premenopausal women, abdominal AT distribution and, 978
of South Asian immigrants' offspring, 1199
of STZ-DM subjects, *see* Body weight of STZ-DM subjects
T, SHBG, body composition, race and, 1243
and thermic effect of SMLCTs versus LCTs, 126
vanadium effects on, 669-671
see also Non-obese subjects; Obesity; Weight gain; Weight loss
- Body weight (BW), diet effects on
high-fat, high-cholesterol diet effects, 460
very-high-fiber vegetable, fruit, nut diet effects, 497
- Body weight (BW), exercise and
exercise effects on BW, 1050
insulin sensitivity, fasting RER and, 1288
in NIDDM, effects of, 1137
see also Body weight of exercising men
- Body weight (BW) of children
of fasting MCAD-deficient children, ketone production and, 162
of GH-deficient prepubertal children, 538
- Body weight (BW) of exercising men
and effects of high and moderate glycemic index meals on performance, 850
S_E, S_I and, 350
- Body weight (BW) of PM women
abdominal AT distribution and, 978

- Body weight (BW) of PM women (*Continued*)
 on HRT, 837, 838
 short-term HRT effects on, 267
- Body weight (BW) of STZ-DM subjects
 muscle SV lactate transport and, 420
 STZ-DM effects on, 261-262
- Bone
 appendicular, DR effects on, 436-442
 effects of estrogen and androgen on BMD and maturation of, in
 CAH and CPP children, 377-379
 GH effects on mineralization of, in GH-deficient prepubertal
 children, 543
see also Bone age; Bone disease; Bone mineral density and
 entries beginning with element: Osteo-
- Bone age of growth hormone-deficient prepubertal children, 538
- Bone disease
 metabolic, DR effects on, 436-442
see also Osteoarthritis; Osteoporosis
- Bone marrow cells, cytogenetic studies of protein malnutrition in,
 1025-1029
- Bone mineral density (BMD)
 alendronate effects on, in male idiopathic osteoporosis, 912-915
 effects of estrogen and androgen on bone maturation and, in CAH
 and CPP children, 377-379
 tibial, DR effects on, 438-440
- Borderline hypertensive young men with CV risk factors, glucose
 disposal rate in, 1175-1180
- BP, *see* Blood pressure
- BPD (biliopancreatic diversion), opioid dysregulation after, and
 naloxone effects on GHRH-induced PP and preprandial GH
 release after BPD-induced weight loss, 382-386
- Brachial index, ankle, and prostaglandin-induced skin BF changes in
 NIDDM, 568-572
- Bradykinin B2 receptor gene -58T/C polymorphism not associated
 with ACE inhibitor-related cough in Chinese NIDDM
 women, 1346-1350
- Brain, GC concentrations in, 1421
- BRL-49653 (rosiglitazone), action of, through regulation of GLUT1
 AND GLUT4 in skeletal muscle and AT, 1294-1300
- Broccoli, effects of, on cytochrome P-450 activities in liver, kidney,
 and colon, 1123-1135
 and on antioxidant enzyme activities, 1130-1135
- Bromocriptine/SKF38393, systemic, effects of, on aberrant beta-cell
 hyperplasia, GLUT2, glucokinase, and *ir1* levels in obesity,
 1377-1384
- Brown adipose tissue (BAT)
 in adolescents with DMD, paradoxical weight loss with extra EE
 at, 1181-1185
 high-protein, CHO-free diet and FA synthesis in, 1493-1498
- BUN (blood urea nitrogen)
 and hyperuricemia development in middle-aged men, 623-625
 in NIDDM with macroalbuminuria, 1194
see also BUN in CRF
- BUN (blood urea nitrogen) in CRF
 with DM, systemic 11β -HSD and, 803
 serum, 208
- BW, *see* Body weight
- Bypass, cardiopulmonary, TBG cleavage during, 1113-1116
- C, *see* Cholesterol
- C3 (complement 3) in NIDDM, 285
- Ca (calcium)
 in GH-deficient prepubertal children, GH therapy effects on, 544
 in idiopathic osteoporotic men, 913
- Ca (calcium) (*Continued*)
 serum, in COPD, 1337
- Cachexia, cancer, hypothalamic NPY mRNA in, 1213-1219
- CAD, *see* Coronary artery disease
- CAH (congenital adrenal hyperplasia), effects of estrogen and
 androgen on bone maturation and BMD in children with,
 377-379
- Calcitonin, serum, DR effects on, 436-442
- Calcium, *see* Ca
- Calories
 in high-fructose diet, 1370
 with KSVLPD, 337
 morbidly obese adolescent intake of, 1458
 and physical activity effects on IR association with dietary fat
 intake, 1188
see also Thermic effects *specific diets, specific food groups, and*
food substances and entries beginning with term: Energy-
- Campestanol fatty acid (FA) esters
 effects of, on cholesterol absorption and HMG-CoA reductase
 activity, 1106-1112
 effects of, on ubiquinone-10 and fat-soluble antioxidant
 concentrations, 523
- Campesterol fatty acid (FA) esters
 effects of, on apo E deficiency effects, 709
 effects of, on ubiquinone-10 and fat-soluble antioxidant
 concentrations, 523
 in very-high-fiber vegetable, fruit, nut diet, 496
- Cancer cachexia, hypothalamic NPY mRNA in, 1213-1219
- Capillary density in SM of older men, insulin-mediated changes in
 leg blood flow and, 1078-1082
- Carbohydrate(s) (CHO) during exercise
 metabolism of, in exercising women, 481-487
 oxidation of, 852
see also Carbohydrate intake and *specific carbohydrates*
- Carbohydrate (CHO) intake
 and dyslipidemia in older subjects, 314, 315
 effects of, on mitochondrial gene mRNA levels in beta cells, 193
 in gout, VAT accumulation and, 395
 with high-fructose diet, 1370
 in IDDM, apo A-IV concentrations and, 1020
 IR, *see* Carbohydrate intake, IR and
 by men with LM, MAF, tofu, and MOS meals, 506
 in NIDDM, insulin action on serum PL FA composition and, 1473
see also High-protein, carbohydrate-free diet
- Carbohydrate (CHO) intake, IR and
 glucose tolerance and, 86-92
 and physical activity effects on IR association with dietary fat
 intake, 1188
- Carbon dioxide partial pressure (P_{CO_2}) in moderate exercise, 402
- Carboxikinase gene, hepatic phosphoenol, PPAR α regulation of,
 966-967
- Carcinogenesis, dietary restriction effects on, 436-442
- Cardiac workload, effects of changes of, on substrate fluxes and
 myocardial insulin responsiveness, 1083-1090
- Cardiopulmonary bypass (CPB), TBG cleavage during, 1113-1116
- Cardiopulmonary exercise by HTN subjects, xanthine, uric acid, and
 hypoxanthine degradation during, 646-650
- Cardiotrophin-1 (CT-1) in whole blood, stability of, 237-240
- Cardiovascular disease (CVD)
 atherothrombotic, interaction between ERT and thrombophilic
 20210 G/A prothrombin gene mutation for, in hyperlipidemia,
 360-365
 exercising NIDDM subjects with, changes in disease and changes
 in $\dot{V}O_{2max}$, 1255-1263

Cardiovascular disease (CVD) (*Continued*)

see also Coronary artery disease; Coronary heart disease; Risk factors for CVD

Cardiovascular (CV) system, see Cardiovascular disease; Heart; Risk factors, cardiovascular entries beginning with terms: Aortic, Arterial, Coronary, Vascular specific blood vessels and specific conditions

Carotenoids

effects of, on concentrations of plasma ubiquinone-10 and fat-soluble antioxidants, 525, 526

in NIDDM and nondiabetic subjects, antioxidant status and, 1155-1158

Carotid artery

correlation between concentrations of serum VEGF and distensibility of, in IDDM and nondiabetic subjects, 825-829

relation between HDL *PON1* gene M/L55 polymorphism and atherosclerosis of, in smoking and nonsmoking men, 1095-1101

Catecholamines

in hepatic glucose production regulation, 744-746

see also Dopamine; Epinephrine; Norepinephrine

Caucasian subjects, see Race and ethnicity

CBF (cerebral blood flow) in older subjects, effects of L-NMMA on, 195

CBG (corticosteroid binding globulin), serum, effects of changes in glucose, insulin, and IGF-1 level on, in lean and obese subjects and in obesity with glucose intolerance, 1248-1252

CE(s) (cholesterol esters), relationship of PL fatty acids and dietary serum, to markers of IR, in men and women, glucose tolerance and, 86-92

Cell adhesion, monocyte-endothelial, LDL-induced soluble cell adhesion molecules and, and autoantibodies to oxidized LDLs in CRF subjects on hemodialysis, 207-215

Cell death (apoptosis), effects of suppressed intestinal, on small intestinal mucosa thickness in STZ-DM, 259-264

Cell differentiation of preadipocyte stromal cells and adipocytes, TZDs and glucocorticoids inducing, 407-413

Cell proliferation

balloon-injured vascular smooth muscle, pioglitazone effects on, 955-962

pancreatic islet, systemic bromocriptine/SKF38393 effects on, in obesity, 1379-1380

peripheral blood mononuclear, effects of PBMC total Cu⁺⁺ and Zn⁺⁺ on, in hemodialysis patients, 270-276

Central precocious puberty (CPP), effects of estrogen and androgen on bone maturation and BMD in, 377-379

Centripetal obesity, metformin reduction of, in nondiabetic morbidly obese subjects with BMI greater than 30, 856-861

Cerebral blood flow (CBF) in older subjects, effects of L-NMMA on, 195

Ceruloplasmin

in IDDM, apo A-IV concentrations and, 1022

in NIDDM, 285

CETP, see: CETP gene locus; Cholesteryl ester transfer protein

CETP gene locus, association between plasma Lp levels and TaqIB polymorphism of, in FH, 651-656

cGMP (cyclic guanosine 3',5'-monophosphate), and NO-induced glucagon secretion from pancreatic alpha cells, 703-707

CHD, see Coronary heart disease

Childhood-to-adulthood lipoprotein (Lp) variables in CHD parent offspring, 1441-1446

Children

distribution and correlates of HDL subclasses in, by race, 370-376

ketone production by fasting MCAD-deficient, 161-165

Children (*Continued*)

leptin in, see Leptin in children

obese, see Children, obese

prepubertal, see Prepubertal children

see also Childhood-to-adulthood lipoprotein; Family history; Neonatal growth restriction; Offspring

Children, obese

changes in obesity related to changes in CVD risk in, 299-305

hemostatic and metabolic abnormalities in, relationship between AT and AT distribution in, 681-687

see also Children, weight loss by obese

Children, weight loss by obese

effects of short-term weight loss on metabolic complications, 1323-1329

homocysteine during weight loss, 1220-1223

Chinese subjects

Chinese women with NIDDM, insertion/deletion of *ACE* gene associated with ACE inhibitor-related cough in, 1346-1350

urinary excretion of epinephrine and NE related to obesity, insulin, and metabolic syndrome in, 135-143

Chitotriosidase genotype frequency, serum, atorvastatin and bezafibrate effects on, in combined hyperlipidemia, 447-450

Chloride, see Cl

CHO(s), see Carbohydrate(s) during exercise; Carbohydrate intake

Cholesterol (C)

in adolescents having been SGA neonates, serum leptin relationship to, 1143, 1144

aerobic exercise effects and, 842, 845

and atherosclerosis in MI survivors and their spouses, 27

basal and PP serum-promoted efflux of, in normolipidemia, 1330-1335

blood, aspirin effects on, in copper deficiency, 558-561

in CAD, see Diabetes mellitus, CAD and

dietary, see Dietary cholesterol

effects of plant stanol FA esters on hepatic HMG-CoA reductase activity and absorption of, 1106-1112

and glucose rate of appearance following galactose ingestion, 95

hepatic, effects of apo E deficiency on plasma and fecal sterol levels, LDL receptor function, and synthesis of bile acids and, probucol and/or phytosterol therapy for, 708-714

in hyperlipidemia, see Cholesterol in hyperlipidemia

in lactating women with GDM history, 717

in NIDDM, see Cholesterol in NIDDM

in NTG and HTG, 279, 280

in obese children, short-term weight loss effects on, 1324, 1326, 1327

in obese women, see Cholesterol in obese women

plasma, see Plasma cholesterol

in sisosterolemia, 1227

synthesis and accretion of, in fetus and neonates, 12-18

in 3-month-old offspring, restricted maternal Fe and, 566

very-high-fiber vegetable, fruit, nut diet effects on, 497

see also Cholesterol esters; Cholesterol precursors; High-density lipoprotein-cholesterol; Hypercholesterolemia; Low-density lipoprotein-cholesterol; Total cholesterol; Very-low-density lipoprotein-cholesterol

Cholesterol esters (CEs), relationship of PL fatty acids and dietary serum, to markers of IR in men and women, glucose tolerance and, 86-92

Cholesterol (C) in hyperlipidemia

in hyperlipidemic women, atherothrombotic disease and, 362

in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731

- Cholesterol (C) in hyperlipidemia (*Continued*)
see also Familial hypercholesterolemia; Hypercholesterolemia in CAD
- Cholesterol (C) in NIDDM
 with ACE gene I/D, 1348
 acylation-stimulation protein-CRP relation and, 285
 in exercising NIDDM subjects with cardiovascular disease, changes in disease and $\dot{V}O_{2\max}$ changes in, 1258, 1260, 1261
 in lean Japanese subjects, bezafibrate effects on, 478
- Cholesterol (C) in obese women
 relationship between IR, weight loss, and risk of CAD in, 796, 798
 serum leptin, blood pressure and, 326
- Cholesterol (C) precursors, effects of plant FA stanol ester mixtures on, 522-523
- Cholesteryl ester transfer protein (CETP)
 lipoprotein profile and, in neonates, birth weight and, 723-728
see also CETP gene locus; Plasma cholesteryl ester transfer protein
- Cholinesterase in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
- CHP (cyclo [his-pro]), antidiabetic activities of zinc, arachidonic acid and, in STZ-DM, 53-59
- Chromium (Cr), tissue contents and subcellular distribution of cobalt, iron, copper, selenium, and zinc in DM, 1168-1174
- Chromosome(s), translocation of GLUT4, in WAT, 674-680
- Chromosome 4 segment (*D4Mit6-Npy* ~1 cm), effects of, on total serum lipids and lipoproteins after high-fat, high-cholesterol diet, 458-462
- Chronic hyperglycemia, effects of inflammation, fat malabsorption or, on apo A-IV concentration in IDDM secondary to chronic pancreatitis, 1019-1024
- Chronic obstructive pulmonary disease (COPD)
 effects of long-term inhaled beclomethasone dipropionate on osteocalcin levels in, 1336-1339
 effects of severity of, on thyroid function, 1397-1401
- Chronic pancreatitis, effects of chronic hyperglycemia, inflammation, or dietary fat malabsorption on apo A-IV concentration in DM secondary to, 1019-1024
- Chronic renal failure, *see* Chronic renal failure, hemodialysis for; Diabetes mellitus with CRF; Supplementation in CRF
- Chronic renal failure (CRF), hemodialysis for
 effects of PBMC total Cu^{++} and Zn^{++} on PBMC proliferation in, 270-276
 LDL-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized LDLs in, 207-215
- Cigarette smoking, *see* Smoking
- Ciprofibrate, gemfibrozil versus, for mixed hyperlipidemias, 729-733
- Circulating free fatty acids (FFAs), inverse relationship between insulin time series disorderliness and, and circulating insulin levels in healthy and NIDDM subjects, 41-46
- Circulating granulocyte-macrophage colony-stimulating factor (GM-CSF), serum FA composition in men and women and, 1479-1483
- Circulating growth hormone-binding protein (GHBP), regional and, in cirrhosis, 1340-1345
- Circulating insulin, levels of, and inverse relationship between circulating FFAs and insulin time series disorderliness in healthy and NIDDM subjects, 41-46
- Cirrhosis
 circulating and regional GHBP in, 1340-1345
 free radical formation and altered PON activity in, 997-1000
- Citalopram, effects of, on hyperglycemic obesity development, 144-150
- CK (creatine kinase) in AIDS, 290
- Cl (chloride)
 furosemide effects on, 242-244
 NE effects on, 1232
 plasma, *see* Plasma Cl
 serum, in DM and CRF, systemic 11β -HSD and, 803
- CL-316243, acipimox effects on plasma FFAs mimicking effects of, in obese DM subjects, 945-951
- Clinical care of metabolically normal obese subjects, 1501-1503
- Clinical features
 of familial gout, 1203-1207
 of NIDDM, Abs to pancreatic islet cells and to glutamic acid decarboxylase in identification of type $1\frac{1}{2}$ diabetes in patients presenting with, 1008-1013
 of pycnodysostosis, 905-911
see also specific conditions
- Co (cobalt), tissue contents and subcellular distribution of iron, selenium, zinc, chromium and, in DM, 1168-1174
- CO_2 partial pressure (PCO_2) in moderate exercise, 402
- CoA, *see* entries beginning with term: Coenzyme A
- Coagulation factors, plasma, in cirrhosis, 1342
- Cobalamin, and differences in levels of, between men and women, 641-644
- Cobalt (Co), tissue contents and subcellular distribution of iron, selenium, copper, zinc, chromium and, in DM, 1168-1174
- Codons 416 and 420 variants of vitamin D-binding protein gene, haplotypes of, 367
- Coenzyme A (CoA), malonyl-, and myocardial insulin responsiveness to cardiac workload and, 1086
- Coenzyme A (CoA) dehydrogenase, fasting medium-chain acyl-, ketone production by children deficient in, 161-165
- Coenzyme A (CoA) reductase, *see* HMG-CoA reductase
- Coenzyme Q10 (ubiquinol-10), plasma, effects of plant stanol FA ester mixtures on concentrations of fat-soluble antioxidants and, 520-529
- Cold acclimation, effects of, on BAT FA synthesis in subjects on high-protein, CHO-free diet and, 1493-1498
- Collagen
 accumulation of, by mesangial cells, effects of Mn-dependent SOD on, 1043-1048
 type IV, urinary excretion of, and glomerular pathology development in DM, 1435-1440
- Collecting duct, inner medullary, angiotensin regulating ET_B in, 661-666
- Colon
 very-high-fiber vegetable, fruit, nut diet effects on function of, 494-503
see also Broccoli, effects of, on cytochrome P-450 activities in liver, kidney, and colon
- Colony-stimulating factor (CSF), circulating GM, serum FA composition in men and women and, 1479-1483
- Combined hyperlipidemias, *see* Mixed hyperlipidemias
- Complement 3 (C3) in NIDDM, 285
- Congenital adrenal hyperplasia (CAH), effects of estrogen and androgen on bone maturation and BMD in children with, 377-379
- Connecting peptides, *see* C-peptides
- Contraception, oral, effects of, on serum DHEA, 488-493
- COPD, *see* Chronic obstructive pulmonary disease
- Copper, *see* Cu
- Coprostanol, effects of, on apo E deficiency, 710

- Coronary artery disease (CAD)
 β_2 -*ADR* gene mutation and, 184-188
 DM with, RLP-C in, 1462-1465
 lipids and apo B as risk factors for, in older urban and rural Mexican subjects, 311-318
- Coronary heart disease (CHD)
 Lp variables from childhood to adulthood in offspring of parents with, 1441-1446
 relationship between IR, weight loss, and risk of, in obese women, 795-800
- Corticosteroid binding globulin (CBG), serum, effects of changes in glucose, insulin, and IGF-1 level on, in lean and obese subjects and obesity with glucose intolerance, 1248-1252
- Corticotropin-releasing hormone, *see: CRH* gene
- Cortisol (hydrocortisone)
 alcohol effects on, during acute hypoglycemia in NIDDM, 454-455
 effects of, on *p47^{phox}* subunit of NADPH oxidase, 548-552
 GH therapy effects on, in pycnodysostosis, 910
 in hepatic glucose production regulation, 744, 746
 high-fat diet effects on postabsorptive and PP, 1352
 in IDDM with DKA, 174, 175
 polymorphism of *CRH* gene regulatory region in relation to obesity, gene-gene interaction, and secretion of, 1059-1062
 serum, in pancreatic cancer, 1037
 serum cortisone/cortisol ratios in assessment of systemic 11β -HSD in healthy subjects and in DM with CRF, 801-804
- Cortisone/cortisol ratios, serum, systemic 11β -HSD assessed with, in healthy subjects and in CRF subjects with DM, 801-804
- Cough, ACE inhibitor-related, in Chinese NIDDM women, insertion/deletion of *ACE* gene and, 1346-1350
- Counterregulatory hormones, *see: Cortisol; Epinephrine; Glucagon; Growth hormone; Norepinephrine*
- CP(s), *see: C-peptides*
- CPB (cardiopulmonary bypass), TBG cleavage during, 1113-1116
- C-peptides (CPs; connecting peptides)
 in children and adolescents during weight loss and, 1221
 fasting, *see: Fasting C-peptides*
 and glucose rate of appearance following galactose ingestion, 95
 minimal model analysis and secretion rate of, in Japanese subjects with varying degrees of glucose tolerance, 812-818
 in MIS, 865
 in NIDDM, *see: C-peptides in NIDDM*
 plasma, *see: Plasma C-peptides*
 serum, *see: Serum C-peptides*
 very-high-fiber vegetable, fruit, nut diet effects on urinary excretion of, 496-498
- C-peptides (CPs; connecting peptides) in NIDDM
 acylation-stimulation protein-CRP and, 285
 fasting, in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
- CPP (central precocious puberty), effects of estrogen and androgen on bone maturation and BMD in children with, 377-379
- Cr (chromium), tissue contents and subcellular distribution of cobalt, iron, selenium, zinc and, in DM, 1168-1174
- C-reactive protein (CRP)
 acylation-stimulation protein concentration related to, in NIDDM, 283-287
 in rheumatoid arthritis, 463-467
- Creatine, effects of resistance training and, on REE and LBF, 1429-1434
- Creatine kinase (CK) in AIDS, 290
- Creatinine
 in CRF, 132
- Creatinine (*Continued*)
 differences in levels of, between men and women, 641
 and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453
 in familial gout, 1206
 furosemide effects on, 242, 243
 galactose ingestion and, 97
 in GH-deficient prepubertal children, GH therapy effects on, 544
 in hyperhomocysteinemic older subjects, 1467, 1469
 in idiopathic osteoporotic men, 913
 NE effects on urinary excretion of, 1231, 1232
 in NIDDM with *ACE* gene *1D*, 1348
 plasma, in metabolic syndrome, 137-140
 serum, *see: Serum creatinine*
 serum leptin relationship to, in adolescents having been SGA neonates, 1141-1146
- CRF, *see: Chronic renal failure, hemodialysis for; Diabetes mellitus with CRF; Supplementation in CRF*
- CRH* gene
 expression of, in cancer cachexia, 1213-1219
 polymorphism of regulatory region of, in relation to cortisol secretion, obesity, and gene-gene interaction, 1059-1062
- CRP, *see: C-reactive protein*
- Cruciferous vegetables, *see: Broccoli*, effects of, on cytochrome P-450 activities in liver, kidney, and colon
- CS-045 (troglitazone), effects of, on visceral adiposity and fatty liver associated with sulfonylureas in NIDDM, 414-417
- CSF (colony-stimulating factor), circulating GM, serum FA composition in men and women and, 1479-1483
- CT-1 (cardiotrophin-1) in whole blood, stability of, 237-240
- Cu (copper)
 deficiency in, aspirin effects on blood cholesterol in, 558-561
 tissue and subcellular distribution of, in DM, 1168-1174
see also: Cu⁺⁺ and Zn⁺⁺; Cu-Zn SOD gene expression
- Cu⁺⁺ and Zn⁺⁺ (copper and zinc), total, in PBMCs of hemodialysis patients, PBMC proliferation and, 270-276
- Cu-Zn SOD (copper-zinc superoxide dismutase)* gene expression, effects of PPAR γ and PPAR α on *p22^{phox}* message gene expression and, in HUVECs and HAECs, 3-11
- CV (cardiovascular) system, *see: Cardiovascular disease; Heart; Risk factors, cardiovascular entries beginning with terms: Aortic, Arterial, Coronary, Vascular specific blood vessels and specific conditions*
- CVD, *see: Cardiovascular disease*
- Cyanide, potassium, glucose effects on viability of hepatocytes exposed to, 342-348
- Cyanocobalamin (vitamin B₁₂), effects of folic acid, pyridoxine and, on fibrinogen, Lp(a), and Hcy in CRF, 131-134
- Cyclic acute intermittent porphyria (AIP) attacks, triptorelin with tobolone in prevention of, 995-996
- Cyclic guanosine 3',5'-monophosphate (cGMP), and NO-induced glucagon secretion from pancreatic alpha cells, 703-707
- Cyclo (his-pro) (CHP), antidiabetic activities of zinc, arachidonic acid and, in STZ-DM, 53-59
- CYP, *see: Cytochrome P-450*
- Cysteine (Cys) in IDDM and NIDDM platelets, 740
- Cytochrome (CYP) P-450 1A1, 1A, 1B2, and 3A4, role of, in 2-, 4-, and 16 α -hydroxylation of 17 β -estradiol, 1001-1003
- Cytochrome P (CYP)-450
 rifampicin effects on depressive action of IL-1 on monooxygenase system linked to, 231-236
see also: Broccoli, effects of, on cytochrome P-450 activities in liver, kidney, and colon

- Cytogenetic studies of protein malnutrition in bone marrow cells, 1025-1029
- Cytokine(s)
effects of, on metabolism of LDLs by UVECs and AECs, 99-106
in hepatic glucose production, 744, 747-748
see also specific cytokines
- Cytokine function tests in COPD, 1399
- DA (dopamine), urinary excretion of, in DMD, 1185
- DBP (diastolic blood pressure), *see* Blood pressure
- Decarboxylase
glutamic acid, Abs to pancreatic islet cells and to, in identification of type 1½ diabetes in patients presenting with NIDDM, 1008-1013
ornithine, STZ-DM effects on activity of, 261-263
- Dehydration, fasting and, in pathogenesis of diabetic ketoacidosis, 171-177
- Dehydroepiandrosterone (DHEA; β -hydroxy-5-androsten-17-one)
genome-wide linkage scan in detection of loci influencing levels of, 1315-1322
serum, in younger and older women, estrogen effects on, 488-493
- Dehydroepiandrosterone sulfate (DHEAS; β -hydroxy-5-androsten-17-one-sulfate), racial differences in patterns of familial aggregation for, and its responsiveness to endurance training, 916-920
- Dehydrogenase
fasting medium chain acyl-coenzyme A, ketone production by children deficient in, 161-165
glycerol phosphate, and TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation, 411
lactate, *see* Lactate dehydrogenase
systemic 11 β -hydroxysteroid, serum cortisone/cortisol ratios in assessment of, in healthy subjects and in DM with CRF, 801-804
- Deletion/insertion of ACE gene associated with ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
- Delta (δ) opioid receptors, and glucose uptake in SM of obese and lean DM subjects, 1402-1408
- Denervation, effects of long-term SM, on IRS-1-mediated insulin signaling in SM, 216-222
- 2-Deoxy-D-glucose, insulin effects on regional BF and uptake of, 65-73
- Deoxyribonucleic acid, *see* DNA
- Depressive action of IL-1 on cytochrome P-450-linked monooxygenase system, rifampicin effects on, 231-236
- Desmosterol, effects of, on apo E deficiency, 709
- Development, *see* Growth
- Dexamethasone (DEX)
glutamine effects on protein restriction and on dexamethasone effects on protein wasting, 293-298
long-lasting hyperleptinemia and anorexia induced by, in older subjects, 1054-1058
- DHEA, *see* Dehydroepiandrosterone
- DHEAS (dehydroepiandrosterone sulfate; β -hydroxy-5-androsten-17-one-sulfate), racial differences in patterns of familial aggregation for, and its responsiveness to endurance training, 916-920
- Diabetes mellitus (DM)
and atherosclerosis in MI survivors and their spouses, 25
and atherothrombotic disease in hyperlipidemic women, 362
CAD and, *see* Diabetes mellitus, CAD and
with CRF, *see* Diabetes mellitus with CRF
delta opioid receptors and glucose uptake in SM of lean and obese DM subjects, 1402-1408
- Diabetes mellitus (DM) (*Continued*)
diet and, *see* Diabetes mellitus, diet and
history of gestational, beta cell function and VAT in lactating women with, 715-719
with obesity, *see* Glucose uptake in DM with obesity
peripheral and hepatic gene expression in, regulated by PPAR γ and PPAR α , 963-971
resting platelets in premenopausal women with, myosin light-chain phosphorylation in, 151-156
secondary to chronic pancreatitis, effects of chronic hyperglycemia, inflammation, or dietary fat malabsorption on apo A-IV concentration in, 1019-1024
in stroke-prone subjects, phytosterolemia in, 1361-1368
tissue contents and subcellular distribution of cobalt, iron, selenium, chromium, copper, and zinc in, 1168-1174
urinary excretion of type IV collagen and glomerular pathology development in, 1435-1440
see also Diabetic ketoacidosis; Diabetic nephropathy; Diabetic retinopathy; Insulin-dependent diabetes mellitus; Japanese subjects, DM; Non-insulin-dependent diabetes mellitus; Obesity, DM with; Serum paraoxonase arylesterase in DM; Streptozotocin-induced diabetes mellitus and *entries beginning with term*: Diabetic
- Diabetes mellitus (DM), CAD and
 β_2 -ADP gene mutation and, 186
RPL-C in, 1462-1465
- Diabetes mellitus (DM), diet and
family history of DM and physical activity effects on dietary fat intake, 1188, 1189
high-fructose diet effects on preservation of beta-cell mass and DM prevention in non-obese subjects, 1369-1376
- Diabetes mellitus (DM) with CRF
with LDL-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized LDLs, 208
systemic 11 β -HSD in, serum cortisone/cortisol ratio assessment of, 801-804
- Diabetic dyslipoproteinemia, severe hypercholesterolemia with, atorvastatin effects in, 984, 986
- Diabetic ketoacidosis (DKA), fasting and dehydration in pathogenesis of, 171-177
- Diabetic nephropathy, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity in, 1014-1018
- Diabetic retinopathy in adolescents and young adults, race and blood glucose modulation of serum PON arylesterase activity and concentration in, 657-660
- Diagnosis of metabolically normal obesity, 1501
- Dialysis, *see* Chronic renal failure, hemodialysis for
- Diastolic blood pressure, *see* Blood pressure
- Diet, *see* Calories; Fasting; Food intake; Malnutrition; Meals; Obesity, diet-induced; Starvation-refeeding cycles; Supplementation *entries beginning with term*: Dietary specific diets, food groups, and food substances
- Dietary cholesterol (C)
chromosome 4 segment (*D4Mit6-Npy* ~1 cm) effects on total serum lipids, and lipoproteins after high-fat, high-cholesterol diet, 458-462
IR and, *see* Dietary cholesterol, and IR
in LF, MAF, tofu, and MOS meals, 506
in very-high-fiber vegetable, fruit, nut diet, 496
- Dietary cholesterol (C), and IR
in insulin-resistant PM women, 594-597
and relationship of dietary fat, serum CEs, and PL FAs to markers of IR, 88

- Dietary cholesterol esters (CEs), serum, relationship between PL fatty acids and, to markers of IR, glucose tolerance and, 86-92
- Dietary fat
- Ala54Threo polymorphism of *FABP2* gene in Korean men associated with hyperinsulinemia and increased oxidation of, but not with intestinal FA absorption, 473-476
 - in dyslipidemic older subjects, 314, 315
 - effects of chronic hyperglycemia, inflammation, or malabsorption of, on apo A-IV concentration in IDDM secondary to chronic pancreatitis, 1019-1024
 - in high-fructose diet, 1370
 - and insulin action on serum PL FA composition in NIDDM, 1473
 - insulin resistance and, *see* Insulin resistance, dietary fat and IR and, *see* Dietary fat, IR and
 - in LF, MAF, tofu, and MOS meals, 506
 - see also* High-fat diet; High-fat, high-cholesterol diet
- Dietary fat, IR and
- physical activity effects on IR association with dietary fat, 1186-1192
 - relationship of serum CEs, PL FA markers, and dietary fat to IR markers, 88
- Dietary fatty acids, *see* Fatty acids
- Dietary fiber, *see* Fiber
- Dietary protein
- EE following glucose load before and after KSVLPD in CRF subjects, 335-341
 - in high-fructose diet, 1370
 - in IDDM, apo A-IV concentrations and, 1020
 - and insulin action on serum PL FA composition in NIDDM, 1473
 - intake of, in gout, VAT accumulation and, 395, 397
 - in LM, MAF, tofu, and MOS meals, 506
 - restriction of, glutamine effects on protein wasting due to dexamethasone and, 293-298
 - in very-high-fiber vegetable, fruit, nut diet, 496
 - see also* Dietary protein, and IR; Dietary protein malnutrition; High-protein, carbohydrate-free diet
- Dietary protein, and IR
- glucose tolerance and, 86-92
 - and physical activity effects on IR association with dietary fat intake, 1188
- Dietary protein malnutrition, cytogenetic studies of, in bone marrow cells, 1025-1029
- Dietary restriction (DR)
- effects of, on appendicular bone, 436-442
 - maternal Fe, effects of, on BP, glucose tolerance, and serum lipids in 3-month-old offspring, 562-567
 - of protein, glutamine effects on protein wasting due to dexamethasone and, 293-298
 - starvation-refeeding cycles, lipogenic enzyme mRNA in WAT after, 734-738
- N,N-Dimethylglycine in HIV infection during short-term HAART, 1275-1281
- Dimethylbiguanide, *see* Metformin
- Disease severity, *see* Severity of disease
- Dismutase, superoxide, *see* Superoxide dismutase
- Distensibility, carotid artery, correlation between serum VEGF concentrations and, in IDDM and nondiabetic subjects, 825-829
- Diversion, biliopancreatic, opioid dysregulation after, and naloxone effects on GHRH-induced PP and preprandial GH release after BPD-induced weight loss, 382-386
- DKA (diabetic ketoacidosis), fasting and dehydration in pathogenesis of, 171-177
- DM, *see* Diabetes mellitus
- DMD (Duchenne muscular dystrophy), paradoxical weight loss with extra EE at BAT in adolescents with, 1181-1185
- DNA (deoxyribonucleic acid)
- in STZ-DM, 261-262
 - systemic bromocriptine/SKF38393 effects on pancreatic islet, in obesity, 1379
- Dopamine (DA), urinary excretion of, in DMD, 1185
- Dose, sibutramine with low-dose leptin for diet-induced obesity, 889-893
- DR, *see* Dietary restriction
- Duchenne muscular dystrophy (DMD), paradoxical weight loss with extra EE at BAT in adolescents with, 1181-1185
- Duodenal/pancreatic homeobox, and FFA effects on beta cell function, 613-618
- Dyslipidemia
- in metabolic syndrome, 137
 - obesity and, in young adults, *APOE* gene polymorphism modulating association between, 696-702
 - see also* Dyslipoproteinemia; Hypercholesterolemia; Hyperlipidemia(s); Hypertriglyceridemia
- Dyslipoproteinemia
- diabetic, severe hypercholesterolemia with, atorvastatin effects in, 984, 986
 - and risk of atherosclerosis in primary, 166-170
 - see also* Hyperlipoproteinemia
- Dystrophy, Duchenne muscular, paradoxical weight loss with extra EE at BAT in adolescents with, 1181-1185
- E, *see* Epinephrine
- E₂, *see* Estradiol; 17 β Estradiol
- ECs, *see* Vascular endothelial cells
- EE, *see* Energy expenditure
- Elastase, effects of, on TBG, 1114
- Elderly subjects, *see* Older subjects
- Endothelial cells, *see* Vascular endothelial cells
- Endothelial growth factor, serum vascular, in IDDM and nondiabetic subjects, correlation between carotid artery distensibility and, 825-829
- Endothelin-1 (ET-1) gene expression, NOS levels and, in fructose-induced hypertension, 74-78
- Endothelin_B (ET_B) receptor, angiotensin regulation of, in IMCD, 661-666
- End-stage renal disease, *see* Chronic renal failure, hemodialysis for; Diabetes mellitus with CRF; Supplementation in CRF
- Endurance exercise
- β_2 -*ADR* gene Gln27Glu mutation and, 1391-1392
 - effects of creatine and, on REE and LBF, 1429-1434
 - racial differences in patterns of familial aggregation for DHEAS and its responsiveness to, 916-920
- Energy balance, body composition and, of PM women, short-term HRT effects on, 265-269
- Energy expenditure (EE)
- by exercising NIDDM subjects, 1137
 - extra, at BAT in adolescents with DMD, paradoxical weight loss with, 1181-1185
 - and physical activity effects on IR association with dietary fat intake, 1188, 1189
 - pre- and post-KSVLPD, in CRF, 335-341
 - sibutramine and low-dose leptin effects on, 891
 - see also* Resting energy expenditure
- Energy intake, *see* Calories
- Environmental factors, influence of, on *APOE* gene polymorphism effects on plasma lipid concentrations, 936-944

- Epinephrine (E; EPI; adrenaline)
 and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453, 1455
 during exercise, *see* Epinephrine during exercise
 in IDDM with DKA, 174, 175
 plasma, *see* Plasma epinephrine
 urinary excretion of, related to obesity, insulin, and metabolic syndrome in Chinese subjects, 135-143
- Epinephrine (E; EPI; adrenaline) during exercise
 CHO oxidation and, 852
 moderate exercise, 401
- ERT (estrogen replacement therapy), *see* Hormone replacement therapy, PM women on
- Erythrocyte (red blood cell; RBC) folate, and differences in levels of, between men and women, 641, 642, 644
- Erythrocyte (red blood cell; RBC) membrane lipids, *APOE* gene polymorphism effects on composition of, in essential hypertension, 157-160
- ESRD (end-stage renal disease), *see* Chronic renal failure, hemodialysis for; Diabetes mellitus with CRF; Supplementation in CRF
- Essential hypertension, *see* Hypertension
- Estradiol (E_2)
 and CV risk factors in men, 882-888
 in young adult men, race and, 1243
- 17 β (beta) Estradiol (E_2)
 and differences in levels of between men and women, 641, 644
 role of cytochrome P-450 1A1, 1A, 1B2, and 3A4 in 2-, 4-, and 16 α -hydroxylation of, 1001-1003
- Estrogen
 effects of, on bone maturation and BMD in children with CAH and/or CPP, 377-379
 effects of, on serum DHEA in younger and older women, 488-493
- Estrogen replacement therapy, *see* Hormone replacement therapy, PM women on
- ET-1 (endothelin-1) gene expression, NOS levels and, in F-induced hypertension, 74-78
- ET_B (endothelin_B) receptor, angiotensin regulating, in IMCD, 661-666
- Ethnicity, *see* Race and ethnicity
- Evening primrose oil, effects of ALA or, on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in STZ-DM, 868-875
- Exendin-4, insulinotropic actions of, 583-589
- Exercise
 and abdominal AT distribution in premenopausal and postmenopausal women, 976-982
 acute, effects of protein wasting in AIDS on protein metabolic response to, 288-292
APOE gene polymorphism and, 938
 cardiopulmonary, by HTN subjects, xanthine and uric acid degradation during, 646-650
 CHOs during, *see* Carbohydrate(s) during exercise
 effects of, on dietary fat intake/IR association, 1186-1192
 effects of, on metformin and acarbose efficacy, 1049-1053
 endurance, *see* Endurance exercise
 hypoxanthine and, *see* Hypoxanthine, exercise and
 minimal model analysis of insulin sensitivity in, fasting RER and, 1286-1293
 moderate, *see* Moderate exercise
 in NIDDM, *see* Non-insulin-dependent diabetes mellitus, exercise effects in
 by older subjects, antipyrine oxidation and oxidative stress induced by, 1484-1488
- Exercise (*Continued*)
see also Exercise by obese subjects; Men, exercising; VO_2 during exercise; Women, exercising
- Exercise by obese subjects
 changes in serum hypoxanthine levels in, 627-630
 unaffected by exercise-induced increase in hexokinase II mRNA, 602-606
- Extracellular pH in KCN- and IAA-exposed hepatocytes, 344-345
- Ezetimibe (SCH 58235 or SCH 48461) with HMG-CoA reductase inhibitors, hypocholesterolemic effects of, 1234-1241
- F (fructose), ET-1 gene expression, NOS levels and, in hypertension induced by, 74-78
- FA(s), *see* Fatty acids
- FABP2* gene, *see* Ala54Threo polymorphism of *FABP2* gene
- FAI, *see* Free androgen index
- Familial aggregation for DHEAS, racial differences in patterns of, and its responsiveness to endurance training, 916-920
- Familial gout, clinical features of, and genetic associations with related disorders, 1203-1207
- Familial hypercholesterolemia (FH)
 association between plasma Lp levels and TaqIB polymorphism in *CETP* gene locus in, 651-656
 hemorrhologic abnormalities and atherosclerotic risks in, 166-170
 heterozygous, LDL effects on apo A-I kinetics in, 635-639
- Familial hypertriglyceridemia (FHTG), hemorrhologic abnormalities and atherosclerotic risks in, 166-170
- Family history
 of DM, and physical activity effects on IR association with dietary fat intake, 1188, 1189
 of pycnodysostosis patients, 906
see also Children; Offspring
- Farnesol derivatives, effects of, on A11-*trans*-retinoic acid metabolism, 1356-1360
- Fasting
 dehydration and, in pathogenesis of diabetic ketoacidosis, 171-177
 hyperinsulinemia compared with short-term, in suppression of insulin secretion in obese men, 107-111
 in NIDDM, quantitative contributions of gluconeogenesis to glucose production during, 47-52
see also entries beginning with term: Fasting
- Fasting blood glucose (FBG)
 in diabetic nephropathy, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity and, 1015
 in DM with CRF, systemic 11 β -HSD and, 803
 in fasting MCAD-deficient children, 162, 163
- Fasting cholesterol (C) in morbidly obese adolescents, metformin effects on, 1460
- Fasting C-peptides (CPs; connecting peptides)
 in normotensive offspring of hypertensive parents, 931
 in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
 serum, *see* Fasting serum C-peptides
- Fasting free fatty acids (FFAs; nonesterified fatty acids)
 in morbidly obese adolescents, metformin effects on, 1460
 and RXR expression in skeletal muscle of nondiabetic and obese NIDDM subjects, 835
- Fasting glucose
 in adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 Ala54Threo polymorphism of *FABP2* gene and, *see* Fasting glucose, Ala54Threo polymorphism of *FABP2* gene and
 circulating GM-CSF, serum FA composition and, 1480
 in DM, *see* Fasting glucose in DM

- Fasting glucose (*Continued*)
 and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
 HF diet effects on, 1372
 in lean subjects, effects of changes in glucose, IGF-1, and insulin level on, 1249
 in metabolic syndrome, 137-140
 in nondiabetic subjects, *see* Fasting glucose in nondiabetic subjects
 in obesity, *see* Fasting glucose in obesity
 and pancreatic polypeptide secretion, 224
 plasma, *see* Fasting plasma glucose
 serum, *see* Fasting serum glucose
- Fasting glucose, Ala54Threo polymorphism of *FABP2* gene and effects on, 474
 in older women, insulin sensitivity and, 1103
- Fasting glucose in DM
 in diabetic PM women on HRT, serum PON arylesterase effects on, 321
 in IDDM, carotid distensibility, serum VEGF and, 827
 in lactating women with GDM history, 717
 serum, *see* Fasting serum glucose in DM
see also Fasting glucose in NIDDM
- Fasting glucose in NIDDM
 in lean Japanese subjects, bezafibrate effects on, 478
 and RXR expression in skeletal muscle of obese NIDDM subjects, 835
 serum, acylation-stimulation protein-CRP relation and, 284
see also Fasting plasma glucose in NIDDM
- Fasting glucose in nondiabetic subjects
 carotid distensibility, serum VEGF and, 827
 and RXR expression in skeletal muscle of nondiabetic subjects, 835
- Fasting glucose in obesity
 with and without glucose intolerance, effects of changes in glucose, IGF-1, and insulin level on, 1249
 with and without hyperinsulinemia, 180
 in morbidly obese adolescents, metformin effects on, 1460
 polymorphism of *CRH* gene regulatory region and, 1060
 and RXR expression in skeletal muscle of obese NIDDM subjects, 835
- Fasting immunoreactive insulin (iri)
 and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
 in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
- Fasting insulin
 gene polymorphism and, *see* Fasting insulin, gene polymorphism and
 HF diet effects on, 1372
 in hypertensive subjects and their normotensive offspring, 931, 932
 immunoreactive, *see* Fasting immunoreactive insulin
 in IR, *see* Fasting insulin in IR
 in lactating women with GDM history, 717
 in metabolic syndrome, 137-140
 in morbidly obese adolescents, metformin effects on, 1460
 in NIDDM, *see* Fasting insulin in NIDDM
 in obesity, *see* Fasting insulin in obesity
 serum, *see* Fasting serum insulin
- Fasting insulin, Ala54Threo polymorphism of *FABP2* gene and effects of, 474
 in older women, insulin sensitivity and, 1103
- Fasting insulin, gene polymorphism and of *CRH* gene regulatory region, 1060
- Fasting insulin, gene polymorphism and (*Continued*)
 insulin sensitivity and Ala54Threo gene polymorphism in older women, 1103
see also Fasting insulin, Ala54Threo polymorphism of *FABP2* gene and
- Fasting insulin in IR
 dietary fat, serum CEs, PL FAs and, 88, 90
 and MI prior to age 40 associated with IR, 31
- Fasting insulin in NIDDM
 in lean Japanese subjects, bezafibrate effects on, 478
 plasma, exercise effects on, 1138
 and RXR expression in skeletal muscle of nondiabetic and obese NIDDM subjects, 833
 serum, *see* Fasting serum insulin in NIDDM
- Fasting insulin in obesity
 with and without hyperinsulinemia, 180
 polymorphism of *CRH* gene regulatory region and, 1060
 and RXR expression in skeletal muscle of obese NIDDM subjects, 833
- Fasting leptin in morbidly obese adolescents, metformin effects on, 1460
- Fasting medium-chain acyl-coenzyme A dehydrogenase (MCAD), ketone production by children deficient in, 161-165
- Fasting plasma cholesterol (C) in IR with HTN, 1449, 1450
- Fasting plasma glucose (FPG)
 in fasting MCAD-deficient children, ketone production and, 162
 in gout, 394, 396
 in IDDM, apo A-IV concentrations and, 1020
 in IR with HTN, 1449, 1450
 in mixed hyperlipidemias, 731
 in older men, and changes in leg BF and capillary density in SM, 1080
 in pancreatic cancer, 1037
 in young and older Japanese men, effects of β_2 -*ADR* gene Trp64Arg polymorphism and *FABP2* gene Ala54Threo polymorphism on insulin resistance and, 1301-1307
see also Fasting plasma glucose in NIDDM
- Fasting plasma glucose (FPG) in NIDDM
 aminophylline effects on insulin secretion, 1031
 with hyperlipidemia, simvastatin effects and, 356
 insulin action on, serum PL FA composition and, 1473
 insulin secretory dysfunction, IR and, in Korean subjects, 591
 IVGTT modeling and, 513
 platelet taurine fluxes and, 61
 polymorphisms of insulin gene and, 631
 prostacyclin-induced skin BF changes and, 569
 with sulfonylurea-associated fatty liver, 415, 416
- Fasting plasma high-density lipoprotein-cholesterol (HDL-C) in IR with HTN, 1449, 1450
- Fasting plasma insulin
 in IR with HTN, 1449, 1450
see also Fasting plasma insulin in NIDDM
- Fasting plasma insulin in NIDDM
 aminophylline effects on insulin secretion, 1031
 exercise effects on, 1138
 insulin secretory dysfunction, IR and, in Korean subjects, 591
 polymorphisms of insulin gene and, 631
- Fasting plasma low-density lipoprotein-cholesterol (LDL-C) in IR with HTN, 1449, 1450
- Fasting plasma triglycerides (TG) in IR with HTN, 1449, 1450
- Fasting respiratory exchange ratio (RER) in athletes, minimal model analysis of insulin sensitivity and, 1286-1293
- Fasting serum C-peptides (CPs; connecting peptides)
 and MI prior to age 40 associated with IR, 31

- Fasting serum C-peptides (CPs; connecting peptides) (*Continued*)
 in pancreatic cancer, 1037
 polymorphisms of insulin gene and, in NIDDM, 631
- Fasting serum glucose
 and MI prior to age 40 associated with IR, 31
see also Fasting serum glucose in DM
- Fasting serum glucose in DM
 in diabetic premenopausal women, 153
 in NIDDM, acylation-stimulation protein-CRP relation and, 284
- Fasting serum insulin
 metformin effects on, in nondiabetic morbidly obese subjects, 858
 and MI prior to age 40 associated with IR, 31
 in older men, and changes in leg BF and capillary density in SM, 1080
 in pancreatic cancer, 1037
see also Fasting serum insulin in NIDDM
- Fasting serum insulin in NIDDM
 in Korean subjects, 591
 polymorphisms of insulin gene in Japanese subjects, 631
- Fasting serum triglycerides (TGs), HF diet effects on, 1372
- Fat, *see* Dietary fat and entries beginning with terms: Fat, Fatty elements: Adip-, Lip- and specific types of fat
- Fat-free mass (FFM)
 in anorexic subjects, 877
 of cirrhotic subjects, 1342
 in CRF, KSVLPD effects on, 337
 and CV risk factors in men, 884
 and differences between tHcy in men and women, 641, 644
 in DMD subjects, 1182
 exercise and, *see* Fat-free mass, exercise and
 of GH-deficient prepubertal children, GH therapy effects on, 537-547
 and homocysteine during weight loss by obese children and adolescents, 1220-1223
 limit to body's ability to increase, 1004-1007
 in obesity, *see* Fat free mass in obese subjects
 in older subjects, RMR and, 973
 and pancreatic polypeptide secretion, 224
 in PM women, *see* Fat-free mass in PM women
 in premenopausal women, abdominal AT distribution and, 978
 and protein wasting in AIDS, 290
 and thermic effect of SMLCTs versus LCTs, 126
- Fat-free mass (FFM), exercise and
 creatine and endurance exercise effects on REE and LBF, 1431, 1432
 exercising NIDDM subjects with cardiovascular disease, 1258, 1260, 1261
- Fat-free mass (FFM) in obese subjects
 morbidly obese adolescents, metformin effects on, 1459
 short-term weight loss effects on, 1326
- Fat-free mass (FFM) in PM women
 abdominal AT distribution and, 978
 short-term HRT effects on, 267
- Fat mass (FM)
 in adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 in anorexic subjects, 877
 of cirrhotic subjects, 1342
 in CRF, KSVLPD effects on, 337
 and CV risk factors in men, 886
 distribution of, and basal and PP serum-promoted C efflux in normolipidemia, 1330-1335
 effects of, on RMR in older subjects, 972-975
 exercise and, *see* Fat mass, exercise and
- Fat mass (FM) (*Continued*)
 in GH-deficient prepubertal children, GH therapy effects on, 537-547
 and pancreatic polypeptide secretion, 224
 in PM women, *see* Fat mass in PM women
 in premenopausal women, abdominal AT distribution and, 978
- Fat mass (FM), exercise and
 aerobic exercise effects, 842, 847
 creatine and endurance exercise effects on REE and LBF and, 1431, 1432
 in NIDDM with cardiovascular disease, changes in disease and $\dot{V}_{O_{2max}}$ and, 1258, 1260, 1261
- Fat mass in PM women
 abdominal AT distribution and, 978
 short-term HRT effects on, 267
- Fat-soluble antioxidants, effects of plant stanol FA ester mixtures on concentrations of plasma ubiquinol-10 and, 520-529
- Fatty acids (FAs)
 synthesis of BAT, in subjects on high-protein, CHO-free diet, 1493-1498
see also Ala54Threo polymorphism of *FABP2* gene; Free fatty acids; Monounsaturated fatty acids; Phospholipid fatty acids; Plant stanol fatty acid esters; Polyunsaturated fatty acids; Serum fatty acids; Saturated fatty acids
- Fatty liver associated with sulfonylureas, troglitazone effects on VAT and, in NIDDM, 414-417
- FBG, *see* Fasting blood glucose
- Fe, *see* Iron
- Fecal sterols, effects of apo E deficiency on hepatic cholesterol and bile acid synthesis, LDL receptor function, levels of plasma and, probucol and/or phytosterol therapy for, 708-714
- Female subjects
 resistance to actions of vascular insulin/IGF-1 in, 607-612
see also Women
- Femoral artery, glucose concentrations in, 191
- Femoral artery growth hormone-binding protein (GHBP) in cirrhosis, 1343
- Femoral bone, DR effects on, 438, 439
- Femoral vein growth hormone-binding protein (GHBP) in cirrhosis, 1342, 1343
- Ferritin, plasma, in Cu deficiency, 559
- Fetal cholesterol (C), synthesis and accretion of, 12-18
- Fetal growth restriction, membrane phospholipid fatty acid composition, insulin sensitivity and, 1070-1077
- FFAs, *see* Free fatty acids
- FFM, *see* Fat-free mass
- FH, *see* Familial hypercholesterolemia
- FHTG (familial hypertriglyceridemia), hemorrhheologic abnormalities and atherosclerotic risks in, 166-170
- Fiber
 and dyslipidemia in older subjects, 314, 315
 effects of very-high-fiber vegetable, fruit, nut diet on serum lipids and colonic function, 494-503
 in IR, 88, 1188
- Fibrinogen
 effects of vitamin B₆, folic acid, and cyanocobalamin on Lp(a), Hcy and, in CRF, 131-134
 in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731
 in obese children, metabolic and hemostatic abnormalities and, 682, 684, 685
 in primary dyslipoproteinemias, 167
- Fibrinogen haptoglobin in IDDM, apo A-IV concentrations and, 1022

- Fibroblasts, renal interstitial, glucose effects on hyaluronan production by, through PKC and TGF- β cascade, 789-794
- 58T/C polymorphism of bradykinin B2 receptor gene not associated with ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
- Fluid intake
vanadium effects on, 669
see also Alcohol consumption
- 1,4-Fluorophenyl-3(R)-3(s)-hydroxy-3-(4-fluorophenyl)[propyl]-4(s)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe; SCH 58235 or SCH 48461), hypocholesterolemic effects of lovastatin with, 1234-1241
- Fluvastatin, effects of ezetimibe with, on hypercholesterolemia, 1234-1241
- FM, *see* Fat mass
- Folate
during HAART, 1278
plasma, differences in, between men and women, 641, 642, 644
serum, in hyperhomocysteinemic elder subjects, 1467, 1469
during weight loss by obese children and adolescents, 1220-1223
- Folic acid, effects of pyridoxine, cyanocobalamin and, on fibrinogen, Lp(a), and Hcy, in CRF, 131-134
- Follicle-stimulating hormone (FSH) in young adult men, race and, 1243
- Follow-up of metabolically normal obese subjects, 1501
- Food intake
exercise effects on, 1050
and lipogenic enzyme mRNA in WAT after starvation-refeeding cycles, 734-738
low-dose sibutramine and low-dose leptin effects on obesity related to, 889-893
STZ-DM effects on, 261-262
vanadium effects on, 669-671
see also Calories; Fasting; Meals; Starvation-refeeding cycles; Supplementation entries beginning with term: Dietary and specific diets
- 40 year-old subjects, MI in subjects younger than, associated to IR, 30-35
- FPG, *see* Fasting plasma glucose
- Free androgen index (FAI)
and CV risk factors, 882-888
PP changes in men's, in response to FL, MAF, tofu, and MOS meals, 506
- Free cholesterol (C), plasma, in apo E deficiency, probucol and/or phytosterol therapy effects on, 709
- Free fatty acids (FFAs; nonesterified fatty acids)
Ala54Threo polymorphism of *FABP2* gene and, *see* Free fatty acids, Ala54Threo polymorphism of *FABP2* gene and
in DM, *see* Free fatty acids in DM
effects of, on beta cell functions, involvement of PPAR α and pancreatic/duodenal homeobox in, 613-618
fasting, *see* Fasting free fatty acids
in glucanoma syndrome, 721
and glucose rate of appearance following galactose ingestion, 95
in hepatic glucose production regulation, 744, 745
in hypertensive subjects and their normotensive offspring, insulin sensitivity, Na excretion and, 931
in moderate exercise, 759
and naloxone effects on GH release after BPD-induced weight loss, 385
in obese and lean DM subjects, 1403
oral nicotine effects on, 81, 82
plasma, *see* Plasma free fatty acids
restricted maternal Fe effects on, in 3-month-old offspring, 566
- Free fatty acids (FFAs; nonesterified fatty acids) (*Continued*)
serum, *see* Serum free fatty acids
- Free fatty acids (FFAs; nonesterified fatty acids), Ala54Threo polymorphism of *FABP2* gene and
effects on, 474
with Trp64Arg β_2 -ADR gene polymorphism, 1303-1305
- Free fatty acids (FFAs; nonesterified fatty acids) in DM
blood, S₁ of blood glucose versus S₁ of, in normal, obese, and obese diabetic subjects, 573-582
in IDDM with DKA, 174, 175
see also Free fatty acids in NIDDM
- Free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
acylation-stimulating protein-CRP relation and, 285
circulating and, inverse relationship between insulin time series disorderliness and circulating insulin levels, 41-46
- Free insulin in IDDM with DKA, 173
- Free insulin like-growth factor-1 (IGF-1), effects of changes in level of glucose, insulin, and IGF-1 on, in obese and lean subjects and in obesity with glucose intolerance, 1249
- Free radicals, formation of, and altered PON activity in cirrhosis, 997-1000
- Free testosterone (FT)
high-fat diet effects on postabsorptive and PP, 1352
in idiopathic osteoporotic men, 913
- Free thyroxine (T₄) in COPD, 1398, 1399
- Free triiodothyronine (T₃) in COPD, 1398, 1399
- French subjects, race and variations in vitamin D-binding protein gene and risk of NIDDM in, 366-369
- Frequently sampled intravenous glucose tolerance test (FSIGTT)
of changes in glucose, insulin, and IGF-1 level, and their effects on serum CBG in lean and obese subjects and in obesity with glucose intolerance, 1248-1252
of lactating women with GDM history, 715, 716
in MI associated with IR, 30-35
see also specific conditions
- Fructose (F)
high-fructose diet preserving beta-cell mass and preventing diabetes in non-obese subjects, 1369-1376
hypertension induced by, ET-1 gene expression and NOS levels in, 74-78
- Fruit, very-high-fiber vegetable, fruit, nut diet effects on serum lipids and colonic function, 494-503
- FSH (follicle-stimulating hormone) in young adult men, race and, 1243
- FSIGTT, *see* Frequently sampled intravenous glucose tolerance test
- FT, *see* Free testosterone
- Furosemide, effects of, on urinary excretion of purine bases and oxypurinol, 241-245
- G/A prothrombin gene mutation, 20210 thrombophilic, for atherothrombotic CVD, interaction between ERT and, in hyperlipidemia, 360-365
- GAD (glutamic acid decarboxylase), Abs to pancreatic islet cells and to, in identification of type 1½ diabetes in patients presenting with NIDDM, 1008-1013
- Galactose, glucose appearance rate after ingestion of, 93-98
- Gamma globulin, *see* IgG
- Gamma (γ)-glutamyl transferase (GGT) in NIDDM with sulfonyleurea-associated fatty liver, troglitazone effects on, 415, 416
- Gamma (γ)-tocopherol in NIDDM and nondiabetic subjects, antioxidant status and, 1155-1158
- GCs (guanidino compounds), long-term effects of partial nephrectomy on renal histology, biological parameters and, 1418-1425

- GDM (gestational diabetes mellitus), beta cell function and VAT in lactating women with history of, 715-719
- GPDH (glycerol phosphate dehydrogenase) in TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation, 411
- Gemfibrozil
ciprofibrate versus, for mixed hyperlipidemias, 729-733
in NIDDM, serum Mg and, 1147-1151
- Gender, *see* Sex
- Gene(s)
mitochondrial, regulating beta cells, 200-206
see also Allele and allele frequency; DNA; Gene expression;
Gene-gene interaction; Genome-wide linkage scan; Genotype and genotype frequency; Haplotypes; Locus; Mutation;
Phenotypes; Polymorphism; Transgenic subjects and specific genes
- Gene expression
CRH, in cancer cachexia, 1213-1219
ET-1, fructose-induced hypertension, NOS levels and, 74-78
GLUT1 and GLUT3, subcellular redistribution of GLUT4 and altered, in acanthosis nigricans with severe IR, 771-777
PPAR α and PPAR γ , *see* Gene expression, PPAR γ and PPAR α
retinoic acid and T $_3$ nuclear receptor, effects of diet-induced obesity on, 1161-1167
RXR, in skeletal muscle of nondiabetic and obese NIDDM subjects, 830-834
see also mRNA
- Gene expression, PPAR γ , TZDs and
TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation and, 407-413
TZDs and TNF α effects on PPAR γ expression in 3T3-L1 adipocytes, 36-40, 407
- Gene expression, PPAR γ and PPAR α
effects of diet-induced obesity on, 1161-1167
see also Gene expression, PPAR γ , TZDs and; Gene expression, PPAR γ and PPAR α effects on
- Gene expression, PPAR γ and PPAR α effects on
of CuZn-SOD and p22^{phox} message gene expression in HUVECs and HAEVCs, 3-11
peripheral and hepatic, in DM, 963-971
- Gene-gene interaction
 β_2 -ADR gene Trp64Arg polymorphism and FABP2 gene Ala54Threo polymorphism effects on insulin resistance in young and older Japanese men, 1301-1307
CRH gene regulatory region polymorphism in relation to cortisol secretion in obesity, 1059-1062
between Gln27Glu mutation of β_2 -ADR gene, glucocorticoid β_2 -ADR gene polymorphism, and LPL gene, plasma insulin and lipid levels and, 246-252
- Genetic association of gout and its related disorders, 1203-1207
- Genetic control of VAT and SAT size in metabolically normal obese subjects, 1501-1502
- Genetics, *see* Chromosome(s); Chromosome 4 segment (D4Mit6-Npy -1 cm); Family history; Gene(s) and entries beginning with terms; Familial; Genetic; Heterozygous
- Genome-wide linkage scan, detection of loci influencing DHEA levels with, 1315-1322
- Genotype and genotype frequency
of APOE gene polymorphism, 27
of Gln27Glu mutation of β_2 -ADR gene, 444
serum chitotriosidase, atorvastatin and bezafibrate effects on, in combined hyperlipidemia, 447-450
of TNF- α -238 and -308 polymorphisms, 1449
- Genotype and genotype frequency (*Continued*)
of 2184A/G and 1704G/T RAGE gene polymorphisms in NIDDM and nondiabetic subjects, antioxidant status and, 1154, 1156-1159
of vitamin D-binding protein gene variants, 367
- Gestational age
and birth weight, Lp profile, CETP and, 723-728
see also Small-for-gestational age neonates
- Gestational diabetes mellitus (GDM), history of, beta cell function and VAT in lactating women with, 715-719
- GGT (γ -glutamyl transferase) in NIDDM with sulfonylurea-associated fatty liver, troglitazone effects on, 415, 416
- GH, *see* Growth hormone
- GHb (glycosylated; glycated hemoglobin), *see* HbA_{1c}
- GHP (growth hormone-binding protein), circulating and regional, in cirrhosis, 1340-1345
- GHRH (growth hormone-releasing hormone), post-BPD opioid dysregulation and naloxone effects on PP and preprandial GH release induced by, after BPD-induced weight loss, 382-386
- GK (glucokinase) in obesity, systemic bromocriptine/SKF38393 effects on GLUT2, beta-cell hyperplasia, IRL levels and, 1377-1384
- Glibenclamide, effects of, on VAT and sulfonylurea-associated fatty liver in NIDDM, 414-417
- Gliclazide, effects of, on VSMC dysfunction induced by VSMC-mediated oxidized LDLs, 688-695
- Gln, *see* Glutamine
- Gln27Glu mutation, *see* β_2 -ADR gene Gln27Glu mutation
- Glomerular pathology, urinary excretion of type IV collagen and development of, in DM, 1435-1440
- Glomerulonephritis in CRF, 208
- GLP-1 (glucagon-like peptide-1), insulinotropic actions of, 583-589
- Glu, *see* Glutamic acid
- Glucagon (hyperglycemic-glycogenolytic factor)
and glucose rate of appearance following galactose ingestion, 95
in hepatic glucose production regulation, 744, 745
in IDDM with DKA, 174
in NIDDM, *see* Glucagon in NIDDM
NO-induced secretion of, from pancreatic alpha cells, cGMP and, 703-707
in older subjects, effects of L-NMMA on, 196
in pancreatic cancer, 1040
plasma, in exercising women, 485
serum and urinary insulin response to, in MIS, 864-865
- Glucagon (hyperglycemic-glycogenolytic factor) in NIDDM
alcohol effects on, during acute hypoglycemia, 454-455
PGE $_1$ effects on, 255
- Glucagon-like peptide-1 (GLP-1), insulinotropic actions of, 583-589
- Glucanoma syndrome, AAs, lipid kinetics, and glucose following palliative resection of, 720-722
- Glucobrassicin, 1124, 1131, 1133, 1134
- Glucocheirolin, 1124, 1131, 1133, 1134
- Glucocorticoid(s), TZDs and, inducing differentiation of preadipocyte stromal cells and adipocytes, 407-413
- Glucocorticoid receptor β_2 -ADR gene, interactions between Gln27Glu mutation of β_2 -ADR gene, LPL gene and, plasma insulin and lipid levels and, 246-252
- Glucoseberverin, 1124, 1131, 1133, 1134
- Glucoseucin, 1124, 1131, 1133, 1134
- Glucoseosolin, 1124, 1131, 1133, 1134
- Glucosiberin, 1124, 1131, 1133, 1134
- Glucokinase (GK) in obesity, systemic bromocriptine/SKF38393 effects on GLUT2, beta-cell hyperplasia, IRL levels and, 1377-1384

- Glucumasturtine, 1124, 1131, 1133, 1134
 Gluconapin, 1124, 1131, 1133, 1134
 Gluconeogenesis
 in moderate exercise, 402-403
 see also Gluconeogenesis, contributions of, to glucose production
 Gluconeogenesis, contributions of, to glucose production
 measurement of, 743-744
 in NIDDM during fasting, 47-52
 Glucoraphanin, 1124, 1131, 1133, 1134
 Glucoregulatory hormones
 in hepatic glucose production, 744-749
 see also Catecholamines; Cortisol; Glucagon; Growth hormone;
 Insulin
 Glucosamine sulfate, sulfate as mediator of therapeutic effects of,
 767-770
 Glucose, 335-348
 AAs, lipid kinetics and, following palliative resection of
 glucanoma syndrome, 720-722
 ALA effects on glucose-induced IR and on *irf1* in 3T3-L1
 adipocytes, 1063-1069
 amylin secretion stimulated by, in nondiabetic subjects with
 pancreatic cancer, 1036-1042
 in anorexia nervosa, 876-881
 blood, *see* Blood glucose
 in borderline hypertensive young men with CV risk factors, 1175-
 1180
 contribution of hepatic glycogen synthesis to disposal of, 598-601
 in CRF, EE following glucose load before and after KSVLPD,
 335-341
 effects of, on hyaluronan production by renal interstitial fibroblasts
 through PKC and TGF- β cascade, 789-794
 effects of, on mitochondrial mRNA levels in beta cells, 193
 effects of, on plasma von Willebrand factor concentration, insulin
 sensitivity and, 1452-1456
 effects of, on viability of hepatocytes exposed to KCN and IAA,
 342-348
 exercise and, *see* Glucose in exercise
 in femoral artery and hepatic vein, 191
 in GH-deficient prepubertal children, GH therapy effects on, 544
 GPI-PLD expression in beta cells regulated by insulin and, 1489-
 1492
 in high-fructose diet, 1370
 in IDDM with DKA, 173-175
 in IR, plasma CETP activity and, 785
 in moderate exercise, 402-403, 759
 in NIDDM, *see* Glucose in NIDDM
 in nondiabetic subjects, serum PON arylesterase activity and, 806,
 808, 809
 in obesity, *see* Glucose in obesity
 in older subjects, *see* Glucose in older subjects
 oxidation, *see* Oxidation, glucose
 pioglitazone effects on balloon-injured VSCM proliferation and,
 957
 plasma, *see* Plasma glucose
 serum, *see* Serum glucose
 in South Asian immigrants' offspring, 1200
 steady-state plasma, *see* Steady-state plasma glucose
 see also 2-Deoxy-D-glucose; Glucose effectiveness, S_g and;
 Glucose production; Glucose rate of appearance; Glucose
 tolerance; Glucose uptake in obesity; GLUT1; *GLUT1* and
 GLUT3 gene expression; GLUT2; GLUT4; Hyperglycemia;
 Hypoglycemia and entries beginning with elements: Gluc-,
 Glyc-
 Glucose, insulin effects on BF and uptake of
 on leg BF in sickle cell disease and in healthy subjects, 387-392
 on regional BF, 65-73
 see also Insulin-mediated glucose uptake
 Glucose effectiveness (S_g), S_i and
 estimation of, in NIDDM, with physiologic modeling of IVGTT,
 512-519
 in middle-aged and young athletes versus sedentary men, 349-354
 Glucose in exercise
 exercise effects, 1050
 glucose effectiveness in middle-aged and young athletes, 349-354
 in moderate exercise, 402-403, 759
 Glucose intolerance
 obesity with or without, effects of changes in level of glucose,
 insulin, and IGF-I on serum CBG in, 1248-1252
 see also Glucose tolerance
 Glucose in NIDDM
 alcohol and glucose counterregulation during acute hypoglycemia,
 451-457
 disposal of, in older subjects, L-NMMA effects on, 194-199, 306-
 310
 insulin secretion in response to stimulation of, 1282-1285
 PGE₁ effects on, 255
 quantitative contributions of gluconeogenesis to production of,
 during fasting, 47-52
 SM PKC theta content and, 554
 Glucose in obese children
 with metabolic and hemostatic abnormalities, 682, 684, 685
 short-term weight loss effects on, 1324, 1326, 1327
 Glucose in obesity
 in obese Peruvian Indian and Caucasian women, 326
 see also Glucose in obese children; Glucose uptake in obesity
 Glucose in older subjects
 L-NMMA effects on disposal of, 194-199, 306-310
 in older hyperlipidemic subjects, coronary risk factors and, 314,
 315
 Glucose production
 hepatic, 744-749
 see also Gluconeogenesis, contributions of, to glucose production
 Glucose rate of appearance (R_a)
 following palliative resection in glucanoma syndrome, 721
 in IDDM with DKA, 174
 post-galactose ingestion, 93-98
 Glucose tolerance
 of adolescents having been SGA neonates, serum leptin
 relationship to, 1142-1143
 in DM with obesity, acipimox effects on, 947
 effects of restricted maternal Fe on blood pressure, serum lipids
 and, in 3-month-old offspring, 562-567
 exercise effects on, 1051
 HF diet effects on, 1371-1372
 Japanese subjects with varying degrees of, minimal model analysis
 and C-peptide secretion rate in characterization of
 pathophysiological phenotypes in, 812-818
 in lactating women with GDM history, 716-717
 of NIDDM subjects' offspring, autonomic balance and, 1270-1274
 relationship of dietary fat, serum CEs, and PL FAs to markers of
 IR and, 86-92
 see also Glucose intolerance; Impaired glucose tolerance;
 Intravenous glucose tolerance test; Oral glucose tolerance test
 Glucose transporters, *see* entries beginning with acronym: GLUT
 Glucose uptake, *see* Glucose uptake in obesity; Glucose, insulin
 effects on BF and uptake of; Insulin-mediated glucose uptake

- Glucose uptake in DM with obesity
 with obesity, acipimox effects on, 947-948
 by SM of lean and obese subjects with, 1402-1408
- Glucose uptake in obesity
 glycolytic flux and, by AT of subjects on high-protein, CHO-free diet, 1208-1212
 by SM, 1402-1408
see also Glucose uptake in DM with obesity
- Glucosinolates, *see* Broccoli, effects of, on cytochrome P-450 activities in liver, kidney, and colon
- GLUT1, action of BRL-49653 in skeletal muscle and AT through regulation of, 1294-1300
- GLUT1 and GLUT3 gene expression, subcellular redistribution of GLUT4 and altered, in acanthosis nigricans with severe IR, 771-777
- GLUT2
 in obesity, systemic bromocriptine/SKF38393 effects on beta-cell hyperplasia, glucokinase, irI levels and, 1377-1384
 in pancreatic cancer, 1040
- GLUT4
 action of BRL-49653 in skeletal muscle and AT through regulation of, 1294-1300
 effects of vanadium on translocation of, in WAT in STZ-DM, 674-680
 GLUT1 and GLUT3 gene expression and subcellular redistribution of, in acanthosis nigricans with severe IR, 771-777
- Glutamic acid (Glu)
 in IDDM and NIDDM platelets, 740
 relationship of Gln27Glu mutation of β_2 -*ADR* gene to obesity, IGT, and DM in Japanese subjects, 443-446
- Glutamic acid decarboxylase (GAD), Abs to pancreatic islet cells and to, in identification of type 1½ diabetes in patients presenting with NIDDM, 1008-1013
- Glutamine (Gln)
 effects of, on protein wasting due to dexamethasone and protein restriction, 293-298
 in IDDM and NIDDM platelets, 740
 relationship of Gln27Glu mutation of β_2 -*ADR* gene to obesity, IGT, and DM in Japanese subjects, 443-446
- γ (gamma)-Glutamyl transferase (GGT) in NIDDM with sulfonyleurea-associated fatty liver, troglitazone effects on, 415, 416
- Gly (glycine) in IDDM and NIDDM platelets, 740
- Glycated (glycosylated) hemoglobin, *see* HbA_{1c}
- Glycemic index of meals, effects of high or moderate, on metabolism and exercise performance of men, 849-855
- Glycerol
 following palliative resection in glucanoma syndrome, 721
 in hepatic glucose production regulation, 744
- Glycerol phosphate dehydrogenase (GPDH), and TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation, 411
- Glycine (Gly) in IDDM and NIDDM platelets, 740
- Glycogen
 exercise effects on, 1050
 hepatic, contribution of, to glucose disposal, 598-601
 intracellular, in KCN- and IAA-exposed hepatocytes, 344
 muscle, effects of high and moderate glycemic index meals on, 852
- Glycogenolysis in moderate exercise, 402-403
- Glycolytic flux in AT, effects of high-protein, CHO-free diet on glucose uptake and, 1208-1212
- Glycoprotein (GP), α -1-acid, in NIDDM, 285
- Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) mRNA (messenger ribonucleic acid) in beta cells, regulation of, by glucose and insulin, 1489-1492
- GM-CSF (granulocyte-macrophage colony-stimulating factor), circulating, serum FA composition in men and women and, 1479-1483
- GMP (guanosine 3',5'-monophosphate), cyclic, and NO-induced glucagon secretion from pancreatic alpha cells, 703-707
- Gout
 activity of HTGL and LPL in, 952-954
 familial, clinical features and genetic association of, with related disorders, 1203-1207
 VAT accumulation and risk of IR in, 393-398
- GP (glycoprotein), α -1-acid, in NIDDM, 285
- GPDH (glycerol phosphate dehydrogenase), and TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation, 411
- GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D) mRNA (messenger ribonucleic acid) in beta cells, regulation of, by glucose and insulin, 1489-1492
- G-protein, role of, in vascular insulin/IGF-1 actions, 607-612
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), circulating, serum FA composition in men and women and, 1479-1483
- Growth
 bone, effects of estrogen and androgen on BMD and, in children with CAH and/or CPP, 377-379
 fetal and neonatal restricted, membrane phospholipid fatty acid composition, insulin sensitivity and, 1070-1077
 after GH therapy of pycnodysostosis, 905-911
- Growth factors, *see specific growth factors*
- Growth hormone (GH)
 in hepatic glucose production regulation, 744-746
 in IDDM with DKA, 174, 175
 naloxone effects on GHRH-induced release of, after BPD-induced weight loss, 382-386
 in older subjects, effects of L-NMMA on glucose uptake and delivery to, 196
 plasma, *see* Plasma growth hormone
see also Growth hormone, therapy with; Growth hormone-releasing hormone
- Growth hormone (GH), therapy with
 alterations in body composition and AT distribution in GH-deficient prepubertal children during, 537-547
 of pycnodysostosis, 905-911
- Growth hormone-binding protein (GHBP), circulating and regional, in cirrhosis, 1340-1345
- Growth hormone-releasing hormone (GHRH), post-BPD opioid dysregulation and naloxone effects on PP and preprandial GH release induced by, after BPD-induced weight loss, 382-386
- Guanidino compounds (GCs), long-term effects of partial nephrectomy on renal histology, biological parameters and, 1418-1425
- Guanosine 3',5'-monophosphate (GMP), cyclic, and NO-induced glucagon secretion from pancreatic alpha cells, 703-707
- HAART (highly active antiretroviral therapy), short-term HIV infection, N-methylglycine and N,N-dimethylglycine during, 1275-1281
- HAECs (human aortic endothelial cells), *see* Aortic endothelial cells
- Haplotypes of vitamin D-binding protein gene variants, 367
- Haptoglobin
 in IDDM, apo A-IV concentrations and, 1022
 in NIDDM, 285

- Hb (hemoglobin)
and protein wasting in AIDS, 290
see also HbA_{1c}
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin)
in DM, *see* HbA_{1c} in DM
exercise and, *see* HbA_{1c}, exercise and
and hyperuricemia development in middle-aged men, 623-625
in nondiabetic subjects, *see* HbA_{1c} in nondiabetic subjects
in pancreatic cancer, 1037
Trp64Arg polymorphism of β_2 -*ADR* gene and Ala54Threo polymorphism of *FABP2* gene and, 1304
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin), exercise and effects of exercise on HbA_{1c}, 1051
and exercise effects of HKII mRNA, 603
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin) in DM
with CAD, RLP-C and, 1463, 1464
with CRF, systemic 11 β -HSD and, 803
diabetic PM women on HRT, serum PON arylesterase effects on, 321
diabetic premenopausal women, myosin light-chain phosphorylation in resting platelets from, 153
in IDDM, *see* HbA_{1c} in IDDM
in NIDDM, *see* HbA_{1c} in NIDDM
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin) in IDDM
apo A-IV concentrations and, 1020
carotid distensibility, serum VEGF and, 827
Mg effects on, 1410
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin) in NIDDM
with *ACE* gene I/D, 1348
acylation-stimulating protein-CRP relation and, 284, 285
aminophylline effects on insulin secretion, 1031
antioxidant status and, 1156
insulin gene polymorphism and, 631
in lean Japanese subjects, bezafibrate effects on, 478
with macroalbuminuria, 1194
platelet taurine fluxes and, 61
prostacyclin-induced skin BF changes and, 569, 571
and RXR expression in skeletal muscle of obese NIDDM subjects, 833
with sulfonyleurea-associated fatty liver, troglitazone effects on, 415, 416
- HbA_{1c} (hemoglobin A_{1c}; glycosylated hemoglobin) in nondiabetic subjects
carotid distensibility, serum VEGF and, 827
and Mg effects on IMGU and serum lipids, 1410
serum PON arylesterase activity and, 806, 808
- HCO₃ (bicarbonate)
in IDDM with DKA, 173, 174
in moderate exercise, 402
- Hct, *see* Hematocrit
- Hcy, *see* Homocysteine
- HD (Hirschsprung's disease), and susceptibility to NIDDM development, 1389-1390
- HDL, *see* High-density lipoprotein(s)
- HDL-C, *see* High-density lipoprotein-cholesterol
- Healthy (normal) subjects
angiotensin II effects on lipolysis in, 468-472
atorvastatin effects in, 983-988
blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity in, 1014-1018
circulating FFAs and insulin time series in, 41-46
circulating and regional GHBP in, 1340-1345
contribution of net hepatic glycogen synthesis to glucose disposal in, 598-601
- Healthy (normal) subjects (*Continued*)
effects of plant stanol FA ester mixtures on concentrations of plasma ubiquinol-10 and fat-soluble antioxidants in, 520-529
elderly, *see* Older subjects
environmental factors and *APOE* gene polymorphism effects on plasma lipid concentrations in, 936-944
exercising, *see* Healthy subjects, exercising
fasting effects on insulin secretion in, 107-111
furosemide effects on renal excretion of oxypurinol and purines in, 241-245
GH release in, 382-386
gluconeogenesis and glucose production in, 47-52
glucose metabolism in, 876-881
glucose R_s after galactose ingestion by, 93-98
HRT effects on serum PON arylesterase in, 319-324
insulin effects on glucose uptake and leg blood flow in, 387-392
interrelation between glucocorticoid receptor β_2 -*ADR* gene, LPL, and Gln27Glu mutation of β_2 -*ADR* gene, plasma insulin, and lipid levels in, 246-252
IR in, *see* Healthy subjects, insulin-resistant
LDL-induced monocyte-endothelial cell adhesion in, 207-215
loci influencing DHEA levels in, 1315-1322
Lp distribution of apo C-III and its relationship to plasma TG-rich remnant lipoprotein in, 112-119
LPL activity in, 952-954
macrophage HMG-CoA reductase in, 1224-1229
NE effects on urinary excretion of purine bases and oxypurinol in, 1230-1233
O₂ supply and skeletal muscle cell lipids in, 380-381
obese, *see* Healthy subjects, obese
OPG/OCIF in, 1-2
pancreatic polypeptide secretion in, 223-230
paradoxical weight loss in, 1181-1185
PBMC proliferation in, 270-276
plasma Lp(a)-containing apo E (or free of apo E) in, 277-282
platelet Na⁺/K⁺ ATPase as marker of hyperthyroidism in, 1393-1396
platelet taurine, content, uptake, and release in, 60-64
risk factors for atherosclerosis in, 24-29, 166-170
S₁ of blood glucose versus S₁ of blood FFAs in, 573-582
stress hormone effects on protein synthesis in T lymphocytes in, 1308-1314
suppressive effects of cortisol on *p47^{phox}* subunit of NADPH oxidase in, 548-552
systemic 11 β -HSD assessed with serum cortisone/cortisol ratios in, 801-804
testosterone, SHBG, and body composition in healthy young men, race and, 1242-1247
thermic effect of SMLCTs versus LCTs in, 125-130
TNF- α -238 and -308 polymorphisms in, 1447-1451
Trp64Arg polymorphism of β_2 -*ADR* gene in, 184-188
urinary E and NE in, 135-143
urinary excretion of olive oil phenols and their metabolites in, 1426-1428
variations in vitamin D-binding protein gene in, 366-369
on very-high-fiber vegetable, fruit, nut diet, effects of, on serum lipids and colonic function, 494-503
see also Men; Women
- Healthy (normal) subjects, exercising
cardiopulmonary exercise, xanthine, uric acid, and hypoxanthine degradation during, 646-650
effects of creatine and endurance exercise on REE and LBF in, 1429-1434
and exercise effects on serum hypoxanthine level, 627-630

- Healthy (normal) subjects, exercising (*Continued*)
 fasting respiratory exchange ratio in, 1286-1293
 relationship between maximal aerobic fitness and changes in cardiovascular disease in, 1255-1263
see also Men, exercising; Women, exercising
- Healthy (normal) subjects, insulin-resistant
 LDL particle size and proinsulin in insulin-resistant older men, 120-124
 MI prior to age 40 and, 30-35
 VAT accumulation and risk of IR, 393-398
- Healthy (normal) subjects, obese
 adiposity and CVD risk in, 299-305
 relationship between IR, weight loss, and risk of coronary heart disease in obese women, 795-800
- Heart
 aspirin effects on size of, 559
see also Heart rate *entries beginning with terms*: Coronary, Myocardial, Ventricular and element: Card-
- Heart rate (HR)
 in exercise, *see* Heart rate in exercise
 gene polymorphism and, *see* Heart rate, gene polymorphism and
 glucose effects on plasma von Willebrand factor and, 1455
 insulin effects on, 67
 LDL particle size, IR, proinsulin and, 122
 L-NMMA effects on, in older subjects, 195, 307
 of older men, and changes in leg BF and capillary density in SM, 1080
 in SCD subjects, 389
 variability in, and autonomic balance of NIDDM subjects' offspring, 1270-1274
- Heart rate (HR), gene polymorphism and
 polymorphism of *CRH* gene regulatory region in obesity, 1060
 and Trp64Arg polymorphism of β_1 -*ADR* gene and Ala54Threo polymorphism of *FABP2* gene, 1303-1305
- Heart rate (HR) in exercise
 effects of high and moderate glycemic index meals on, 852
 by NIDDM subjects with cardiovascular disease, changes in disease and in, 1258, 1260, 1261
see also Heart rate in moderate exercise
- Heart rate (HR) in moderate exercise
 aortopulmonary shunt and, 401-402
 by women, 482
- Height
 of cirrhotic subjects, 1342
 of COPD subjects, 1398
 and CV risk factors in men, 884
 of DMD patients, 1182
 of exercising men, S_i and S_g in, 350
 of growth hormone-deficient prepubertal children, 538
 of mixed hyperlipidemic subjects, 731
 of NIDDM subjects, IVGTT modeling and, 513
 of older subjects, RMR and, 973
 and pancreatic polypeptide secretion, 224
 of premenopausal and postmenopausal women, abdominal AT distribution and, 978
 of South Asian immigrants' offspring, 1199
 T, SHBG, and body composition and, in young adult men, 1243
 and thermic effect of SMLCTs versus LCTs, 126
- Hematocrit (Hct)
 aspirin effects on, 559
 in CRG, 208
 and hyperuricemia development in middle-aged men, 623-625
 maternal, maternal Fe restriction and, 564
 in primary dyslipoproteinemias, 167
- Hemodialysis, *see* Chronic renal failure, hemodialysis for
- Hemodynamics, *see* Systemic hemodynamics
- Hemoglobin, *see entries beginning with acronym*: Hb
- Hemorrhologic abnormalities in primary dyslipoproteinemias, risk of atherosclerosis and, 166-170
- Hemostatic abnormalities
 metabolic and, in obese children, and relationship between AT and AT distribution in, 681-687
see also specific conditions
- Hemostatic risk factors, vascular, ALA or evening primrose oil effects on, in STZ-DM, 868-875
- Hepatic alpha (α)-amino-nitrogen, PGE₁ and conversion of, to urea nitrogen in poorly controlled NIDDM, 253-258
- Hepatic blood flow (BF) in cirrhosis, 1342
- Hepatic cholesterol (C), effects of apo E deficiency on LDL receptor function, plasma and fecal sterol levels, synthesis of bile acid and, probucol and/or phytosterol therapy of, 708-714
- Hepatic gene expression in DM regulated by PPAR γ and PPAR α , 963-971
- Hepatic glucose production (HGP), regulation of, 744-749
- Hepatic glycogen, contribution of net synthesis of, to glucose disposal, 598-601
- Hepatic 3-hydroxy-methylglutarate-coenzyme A reductase, *see* HMG-CoA reductase
- Hepatic insulin receptor substrate (IRS)-2 expression, HF diet effects on, 1369-1376
- Hepatic lipase (HL)
 effects of, on plasma HDL removal rate in Tg subjects, 530-536
 HTGL activity in gout, 952-954
- Hepatic mitogen-activated phosphokinase phosphatase-1 (MKP-1) gene, PPAR α regulation of, 966-967
- Hepatic paraoxonase (PON), altered activity of, and free radical formation in cirrhosis, 997-1000
- Hepatic phosphoenol carboxykinase (PEPCK) gene, PPAR α regulation of, 966-967
- Hepatic plasma flow in cirrhosis, 1342
- Hepatic triglyceride lipase (HTGL), activity of, in gout, 952-954
- Hepatic vein blood, backflow of, 189-193
- Hepatic vein growth hormone-binding protein (GHBP) in cirrhosis, 1342
- Hepatocytes exposed to potassium cyanide and iodoacetic acid, glucose effects on viability of, 342-348
- Heredity, *see* Chromosome(s); Chromosome 4 segment (*D4Mit6-Npy* -1 cm); Family history; Gene(s) and *entries beginning with terms*: Familial, Genetic, Heterozygous
- Heterozygous familial hypercholesterolemia (FH), LDL effects on apo A-I kinetics in, 635-639
- Hexokinase (HK), effects of high-protein, CHO-free diet on, 1208-1212
- Hexokinase II (HKII) mRNA (messenger ribonucleic acid) in obese or NIDDM subjects, exercise effects on, 602-606
- HF (high-fructose) diet, preservation of beta-cell mass and diabetes prevention with, in non-obese subjects, 1369-1376
- HGP (hepatic glucose production), regulation of, 744-749
- HHcy (hyperhomocysteinemia) in elderly subjects, 1466-1471
- High-density lipoprotein(s) (HDL; alpha-lipoprotein)
 and ATCVD in hyperlipidemic women, 362
 in children, relation of serum leptin to, 1093
 and metabolic complications of obesity, 430
 plasma, thyroid hormone effects on removal rate of, in Tg subjects, 530-536
 in South Asian immigrants' offspring, 1199, 1200
see also High-density lipoprotein-cholesterol; High-density lipoprotein *PONI* gene M/L55 polymorphism; Lipoprotein(a)

- High-density lipoprotein (HDL) *PON1* gene M/L55 polymorphism, relation between carotid artery atherosclerosis and, in smoking and nonsmoking men, 1095-1101
- High-density lipoprotein-cholesterol (HDL-C)
- in adolescents, *see* High-density lipoprotein-cholesterol in adolescents
 - in atherosclerosis, *see* High-density lipoprotein-cholesterol, atherosclerosis and
 - in CAD, *see* High-density lipoprotein-cholesterol in CAD
 - childhood-to-adulthood, in offspring of CHD parents, variables in, 1444
 - in children, distribution and correlates of, with sex and race, 370-376
 - chitotriosidase activity and concentration of, 449
 - in CRF, effects of vitamin B₆, folic acid, and cyanocobalamin on, 132
 - and CV risk factors in men, 884
 - diet effects on, *see* High-density lipoprotein-cholesterol, diet effects on
 - and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453
 - exercise and, *see* High-density lipoprotein-cholesterol in exercise
 - gene polymorphism and, *see* High-density lipoprotein-cholesterol, gene polymorphism and
 - and Gln27Glu mutation of β_2 -*ADR*, 444, 445
 - in gout, *see* High-density lipoprotein-cholesterol in gout
 - in hyperlipidemia, *see* High-density lipoprotein-cholesterol in hyperlipidemia
 - in hypertensive subjects and their normotensive offspring, insulin sensitivity, Na excretion and, 931
 - and hyperuricemia development in middle-aged men, 623, 624
 - in IDDM, apo A-IV concentrations and, 1021, 1022
 - IR and, *see* High-density lipoprotein-cholesterol in IR
 - and Lp distribution of apo C-III, 113
 - maternal and neonatal profile of, 725, 726
 - in metabolic syndrome, 137-140
 - in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
 - in nondiabetic subjects, serum PON arylesterase activity and, 806, 808
 - in normolipidemia, serum-promoted C efflux and, 1332, 1333
 - in obesity, *see* High-density lipoprotein-cholesterol in obesity
 - plasma, *see* Plasma high-density lipoprotein-cholesterol
 - in PM women, *see* High-density lipoprotein-cholesterol in PM women
 - in premenopausal women, abdominal AT distribution and, 978, 990
 - serum, *see* Serum high-density lipoprotein-cholesterol
 - see also* High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (HDL-C), Ala54Threo polymorphism of *FABP2* gene and effects of polymorphism, 474
- in older women, insulin sensitivity and, 1103
 - with Trp64Arg β_2 -*ADR* gene polymorphism, 1303-1305
- High-density lipoprotein-cholesterol (HDL-C), atherosclerosis and in carotid artery atherosclerosis, 1097
- in MI survivors and their spouses, 27
- High-density lipoprotein-cholesterol (HDL-C), diet effects on
- high-fat, high-cholesterol diet effects, 461
 - very-high-fiber vegetable, fruit, nut diet effects, 497
- High-density lipoprotein-cholesterol (HDL-C), gene polymorphism and
- APOE* gene polymorphism effects on, 938, 939
 - in FH, TaqIB polymorphism in *CETP* gene locus, 653-654
- High-density lipoprotein-cholesterol (HDL-C), gene polymorphism and (*Continued*)
- Ser⁴⁴⁷-Stop polymorphism of LPL gene associated with variation in serum, 894-904
 - see also* High-density lipoprotein-cholesterol, Ala54Threo polymorphism of *FABP2* gene and
- High-density lipoprotein-cholesterol (HDL-C) in adolescents distribution and correlates of, with sex and race, 370-376
- having been SGA neonates, serum leptin relationship to, 1142-1144
- High-density lipoprotein-cholesterol in CAD
- β_2 -*ADR* gene mutation and, 186
 - with DM, RLP-C and, 1463, 1464
- High-density lipoprotein-cholesterol (HDL-C) in exercise
- aerobic exercise, 842, 845
 - moderate exercise, 759
 - by NIDDM subjects with cardiovascular disease, changes in disease and changes in, 1258, 1260, 1261
- High-density lipoprotein-cholesterol (HDL-C) in FH
- in heterozygous FH, 636
 - TaqIB polymorphism in *CETP* gene locus and, 653, 654
- High-density lipoprotein-cholesterol (HDL-C) in gout
- HTLG and LPL activity in gout and, 953
 - VAT accumulation and IR risk and, 394, 396
- High-density lipoprotein-cholesterol (HDL-C) in hyperlipidemia
- mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731
 - with NIDDM, 356
 - in older hyperlipidemic subjects, coronary risk factors and, 314, 315
 - and PP lipemia in hyperlipidemic women, 331
 - in primary dyslipoproteinemias, 167
 - see also* High-density lipoprotein-cholesterol in FH
- High-density lipoprotein-cholesterol (HDL-C) in IR
- LDL particle size, IR, proinsulin and, 122
 - MI prior to age 40 associated with IR, 31
 - plasma, in IR with HTN, 1449, 1450
 - plasma *CETP* activity and, 785
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM
- acylation-stimulating protein-CRP relation and, 285
 - with cardiovascular disease, changes in disease and changes in, 1258, 1260, 1261
 - with hyperlipidemia, 356
 - in lean Japanese subjects, bezafibrate effects on, 478
 - platelet taurine fluxes and, 61
 - prostacyclin-induced skin BF changes and, 571
 - with sulfonylurea-induced fatty liver, troglitazone effects on, 415, 416
- High-density lipoprotein-cholesterol (HDL-C) in obese women
- in Peruvian Indian and Caucasian women, 326
 - relationship between IR, weight loss, risk of CAD and, 796-798
- High-density lipoprotein-cholesterol (HDL-C) in obesity
- CVD risk and, 300-302
 - in dyslipidemic young adults, 698, 699
 - with and without hyperinsulinemia, 180
 - and metabolic complications of obesity, 430
 - polymorphism of *CRH* gene regulatory region and, 1060
 - see also* High-density lipoprotein-cholesterol in obese women
- High-density lipoprotein-cholesterol (HDL-C) in PM women
- abdominal AT distribution and, 978, 990
 - diabetic women on HRT, serum PON arylesterase effects on, 321
 - in hyperlipidemic women, PP lipemia and, 331
 - IR, dietary cholesterol and, 595, 596
- High-density lipoprotein₁, *see* Lipoprotein(a)

- High-density lipoprotein₂-cholesterol (HDL₂-C)
 exercise and, *see* High-density lipoprotein₃-cholesterol, exercise effects
 high-fat, high-cholesterol diet effects on, 461
 maternal and neonatal profile of, 725, 726
 in normolipidemia, serum-promoted C efflux and, 1332
 in PM women, *see* High-density lipoprotein₂-cholesterol in PM women
see also High-density lipoprotein₂-cholesterol, gene polymorphism and
- High-density lipoprotein₂-cholesterol (HDL₂-C), exercise effects
 aerobic exercise effects, 842, 845
 on NIDDM subjects with cardiovascular disease, changes in disease and changes and, 1258, 1260, 1261
- High-density lipoprotein₂-cholesterol (HDL₂-C), gene polymorphism and
 in older women, Ala54Threo polymorphism of *FABP2* gene, insulin sensitivity and, 1103
 plasma, in HTN with *APOE* gene polymorphism, 159
- High-density lipoprotein₂-cholesterol (HDL₂-C) in PM women
 in hyperlipidemic women, PP lipemia and, 331
 IR, dietary cholesterol and, 595, 596
- High-density lipoprotein₃-cholesterol (HDL₃-C)
 aerobic exercise effects on, 842, 845
 gene polymorphism and, *see* High-density lipoprotein₃-cholesterol, gene polymorphism and
 high-fat, high-cholesterol diet effects on, 461
 maternal and neonatal profile of, 725, 726
 in normolipidemia, serum-promoted C efflux and, 1332
 in PM women, *see* High-density lipoprotein₃-cholesterol in PM women
- High-density lipoprotein₃-cholesterol (HDL₃-C), gene polymorphism and
 in older women, Ala54Threo polymorphism of *FABP2* gene, insulin sensitivity and, 1103
 plasma HDL₃-C in HTN with *APOE* gene polymorphism, 159
- High-density lipoprotein₃-cholesterol (HDL₃-C) in PM women
 in hyperlipidemic women, PP lipemia and, 331
 IR, dietary cholesterol and, 595, 596
- High-fat diet, effects of, on postabsorptive and PP T, 1351-1355
- High-fat, high-cholesterol diet, chromosome 4 segment (*D4Mit6-Npy* 71 cm) effects on total serum lipids and lipoproteins after, 458-462
- High-fructose (HF) diet, preservation of beta-cell mass and diabetes prevention with, in non-obese subjects, 1369-1376
- High glycemic index meals, effects of moderate and, on metabolism and exercise performance by men, 849-855
- High-protein, carbohydrate (CHO)-free diet
 cold acclimation effects on BAT FA synthesis in subjects on, 1493-1498
 glycolytic flux and glucose uptake in AT with, 1208-1212
- Highly active antiretroviral therapy (HAART), short-term, of HIV infection, N-methylglycine and N,N-dimethylglycine during, 1275-1281
- Hirschsprung's disease (HD), and susceptibility to NIDDM development, 1389-1390
- Hispanic population, *see* Mediterranean Spanish population; Race and ethnicity
- Histidine (His)
 antidiabetic activities of cyclo (his-pro), zinc, and arachidonic acid in STZ-DM, 53-59
 in IDDM and NIDDM platelets, 740
- Histology, renal, long-term effects of partial nephrectomy on guanidino compounds, biological parameters and, 1418-1425
- HIV (human immunodeficiency virus) infection, *see* Acquired immunodeficiency syndrome
- HK (hexokinase), effects of high-protein, CHO-free diet on, 1208-1212
- HKII (hexokinase II) mRNA (messenger ribonucleic acid) in obese or NIDDM subjects, exercise effects on, 602-606
- HL, *see* Hepatic lipase
- HLP, *see* Hyperlipoproteinemia
- HMG-CoA (3-hydroxy-methylglutarate-coenzyme A) reductase
 in diet-induced hypercholesterolemia, activity of, 1235-1236
 effects of plant stanol FA esters on C absorption and activity of, 1106-1112
 inhibitors of, *see* Atorvastatin; Fluvastatin; Lovastatin; Pravastatin; Simvastatin in NIDDM
 macrophage, in sitosterolemia, 1224-1229
 probucol and/or phytosterol effects on, in apo E deficiency, 710
- HOMA insulin resistance index, *see* Homeostasis model assessment insulin resistance index
- Homeobox, pancreatic/duodenal, and FFA effects on beta cell function, 613-618
- Homeostasis model assessment (HOMA) insulin resistance (IR) index
 in adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 dietary fatty acids and, 89-91
 and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
 in gout, VAT and, 393-398
 in IR with HTN, 1449, *see also* Homeostasis model assessment insulin resistance index in NIDDM
 in normolipidemia, serum-promoted C efflux and, 1332, 1333
- Homeostasis model assessment (HOMA) insulin resistance (IR) index in NIDDM
 bezafibrate effects on, in non-obese Japanese subjects, 477-480
 with sulfonylurea-induced fatty liver, troglitazone effects on, 415, 416
- Homocysteine (Hcy)
 and ATCVD in hyperlipidemic women, 362
 in CRF, vitamin B₆, folic acid, and cyanocobalamin effects on fibrinogen, Lp(a) and, 131-134
 HHcy in elderly subjects, 1466-1471
 levels of, as risk factor for atherosclerosis in MI survivors and their spouses, 26-27
 in South Asian immigrants' offspring, 1200
 total, in men and women, differences in, 640-645
 during weight loss by obese children and adolescents, 1220-1223
- Hormone replacement therapy (HRT), PM women on
 effects of, on serum DHEA, 488-493
 effects of, on serum PON arylesterase in diabetic women, 319-324
 interaction between thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic CVD and, in hyperlipidemic women, 360-365
 IR and, 595, 596
 relationship between AT distribution, insulin sensitivity and, in obese women, 835-840
 short-term, effects of, on energy balance and body composition, 265-269
- Hormone-sensitive lipase (HSL), translocation of perilipin and, upon lipolysis stimulation during lactation, 1264-1269
- HR, *see* Heart rate
- HRT, *see* Hormone replacement therapy, PM women on
- 11 β -HSD (11 β -hydroxysteroid dehydrogenase), systemic, serum cortisone/cortisol ratios in assessment of, in healthy and in diabetic CRF subjects, 801-804

- HSL (hormone-sensitive lipase), translocation of perilipin upon lipolysis stimulation during lactation, 1264-1269
- HTG, *see* Hypertriglyceridemia
- HTGL (hepatic triglyceride lipase), activity of, in gout, 952-954
- HTN, *see* Hypertension
- Human aortic endothelial cells, *see* Aortic endothelial cells
- Human immunodeficiency virus infection, *see* Acquired immunodeficiency syndrome
- Human umbilical vein endothelial cells, *see* Umbilical vein endothelial cells
- Hyaluronan, effects of glucose on production of, by renal interstitial fibroblasts through PKC and TGF- β cascade, 789-794
- Hydrocortisone, *see* Cortisol
- Hydroperoxide, lipid, aspirin effects on SOD and, in Cu deficiency, 559
- β -Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone
- β (beta)-Hydroxy-5-androsten-17-one-sulfate (dehydroepiandrosterone sulfate), racial differences in familial aggregation for, and its responsiveness to endurance training, 916-920
- 3-Hydroxybutyrate (3-OHB) in fasting MCAD-deficient children, 162-165
- 17-Hydroxycorticosteroid (17-OHCS), exercise effects on urinary excretion of, in NIDDM, 1138
- 4-Hydroxyglucobrassicin, 1124, 1133, 1134
- Hydroxylation, T, after broccoli intake, 1126
- 2-, 4-, and 16 α -Hydroxylation of 17 β -estradiol, role of cytochrome P-450 1A1, 1A, 1B2, and 3A4 in, 1001-1003
- 3-Hydroxy-methylglutarate-coenzyme A reductase, *see* HMG-CoA reductase
- 11 β (beta)-Hydroxysteroid dehydrogenase (HSD), systemic, serum cortisone/cortisol ratios in assessment of, in healthy and in diabetic CRF subjects, 801-804
- 25-Hydroxyvitamin D in idiopathic osteoporotic men, 913
- Hypercholesterolemia
severe, in diabetic dyslipoproteinemia, atorvastatin effects in, 984, 986
see also Familial hypercholesterolemia; Hypercholesterolemia in CAD
- Hypercholesterolemia in CAD
 β_2 -ADP gene mutation, 186
in elderly rural and urban Mexican subjects, as risk factor for CAD, 311-318
- Hyperglycemia
chronic, effects of inflammation, fat malabsorption or, on apo A-IV concentration in IDDM secondary to chronic pancreatitis, 1019-1024
with obesity, citalopram effects on development of, 144-150
see also specific conditions
- Hyperglycemic-glycogenolytic factor, *see* Glucagon
- Hyperhomocysteinemia (HHcy) in elderly subjects, 1466-1471
- Hyperinsulinemia
in obese NIDDM subjects, parasympathetic drive to pancreas and, 223-230
see also Men, hyperinsulinemic
- Hyperleptinemia, dexamethasone-induced anorexia and long-term, in older subjects, 1054-1058
- Hyperlipidemia(s)
in elderly rural and urban Mexican subjects, as risk factor for CAD, 311-318
see also Hypercholesterolemia; Hyperlipidemic women; Hyperlipoproteinemia; Hypertriglyceridemia; Mixed hyperlipidemias; Postprandial lipemia
- Hyperlipidemic women
interaction between ERT and thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic CVD in, 360-365
PM, PP lipemia and metabolic disturbances in, 330-334
- Hyperlipoproteinemia (HLP)
atorvastatin effects on LDL subtypes in, 983-988
mixed and type III, hemorrhologic abnormalities and atherosclerotic risks in, 166-170
- Hyperplasia
of beta cells in obesity, systemic bromocriptine/SKF38393 effects on GLUT2, glucokinase, iRl levels and, 1377-1384
congenital adrenal, effects of estrogen and androgen on bone maturation and BMD in children with, 377-379
- Hypertension (HTN)
and ATCVD in hyperlipidemic women, 362
borderline, in young men with CV risk factors, glucose disposal rate in, 1175-1180
CAD and, *see* Hypertension in CAD
in CRF, 208
in diabetic nephropathy, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity and, 1015
effects of APOE gene polymorphism related to erythrocyte membrane lipid composition or sodium-lithium countertransport in, 157-160
in familial gout, 1206
F-induced, ET-1 gene expression and NOS levels in, 74-78
insulin sensitivity and Na excretion in subjects with, and their normotensive offspring, 929-935
IR in, TNF- α 238 and -308 polymorphisms and, 1447-1451
in metabolic syndrome, 137-140
as risk factor for atherosclerosis in MI survivors and their spouses, 25
VSMC potassium and NHE-1 in, 778-782
xanthine, uric acid, and hypoxanthine degradation during exercise in, 646-650
- Hypertension (HTN) in CAD
 β_2 -ADP gene mutation and, 186
with DM, RLP-C in, 1463, 1464
- Hyperthyroidism, platelet Na⁺/K⁺ ATPase as marker in, 1393-1396
- Hypertriglyceridemia (HTG)
apo E-containing Lp(a) in, 277-282
familial, hemorrhologic abnormalities and atherosclerotic risks in, 166-170
postprandial, in hyperlipidemic NIDDM, simvastatin effects on, 355-359
- Hyperuricemia, development of, in middle-aged men, 621-626
- Hypoglycemia, acute, alcohol and glucose counterregulation during, in NIDDM, 451-457
- Hypothalamic neuropeptide Y, *see* Neuropeptide Y, hypothalamic
- Hypoxanthine, exercise and
HTN and degradation of, 646-650
serum, changes in levels of, in obese subjects, 627-630
- Hypoxanthine, urinary excretion of
furosemide effects on, 241-245
norepinephrine effects on, 1230-1233
- IAA (iodoacetic acid), glucose effects on viability of hepatocytes exposed to, 342-348
- I/D (insertion/deletion) of ACE gene associated with ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
- IDDM, *see* Insulin-dependent diabetes mellitus
- Idiopathic osteoporosis in men, alendronate effects on BMD in, 912-915

- IGF, *see entries beginning with terms*: Insulin-like growth factor
- IgG (immunoglobulin G; gamma-globulin)
and ATCVD in hyperlipidemic women, 362
nephropathy in CRF, 208
- IgM (immunoglobulin M), and ATCVD in hyperlipidemic women, 362
- IGT, *see* Impaired glucose tolerance
- IL-1 (interleukin-1), depressive action of, on cytochrome P-450-linked-monoxygenase system, rifampicin effects on, 231-236
- IL-1 β (interleukin-1 β) in hepatic glucose production, 744, 748
- IL-6 (interleukin-6), *see* Interleukin-6
- IL-10 (interleukin-10), ROS generation and, 548-552
- Ile (isoleucine) in IDDM and NIDDM platelets, 740
- IMCD (inner medullary collecting duct), angiotensin regulating ET_B in, 661-666
- IMCLs (intramyocellular lipids), O₂ supply and, in women, 380-381
- IMGU, *see* Insulin-mediated glucose uptake
- Immunoglobulin, *see* IgG; IgM
- Immunoreactive insulin (iri)
ALA effects on, in 3T3 adipocytes, 1063-1069
fasting, *see* Fasting immunoreactive insulin
in gout, 394, 396
in hyperinsulinemia, 108, 109
in obesity, systemic bromocriptine/SKF38393 effects on GLUT2 mRNA, beta-cell hyperplasia, GK mRNA and, 1377-1384
in pancreatic cancer, 1038
- Impaired glucose tolerance (IGT)
relationship of Gln27Glu mutation of β_2 -ADR gene to obesity, DM and, in Japanese subjects, 443-446
see also Glucose tolerance and specific conditions
- Incidence
of hyperuricemia in middle-aged men, 623
see also specific conditions
- Infarction, myocardial, *see* Myocardial infarction
- Inflammation, effects of chronic hyperglycemia, fat malabsorption or, on apo A-IV concentration in IDDM secondary to chronic pancreatitis, 1019-1024
- Inflammatory cytokines, *see* Cytokines
- Inhaled beclomethasone dipropionate, effects of long-term, on osteocalcin levels in COPD, 1336-1339
- Inheritance, *see* Chromosome(s); Chromosome 4 segment (*D4Mit6-Npy* \sim 1 cm); Family history; Gene(s) and *entries beginning with terms*: Familial, Genetic, Heterozygous
- Injury, pioglitazone effects on balloon-injured VSCM proliferation, 955-962
- Inner medullary collecting duct (IMCD), angiotensin regulating ET_B in, 661-666
- Insertion/deletion (I/D) of ACE gene associated with ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
- Insulin
BRL-49653 effects on, 1295-1296
effects of, on renin release, 763-766
exercise and, *see* Insulin, exercise and
fasting, *see* Fasting insulin
glucose blood flow and, *see* Glucose, insulin effects on BF and uptake of
GPI-PLD expression in beta cells regulated by glucose and, 1489-1492
in hepatic glucose production regulation, 744, 745
high-fat diet effects on postabsorptive and PP, 1352
immunoreactive, *see* Immunoreactive insulin
in leg blood flow, *see* Leg blood flow, insulin in
maternal and neonatal Lp profile, CETP and, 725, 726
- Insulin (*Continued*)
myocardial, effects of cardiac workload changes on substrate fluxes and responsiveness of, 1083-1090
in normolipidemia, serum-promoted C efflux and, 1332
in offspring of South Asian immigrants, 1197-1202
in pancreatic cancer, 1040
plasma, *see* Plasma insulin
serum, *see* Serum insulin
in young adult men, race and, 1243
see also Hyperinsulinemia; Insulin, diet effects on; Insulin, GH and; Insulin compartment; Insulin-dependent diabetes mellitus; Insulin in hyperlipidemia; Insulin-mediated glucose uptake; Insulin in obesity; Insulin receptor substrate-1; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Insulin signaling; Insulin syndrome; Insulin time series; Insulinitis; Insulinotropic actions; Metabolic syndrome; Non-insulin-dependent diabetes mellitus and *entries beginning with terms*: Insulin-like
- Insulin, diet effects on
PP insulin concentration in men fed LM, MAF, tofu, and MOS meals, 506
see also Serum insulin, diet effects on
- Insulin, exercise and
exercise effects, 1050-1051
moderate exercise, 759
- Insulin, GH and
GH therapy effects on insulin in GH-deficient prepubertal children, 544
and naloxone effects on GHRH-induced GH release after BPD-induced weight loss, 385
- Insulin compartment, physiologic modeling of IVGTT in NIDDM as new approach to, 512-519
- Insulin-dependent diabetes mellitus (type 1 diabetes mellitus; IDDM)
blood glucose level and activity modulated by serum PON arylesterase in young adults with diabetic retinopathy and, 657-660
correlation between serum VEGF and carotid artery distensibility in, 825-829
with DKA, 171-177
effects of chronic hyperglycemia, inflammation, or dietary fat malabsorption on apo A-IV concentration in, 1019-1024
Mg effects on IMGU and serum lipids in, 1409-1417
platelet amino acids in, 739-741
- Insulin in hyperlipidemia
in older subjects, coronary risk factors and, 314, 315
in PM women, 331
- Insulin-like growth factor-1 (IGF-1)
deficiency of, in pycnodysostosis, 905-911
effects of changes in level of glucose, insulin and, on serum CBG in lean subjects, 1248-1252
GH and, *see* Insulin-like growth factor-1, GH and
in obesity, *see* Insulin-like growth factor-1 in obesity
plasma, *see* Plasma insulin-like growth factor-1
resistance to actions of vascular insulin/, in female subjects, 607-612
- Insulin-like growth factor-1 (IGF-1), GH and
in GH-deficient children, GH therapy effects on, 544
and naloxone effects on GHRH-induced GH release after BPD-induced weight loss, 385
- Insulin-like growth factor-1 (IGF-1) in obesity
effects of changes in level of glucose, insulin and, on serum CBG in obese subjects and in glucose-intolerant obese subjects, 1248-1252
polymorphism of *CRH* gene regulatory region and, 1060

- Insulin-like growth factor-binding protein-1 (IGFBP-1) in South Asian immigrants' offspring, 1200
- Insulin-like growth factor-binding protein-3 (IGFBP-3)
in cirrhosis, 1342
serum, serum leptin with, for acromegaly, plasma IGF-1 compared with, 1117-1121
in South Asian immigrants' offspring, 1200
- Insulin-mediated glucose uptake (IMGU)
in IDDM, Mg effects on IMGU and serum lipids in, 1409-1417
in older subjects, L-NMMA and, 194-199, 306-310
see also Glucose, insulin effects on BF and uptake of
- Insulin in obese children
metabolic and hemostatic abnormalities and, 682, 684, 685
during weight loss, 1221
- Insulin in obesity
in adolescents during weight loss, 1221
with and without glucose intolerance, effects of changes in level of, 1248-1252
insulin activation in upper body obesity, 19-23
and metabolic complications of obesity, 430, 431
in obese children, *see* Insulin in obese children
in obese women, serum leptin, blood pressure and, 326, 327
systemic bromocriptine/SKF38393 effects on beta-cell content of, 1379
see also Hyperinsulinemia; Plasma insulin in obesity
- Insulin receptor substrate-1 (IRS-1), effects long-term SM
denervation on insulin signaling in SM mediated by, 216-222
- Insulin receptor substrate-2 (IRS-2), HF diet effects on expression of
hepatic and skeletal muscle, 1369-1376
- Insulin release and secretion
hyperinsulinemia compared with short-term fasting in suppression of, in obese men, 107-111
see also Insulin release and secretion in NIDDM
- Insulin release and secretion in NIDDM
aminophylline effects on, 1030-1035
IR and dysfunctional, in Korean NIDDM subjects, 590-593
in non-obese Japanese NIDDM subjects, bezafibrate effects on, 477-480
in response to glucose or nonglucose stimulation, 1282-1285
- Insulin resistance (IR)
ALA effects on irf and glucose-induced, in 3T3-L1 adipocytes, 1063-1069
dietary cholesterol and, *see* Dietary cholesterol, and IR
dietary fat and, *see* Insulin resistance, dietary fat and
in HTN, TNF- α -238 and -308 polymorphisms and, 1447-1451
in Korean NIDDM subjects, insulin secretory dysfunction and, 590-593
in metabolically normal obesity subtype, 1501
myocardial infarction prior to age 40 associated with, 30-35
in nondiabetic subjects, effects of, on serum PON arylesterase activity, 805-811
risk of, in gout, VAT accumulation and, 393-398
severe, altered *GLUT1* and *GLUT3* gene expression and subcellular redistribution of *GLUT4* in acanthosis nigricans with, 771-777
see also Healthy subjects, insulin-resistant; Insulin resistance index; Insulin resistance syndrome; Insulin sensitivity; Men, insulin-resistant; Women, insulin-resistant
- Insulin resistance (IR), dietary fat and
physical activity effects on dietary fat intake association with, 1186-1192
relationship of dietary fat, serum CEs, and PL FAs to markers of, glucose tolerance and, 86-92
- Insulin resistance (IR) index
in metabolic syndrome, 137-140
see also Homeostasis model assessment insulin resistance index
- Insulin resistance syndrome (metabolic syndrome), urinary excretion of E and NE related to obesity, insulin and, in Chinese subjects, 135-143
- Insulin sensitivity (S_i)
in DM, *see* Insulin sensitivity in DM
effects of changes in level of glucose, insulin, and IGF-1 on, in lean subjects, 1249
and effects of glucose on plasma von Willebrand factor concentration, 1452-1456
membrane PL FA composition and, and early growth restriction, 1070-1077
minimal model analysis of, in athletes, fasting RER and, 1286-1293
and Na excretion in hypertensive subjects and their normotensive offspring, 929-935
in obesity, *see* Insulin sensitivity in obesity
in older women and, Ala54Threo polymorphism of *FABP2* gene and, 1102-1105
plasma CETP activity and, 783-788
serum leptin relationship to, in adolescents having been SGA neonates, 1141-1146
 S_g and, *see* Glucose effectiveness, S_i and
vanadium effects on, 667-673
see also Insulin resistance
- Insulin sensitivity (S_i) in DM
blood glucose versus S_i of blood FFAs in obese diabetic subjects, 573-582
in lactating women with GDM history, 716-717
see also Insulin sensitivity in NIDDM
- Insulin sensitivity (S_i) in NIDDM
in non-obese Japanese NIDDM subjects, bezafibrate effects on, 477-480
physiologic modeling of IVGTT in NIDDM in estimation of S_g and, 512-519
- Insulin sensitivity (S_i) in obesity
effects of changes in levels of glucose, insulin, and IGF-1 on, and in obesity with glucose intolerance, 1249
relationship between AT distribution, HRT and, in obese PM women, 835-840
 S_i of blood glucose versus S_i of blood FFAs in obesity, 573-582
- Insulin signaling in SM, long-term denervation effects on IRS-1-mediated, 216-222
- Insulin syndrome, mutant, renal metabolism of insulin in, 863-867
- Insulin time series, inverse relationship between circulating FFAs and disorderly, in healthy and NIDDM subjects, circulating insulin levels and, 41-46
- Insulinemia, dexamethasone-induced, 1056
- Insulinitis, HF diet effects on, 1370-1371
- Insulinotropic actions of exendin-4 and GLP-1, 583-589
- Interleukin-1 (IL-1), depressive action of, on cytochrome P-450-linked-monooxygenase system, rifampicin effects on, 231-236
- Interleukin-1 β (IL-1 β) in hepatic glucose production, 744, 748
- Interleukin-6 (IL-6)
in hepatic glucose production, 744, 748
serum, thyroid hormones and, in rheumatoid arthritis, 463-467
- Interleukin-10 (IL-10), ROS generation and, 548-552
- Intermittent porphyria attacks, acute, triptorelin with tobolone in prevention of cyclic, 995-996
- Interstitial fibroblasts, renal, glucose effects on hyaluronan production through PKC and TGF- β cascade, 789-794

- Intestinal absorption of FAs in hyperinsulinemic men, Ala54Threo polymorphism of *FABP2* gene and, 473-476
- Intestinal apoptosis, effects of suppressed, on small intestinal mucosa thickness in STZ-DM, 259-264
- Intestinal fatty acid-binding protein 2, *see* Ala54Threo polymorphism of *FABP2* gene
- Intestinal function, colonic, very-high-fiber vegetable, fruit, nut diet effects on, 494-503
- Intestinal mucosa, small, effects of suppressed intestinal apoptosis on thickness of, in STZ-DM, 259-264
- Intracellular adenosine phosphate (ATP) in KCN- and IAA-exposed hepatocytes, 344
- Intracellular glycogen in KCN- and IAA-exposed hepatocytes, 344
- Intramyo cellular lipids (IMCLs), O₂ supply and, in women, 380-381
- Intravenous glucose tolerance test (IVGTT)
frequently sampled, *see* Frequently sampled intravenous glucose tolerance test
physiologic modeling of, estimation of S_i and S_g in NIDDM with, 512-519
in STZ-DM, vanadium effects of GLUT4 translocation and, 674-676, 679
- Iodoacetic acid (IAA), glucose effects on viability of hepatocytes exposed to, 342-348
- IR, *see* Insulin resistance
- irI, *see* Immunoreactive insulin
- Iron (Fe)
effects of maternal restriction of, on BP, glucose tolerance, and serum lipids in 3-month-old offspring, 562-567
tissue contents and subcellular distribution of cobalt, selenium, zinc, chromium and, in DM, 1168-1174
- IRS-1 (insulin receptor substrate-1), long-term SM denervation effects on insulin signaling in SM mediated by, 216-222
- IRS-2 (insulin receptor substrate-2), HF diet effects on expression of hepatic and skeletal muscle, 1369-1376
- Islets of Langerhans, *see* Pancreatic cells
- Isoleucine (Ile) in IDDM and NIDDM platelets, 740
- IVGTT, *see* Intravenous glucose tolerance test
- Japanese men
effects of β_3 -*ADR* gene Trp64Arg polymorphism and *FABP2* gene Ala54Threo polymorphism on insulin resistance and FPG in young and older, 1301-1307
middle-aged, hyperuricemia development in, 621-626
see also Japanese subjects
- Japanese subjects
with varying degrees of glucose tolerance, minimal model analysis and C-peptide secretion rate in characterization of pathophysiological phenotypes in, 812-818
see also Japanese men; Japanese subjects, DM
- Japanese subjects, DM
relationship of Gln27Glu mutation of β_2 -*ADR* gene to obesity, IGT, and DM in, 443-446
see also Japanese subjects, NIDDM
- Japanese subjects, NIDDM
association between β_3 -*ADR* gene Trp64Arg polymorphism and *FABP2* gene Ala54Threo polymorphism in Japanese men, 1302-1303
insulin gene polymorphisms in, 631-634
non-obese, bezafibrate effects on insulin sensitivity and insulin secretion in, 477-480
- K (potassium)
furosemide effects on, 242-244
NE effects on, 1232
- K (potassium) (*Continued*)
plasma, *see* Plasma K
platelet Na⁺/K⁺ ATPase as marker in hyperthyroidism, 1393-1396
serum, in DM and CRF, systemic 11 β -HSD and, 803
and VSMC Na⁺/H⁺ exchanger isoform-1 in hypertensive subjects, 778-782
- KBs (ketone bodies), total, in IDDM with DKA, 174
- KCN (potassium cyanide), glucose effects on viability of hepatocytes exposed to, 342-348
- Ketoacid-supplemented very-low-protein diet (KSVLPD), EE of CRF subjects before and after, following glucose load, 335-341
- Ketoacidosis, diabetic, fasting and dehydration in pathogenesis of, 171-177
- Ketone(s), production of, by fasting MCAD-deficient children, 161-165
- Ketone bodies (KBs), total, in IDDM with DKA, 174
- Kidney
in DM, cobalt, zinc, selenium, and iron distribution in, 1168-1170
see also Broccoli, effects of, on cytochrome P-450 activities in liver, kidney, and colon; Glomerular pathology; Inner medullary collecting duct; Nephropathy and entries beginning with term: Renal
- Kinase
activity of tyrosine, vascular insulin/IGF-1 actions and, 607-612
creatine, in AIDS, 290
effects of high-protein, CHO-free diet on phosphofructo-1-kinase, pyruvate kinase, and hexokinase, 1208-1212
see also Glucokinase; Mitogen-activated phosphokinase phosphatase-1; Phosphoenol carboxykinase gene; Protein kinase C; Protein kinase C theta
- Kinetics
apo A-I, LDL effects on, in heterozygous FH, 635-639
of glucose, alcohol effects on, 453
leucine, *see* Kinetics, leucine
lipid, following palliative resection in glucanoma syndrome, AAs, glucose and, 720-722
of muscle SV lactate transport in STZ-DM, 420, 421
- Kinetics, leucine
in exercising AIDS subjects, 291
following palliative resection in glucanoma syndrome, 721
see also Kinetics, leucine, protein wasting effects on
- Kinetics, leucine, protein wasting effects on
due to protein restriction and dexamethasone, glutamine effects on, 293-298
in exercising AIDS subjects, 291
- Knee, relationship between OPG/OCIF concentrations in synovial fluid and severity of osteoarthritis of, 1-2
- Korean subjects
men, Ala54Threo polymorphism of *FABP2* gene associated with increased dietary fat oxidation and hyperinsulinemia but not with FA absorption in, 473-476
with NIDDM, insulin secretory dysfunction and IR in, 590-593
KSVLPD (ketoacid-supplemented very-low-protein diet), EE of CRF subjects before and after, following glucose load, 335-341
- Lactate
blood, and hypoxanthine response to cardiopulmonary exercise by HTN subjects, 647-648
and glucose rate of appearance following galactose ingestion, 96
in hepatic glucose production regulation, 744, 745
plasma, alcohol effects on, during acute hypoglycemia in NIDDM, 453
release of, in KCN- and IAA-exposed hepatocytes, 342-344

- Lactate (*Continued*)
 STZ-DM effects on muscle SV transport of, 418-424
- Lactate dehydrogenase (LDH)
 gemfibrozil and/or ciprofibrate effects on, in mixed
 hyperlipidemias, 731
 in KCN- and IAA-exposed hepatocytes, 342-344
- Lactation
 translocation of HSL and perilipin upon lipolysis stimulation
 during, 1264-1269
 in women with history of GDM, beta cell function and VAT in,
 715-719
- Lanosterol, effects of, on apo E deficiency, 710
- Large-for-gestational age (LGA) neonates, Lp profile and CETP in,
 724-725
- Lathosterol, effects of, on ubiquinone-10 and fat-soluble antioxidant
 concentrations, 523
- LBF, *see* Limb blood flow
- LCTs and MCTs (long- and medium-chain triacylglycerols), thermic
 effects of SMLCTs versus, in young women, 125-130
- LDH, *see* Lactate dehydrogenase
- LDL(s), *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lean meat (LM) meal, effects of, on PP sex hormone concentrations
 in men, 505-511
- Lean subjects, *see* Non-obese subjects
- Left ventricular mass (LVM) in men, CV risk factors and, 882-888
- Leg blood flow (BF), insulin in
 BF changes coupled with capillary density in SM of older men
 mediated by insulin, 1078-1082
 insulin effects on glucose uptake and leg BF in healthy and SCD
 subjects, 387-392
- Leptin
 in children, *see* Leptin in children
 dexamethasone-induced anorexia and long-term hyperleptinemia in
 older subjects, 1054-1058
 gene polymorphism and, *see* Leptin, gene polymorphism and
 in obesity, *see* Leptin in obesity
 oral nicotine effects on levels of, 82
 plasma, *see* Plasma leptin
 serum, *see* Serum leptin
 and TZD- and glucocorticoid-induced preadipocyte stromal cell
 differentiation, 411
- Leptin, Ala54Threo gene polymorphism and
 effects of, 474
 and Trp64Arg polymorphism of β_2 -*ADR* gene, 1303-1305
- Leptin, gene polymorphism and
 of *CRH* gene regulatory region in obesity, 1060
see also Leptin, Ala54Threo gene polymorphism and
- Leptin in children
 in GH-deficient prepubertal children, 544
 of South Asian immigrants, 1197-1202
- Leptin in obesity
 metformin effects in nondiabetic morbidly obese subjects with
 BMI greater than 30, 856-861
 polymorphism of *CRH* gene regulatory region and, 1060
 release of, stimulated by arachidonic acid and PGE_2 in AT of
 obese subjects, 921-928
 sibutramine and low-dose leptin for diet-induced obesity, 889-893
- Leucine (Leu)
 in IDDM and NIDDM platelets, 740
see also Kinetics, leucine
- Leukemia inhibitory factor (LIF) in cancer cachexia, 1213, 1215,
 1216
- LGA (large-for-gestational age) neonates, Lp profile and CETP in,
 724-725
- LH, *see* Luteinizing hormone in men
- LIF (leukemia inhibitory factor) in cancer cachexia, 1213, 1215,
 1216
- Ligand/activators for PPAR α and PPAR γ , effects of, on *CuZn-SOD*
 and *p22^{phox}* message gene expression in HUVECs and
 HAECs, 3-11
- Limb blood flow (LBF)
 effects of creatine and endurance exercise on REE and, 1429-1434
see also Leg blood flow, insulin in
- Lipase, *see* Hepatic lipase; Hormone-sensitive lipase; Lipoprotein
 lipase; Phospholipase D
- Lipemia, *see* Postprandial lipemia
- Lipid(s)
 AAs, glucose, and kinetics of, following palliative resection in
 glioma syndrome, 720-722
 accumulation of, TZD- and glucocorticoid-induced preadipocyte
 stromal cell differentiation and, 410-411
 blood, aerobic exercise and changes in, related to AT and aerobic
 fitness, 841-848
 exercise effects on, 1051
 in high-protein, CHO-free diet, 1494
 KSVLPD effects on oxidation of, in CRF, 337-338
 metformin effects on, in nondiabetic morbidly obese subjects, 859
 in offspring of South Asian immigrants, 1197-1202
 in older urban and rural Mexican subjects, as risk factor for CAD,
 311-318
 oxidation of, in anorexia nervosa, 877
 and pioglitazone effects on balloon-injured VSCM proliferation,
 957
 plasma, *see* Plasma lipid(s)
 relation of serum leptin to profile of, in children, 1091-1094
 serum, *see* Serum lipids
 skeletal muscle cell, and O_2 supply in women, 380-381
 in STZ-DM, ALA or evening primrose oil effects on risk factors
 due to, 868-875
see also Dietary fat; Dyslipidemia; Lipid hydroperoxide;
 Normolipidemia; Oil; Phospholipid(s); Postprandial lipemia
entries beginning with terms: Fat, Fatty elements; Adip-, Lip-
 and specific lipids
- Lipid(s), gene polymorphism and
 APOE gene polymorphism effects on composition of lipid
 erythrocyte membrane in essential hypertension, 157-160
 in FH, TaqIB polymorphism in *CETP* gene locus and, 653
- Lipid hydroperoxide, aspirin effects on SOD and, in Cu deficiency,
 559
- Lipogenic enzyme mRNA (messenger ribonucleic acid) in WAT
 after starvation-refeeding cycles, 734-738
- α (alpha)-Lipoic acid (ALA)
 effects of, on glucose-induced IR in 3T3-L1 adipocytes and on irl
 during cell incubation, 1063-1069
 effects of evening primrose oil or, on vascular hemostatic and
 lipid risk factors, blood flow, and peripheral nerve conduction
 in STZ-DM, 868-875
- Lipolysis
 effects of angiotensin II on, 468-472
 translocation of HSL and perilipin upon stimulation of, during
 lactation, 1264-1269
- Lipolytic response to isoproterenol by differentiated adipocytes, 411
- Lipoprotein(s) (Lp)
 in carotid artery atherosclerosis subjects, 1097
 CETP and profile of, in neonates, birth weight and, 723-728

- Lipoprotein(s) (Lp) (*Continued*)
 childhood-to-adulthood variables in, in CHD parent offspring, 1441-1446
 plasma, *see* Plasma lipoprotein
 serum, *see* Serum lipoprotein, diet effects on
see also Dyslipoproteinemia; High-density lipoprotein(s); Hyperlipoproteinemia; Lipoprotein(a); Low-density lipoprotein and specific apolipoproteins
- Lipoprotein(a) [Lp(a); high-density lipoprotein₁]
 apo E-containing, in NTG and HTG, 277-282
 in CRF, effects of vitamin B₆, folic acid, and cyanocobalamin on fibrinogen, Hcy and, 131-134
 effects of obesity with and without hyperinsulinemia on, in men, 178-183
 in hyperlipidemic women, *see* Lipoprotein(a) in hyperlipidemic women
 in PM women, IR, dietary cholesterol and, 595, 596
 serum, *see* Serum lipoprotein(a), diet effects on
 in South Asian immigrants' offspring, 1200
- Lipoprotein(a) [Lp(a); high-density lipoprotein₁] in hyperlipidemic women
 ATCVD and, 362
 PP lipemia and, 332
- Lipoprotein lipase (LPL)
 activity of, in gout, 952-954
see also Lipoprotein lipase, PP lipemia and; Lipoprotein lipase gene polymorphism
- Lipoprotein lipase (LPL), PP lipemia and
 activity of skeletal muscle, in moderate exercise, 756-762
 in hyperlipidemic PM women, 332
- Lipoprotein lipase (LPL) gene polymorphism
 interactions between Gln27-Glu mutation of β_2 -ADP gene, glucocorticoid receptor gene and, plasma insulin and lipid levels and, 246-252
 Ser₄₄₇-Stop, associated with variation in serum HDL-C, 894-904
- Lithium-sodium (Na) countertransport in essential hypertension, APOE gene polymorphism effects on, 157-160
- Liver
 aspirin effects on size of, 559
 in DM, chromium, selenium, zinc, and iron distribution in, 1168-1169, 1171
 troglitazone effects on VAT and sulfonylurea-associated fatty, in NIDDM, 414-417
see also Broccoli, effects of, of cytochrome P-450 activities in liver, kidney, and colon
- LM (lean meat) meal, effects of, on PP sex hormone concentrations in men, 505-511
- Locus (loci)
 CETP gene, in FH, association between plasma Lp levels and TaqIB polymorphism in, 651-656
 influencing DHEA levels, genome-wide linkage scan in detection of, 1315-1322
 variations in vitamin D-binding protein gene Gc, and risk of NIDDM in French subjects, 366-369
- Long-chain triacylglycerols (LCTs), thermic effects of SMLCTs versus, in young women, 125-130
- Long-lasting hyperleptinemia, dexamethasone-induced anorexia and, in older subjects, 1054-1058
- Long-term denervation, effects of SM, on IRS-1-mediated insulin signaling in SM, 216-222
- Long-term effects
 of inhaled beclomethasone dipropionate, effects of, on osteocalcin levels in COPD, 1336-1339
- Long-term effects (*Continued*)
 of partial nephrectomy on biological parameters, renal histology, and guanidino compounds, 1418-1425
- Lovastatin, hypocholesterolemic effects of SCH 48461 and SCH 58235 with, 1234-1241
- Low-density lipoprotein (LDL)
 and ATCVD in hyperlipidemic women, 362
 atorvastatin effects on subtypes of, in hyperlipoproteinemia, 983-988
 cytokine effects on metabolism of, by UVECs and AECs, 99-106
 effects of, on apo A-I kinetics in heterozygous FH, 635-639
 in older men, IR, proinsulin, and particle size of, 120-124
 oxidized, *see* Oxidized low-density lipoproteins
 in South Asian immigrants' offspring, 1199, 1200
see also Low-density lipoprotein-cholesterol
- Low-density lipoprotein-cholesterol (LDL-C)
 in adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 and atherosclerosis, *see* Low-density lipoprotein-cholesterol, atherosclerosis and
 in CAD, *see* Low-density lipoprotein-cholesterol in CAD
 childhood-to-adulthood variables in, in CHD parent offspring, 1444
 chitotriosidase activity and concentration of, 449
 in CRF, effects of vitamin B₆, folic acid, and cyanocobalamin on, 132
 and CV risk factors in men, 884
 diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
 and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453
 exercise and, *see* Low-density lipoprotein-cholesterol, exercise and
 gene polymorphism effects on, *see* Low-density lipoprotein-cholesterol, gene polymorphism effects on
 in gout, 953
 in hyperlipidemia, *see* Low-density lipoprotein-cholesterol in hyperlipidemia
 in IDDM, apo A-IV concentrations and, 1021
 IR and, *see* Low-density lipoprotein-cholesterol, and IR
 and Lp distribution of apo C-III, 113
 maternal and neonatal Lp profile of, 725, 726
 in metabolic syndrome, 137-140
 in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
 in normolipidemia, serum-promoted C efflux and, 1332
 in NTG and HTG, 279
 in obesity, *see* Low-density lipoprotein-cholesterol in obesity
 in PM women, *see* Low-density lipoprotein-cholesterol in PM women
 in premenopausal women, abdominal AT distribution and, 978, 990
 in primary dyslipoproteinemias, 167
- Low-density lipoprotein-cholesterol (LDL-C), Ala54Threo *FABP2* gene polymorphism and
 effects of, 474
 with Trp64Arg polymorphism of β_2 -ADP gene, in older women, insulin sensitivity and, 1303-1305
- Low-density lipoprotein-cholesterol (LDL-C), APOE gene polymorphism and
 effects of, on plasma LDL-C in HTN, 159
 environmental factors modulating APOE gene polymorphism effects, 938, 939
- Low-density lipoprotein-cholesterol (LDL-C), atherosclerosis and
 in carotid artery atherosclerosis, 1097
 in MI survivors and their spouses, 27

- Low-density lipoprotein-cholesterol (LDL-C), diet effects on
 high-fat, high-cholesterol diet effects, 461
 very-high-fiber vegetable, fruit, nut diet effects, 497
- Low-density lipoprotein-cholesterol (LDL-C), exercise and
 aerobic exercise effects, 842
 by NIDDM subjects with cardiovascular disease, changes in
 disease and changes in, 1258, 1260, 1261
- Low-density lipoprotein-cholesterol (LDL-C), gene polymorphism
 effects on
 of *CRH* regulatory gene region in obese subjects, 1060
 LPL gene polymorphism, 887
 TaqIB polymorphism in *CETP* gene locus and, 653, 654
see also Low-density lipoprotein-cholesterol, Ala54Threo *FABP2*
 gene polymorphism and; Low-density lipoprotein-cholesterol,
APOE gene polymorphism and
- Low-density lipoprotein-cholesterol (LDL-C), and IR
 LDL particle size, insulin resistance, proinsulin and, 122
 in MI prior to age 40 associated with IR, 31
 plasma *CETP* activity and, 785
see also Low-density lipoprotein-cholesterol in insulin-resistant
 women
- Low-density lipoprotein-cholesterol (LDL-C) in CAD
 β_2 -*ADR* gene mutation and, 186
 with DM, RLP-C in, 1463, 1464
- Low-density lipoprotein-cholesterol (LDL-C) in FH
 in heterozygous FH, 636
 TaqIB polymorphism in *CETP* gene locus and, 653, 654
- Low-density lipoprotein-cholesterol (LDL-C) in hyperlipidemia
 in hyperlipidemic PM women, PP lipemia and, 331
 in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects
 on, 731
 with NIDDM, 356
 in older subjects, coronary risk factors and, 314, 315
see also Low-density lipoprotein-cholesterol in FH
- Low-density lipoprotein-cholesterol (LDL-C) in insulin-resistant
 women
 in obese women, relationship between IR, weight-loss, and risk of
 CAD in, 796-798
 PM women, dietary cholesterol and, 595, 596
- Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
 with cardiovascular disease, changes in disease and changes in,
 1258, 1260, 1261
 with hyperlipidemia, 356
 serum, gemfibrozil or simvastatin effects on, 1149
- Low-density lipoprotein-cholesterol (LDL-C) in obesity
 CVD risk and, 300-302
 in dyslipidemic young adults, 697, 699
 with and without hyperinsulinemia, 180, 181
 in nondiabetic morbidly obese subjects with BMI greater than 30,
 metformin effects on, 856-861
 in obese women, relationship between IR, weight loss, and risk of
 CAD in, 796-798
 polymorphism of *CRH* gene regulatory region and, 1060
- Low-density lipoprotein-cholesterol (LDL-C) in PM women, serum
 PON arylesterase and
 in diabetic women on HRT, 321
 in nondiabetic women, 806, 808
- Low-density lipoprotein-cholesterol (LDL-C) in PM women
 abdominal AT distribution and, 978, 990
 in hyperlipidemic women, PP lipemia and, 331
 IR, dietary cholesterol and, 595, 596
 serum PON arylesterase activity and, *see* Low-density lipoprotein-
 cholesterol in PM women, serum PON arylesterase and
- Low-density lipoprotein (LDL) receptor, effects of apo E deficiency
 on hepatic cholesterol and bile acid synthesis, plasma and
 fecal sterol levels, and function of, probucol or phytosterol
 therapy for, 708-714
- Low-dose leptin, sibutramine and, in diet-induced obesity treatment,
 889-893
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LPL, *see* Lipoprotein lipase
- Lutein in NIDDM and nondiabetic subjects, antioxidant status and,
 1155-1158
- Luteinizing hormone (LH) in men
 effects of LM, MAF, tofu, and MOS meals on PP concentration
 of, 506
 in young adult men, race and, 1243
- LVM (left ventricular mass) in men, CV risk factors and, 882-888
- Lycopene in NIDDM and nondiabetic subjects, antioxidant status
 and, 1155-1158
- Lymphocyte methylenetetrahydrofolate reductase (MTHFR), blood
 S-adenosylmethionine concentrations and activity of, in DM
 and diabetic nephropathy, 1014-1018
- Lysine (Lys) in IDDM and NIDDM platelets, 740
- Macroalbuminuria
 in metabolic syndrome, 137
 in NIDDM, *see* Macroalbuminuric non-insulin-dependent diabetes
 mellitus
- Macroalbuminuric non-insulin-dependent diabetes mellitus (NIDDM)
 pioglitazone effects on podocyte urinary excretion in, 1193-1196
 platelet taurine fluxes and, 61
 prostacyclin-induced skin BF changes in, 569
- Macrophage(s), circulating GM-CSF and serum FA composition in
 men and women, 1479-1483
- Macrophage 3-hydroxy-methylglutarate-coenzyme A (HMG-CoA)
 reductase in sitosterolemia, 1224-1229
- MAF (meat with animal fat) meal, PP sex hormone response to, in
 men, 505, 508-509
- Magnesium (Mg)
 effects of, on IMGU and serum lipids in IDDM, 1409-1417
 serum, during gemfibrozil or simvastatin therapy in NIDDM,
 1147-1151
- Malabsorption, dietary fat, effects of chronic hyperglycemia,
 inflammation, or, on apo A-IV concentration in IDDM
 secondary to chronic pancreatitis, 1019-1024
- Male subjects, *see* Men
- Malnutrition, dietary protein, cytogenetic studies of, in bone marrow
 cells, 1025-1029
- Malonyl-coenzyme A (CoA), and myocardial insulin responsiveness
 to cardiac workload and, 1086
- Manganese (Mn)-dependent superoxide dismutase (SOD), effects of
 overexpression of, on collagen accumulation by mesangial
 cells, 1043-1048
- Maternal iron (Fe) restriction, effects of, on BP, glucose tolerance,
 and serum lipids in 3-month-old offspring, 562-567
- Maternal lipoprotein (Lp), neonatal and, 724-726
- Maturation, *see* Growth
- Maximal oxygen uptake, *see* $\dot{V}O_{2max}$ during exercise
- MCAD (medium-chain acyl-coenzyme A dehydrogenase), fasting,
 ketone production by children deficient in, 161-165
- MCH (melatonin-concentrating hormone) mRNA (messenger
 ribonucleic acid) in cancer cachexia, 1213-1219
- MCTs (medium- and long-chain triacylglycerols), thermic
 effects of SMLCTs versus, in young women, 125-130

- Meals
 high and moderate glycemic index, effects of, on metabolism and exercise performance by men, 849-855
 LM, MAF, tofu, and MOS, effects of, on PP sex hormone concentration in men, 505-511
see also Calories; Food intake *entries beginning with terms:*
 Dietary, Postprandial, Preprandial *specific food groups and food substances*
- Meat with animal fat (MAF) meal, PP sex hormone response to, in men, 505, 508-509
- Meat with safflower oil (MOS) meal, PP sex hormone response to, in men, 508-509
- Mediterranean Spanish population, influence of environmental factors on effects of *APOE* gene polymorphism on plasma lipid concentrations in, 936-944
- Medium chain acyl-coenzyme A dehydrogenase (MCAD), fasting, ketone production by children deficient in, 161-165
- Medium- and long-chain triacylglycerols (MLCTs), structured, thermic effect of LCTs versus, in young women, compared, 125-130
- Medullary collecting duct, inner, angiotensin regulating ET_B receptor in, 661-666
- Melatonin-concentrating hormone (MCH) mRNA (messenger ribonucleic acid) in cancer cachexia, 1213-1219
- Membrane phospholipid (PL) fatty acids (FAs), insulin sensitivity, composition of, and early growth restriction, 1070-1077
- Men
 circulating GM-CSF and serum FA composition in, 1479-1483
 exercising, *see* Men, exercising
 hyperinsulinemic, *see* Men, hyperinsulinemic
 with idiopathic osteoporosis, alendronate effects on BMD in, 912-915
 insulin-resistant, *see* Men, insulin-resistant
 Japanese, *see* Japanese men
 middle-aged, *see* Middle-aged men
 older, *see* Older men
 relation between HDL *PON1* gene M/L55 polymorphism and carotid artery atherosclerosis in nonsmoking and smoking, 1095-1101
 sex hormones in, *see* Men, sex hormones in
 SHBG in, *see* Sex hormone-binding globulin in men
 total homocysteine differences between women and, 640-645
see also Healthy subjects; Sex; Young men *and specific conditions*
- Men, exercising
 effects of high and moderate glycemic index meals on metabolism and exercise performance of, 849-855
 middle-aged and young, S_g and S_i in sedentary men versus, 349-354
see also Exercise
- Men, hyperinsulinemic
 Korean, Ala54Threo polymorphism of *FABP2* gene associated with increased dietary fat oxidation and hyperinsulinemia but not with FA absorption in, 473-476
see also Men, obese hyperinsulinemic
- Men, insulin-resistant
 relationship of dietary fat, serum CEs, and PL FAs to markers of IR in, 86-92
 young Japanese men, effects of β_1 -*ADR* gene Trp64Arg polymorphism and *FABP2* gene Ala54Threo polymorphism on FPG in, 1301-1307
see also Insulin resistance; Older insulin-resistant men
- Men, obese hyperinsulinemic
 hyperinsulinemia compared with insulin secretion suppression in, 107-111
- Men, obese hyperinsulinemic (*Continued*)
 Lp(a) in, 178-183
- Men, sex hormones in
 CV risk factors and, 882-888; *see also* Risk factors for CVD
 PP sex hormone concentrations with LM, MAF, tofu, and MOS meals, 505-511
see also Luteinizing hormone in men *and specific sex hormones*
- Menopausal status, *see* Postmenopausal women; Premenopausal women
- Mesangial cells, effects of Mn-dependent SOD on collagen accumulation by, 1043-1048
- Messenger ribonucleic acid, *see* mRNA
- Met, *see* Methionine
- Metabolic bone disease, DR effects on, 436-442
- Metabolic complications
 effects of *APOE* gene polymorphism-related, on erythrocyte membrane lipid composition or sodium-lithium countertransport in essential hypertension, 157-160
 of obesity, *see entries beginning with terms:* Metabolic risk factors for complications
 weight loss effects on, *see* Metabolic complications, weight loss effects on
see also specific abnormalities
- Metabolic complications, weight loss effects on
 of short-term weight loss in obese children, 1323-1329
 of weight loss with sibutramine, 819-824
- Metabolic disorders
 obesity and, 1500-1501
see also specific conditions
- Metabolic risk factors for complications of obesity, AT distribution and
 contributions of total AT, abdominal SAT, and VAT to complications, 425-435
 hemostatic and, in obese children, relationship between AT and AT distribution and, 681-687
- Metabolic risk factors for complications of obesity in children
 effects of changes in BMI and subcutaneous AT on, after short-term weight loss, 1323-1329
 hemostatic and, relationship between AT and AT distribution and, 681-687
- Metabolic syndrome (insulin resistance syndrome; MS), urinary excretion of epinephrine and NE related to obesity, insulin and, in Chinese subjects, 135-143
- Metabolically normal obesity subtype, 1499-1504
 clinical care of, 1501-1503
 diagnosis of, 1501
 evidence of, 1499-1500
 mechanisms underlying, 1501-1502
- Metformin (dimethylbiguanide)
 exercise effects on efficacy of, 1049-1053
 in hyperlipidemic NIDDM, 356
see also Nondiabetic morbidly obese subjects, metformin effects in
- Methionine (Met)
 in IDDM and NIDDM platelets, 740
 serum, during HAART, 1278
- 4-Methoxyglucobrassicin, 1124, 1133, 1134
- Methylenetetrahydrofolate reductase (MTHFR)
 blood S-adenosylmethionine concentrations and activity of, in DM and diabetic nephropathy, 1014-1018
 and tHcy differences between men and women, 640-645
- N-Methylglycine in HIV infection during short-term HAART of, 1275-1281
- Methylmalonic acid during HAART, 1278

- Mevalonate, very-high-fiber vegetable, fruit, nut diet effects on urinary excretion of, 496-498
- Mexican subjects, elderly rural and urban, lipids and apo B as risk factors for CAD in, 311-318
- Mg, *see* Magnesium
- MI, *see* Myocardial infarction
- Microalbuminuria
in metabolic syndrome, 137
in NIDDM, platelet taurine fluxes and, 61
- Middle-aged men
exercising, S_g and S_i in sedentary men versus, 349-354
Japanese, hyperuricemia development in, 621-626
- Mineral density, *see* Bone mineral density
- Mineralization, bone, GH therapy effects on, in prepubertal GH-deficient children, 543
- Minimal model analysis
C-peptide secretion rate and, in characterization of pathophysiological phenotypes in Japanese subjects with varying degrees of glucose tolerance in, 812-818
of insulin sensitivity in athletes, fasting RER and, 1286-1293
- MIS (mutant insulin syndrome), renal metabolism of insulin in, 863-867
- Mitochondrial gene, beta cells regulated by, 200-206
- Mitogen-activated phosphokinase phosphatase-1 (MKP-1), hepatic, PPAR α regulation of, 966-967
- Mixed (combined) hyperlipidemias
bezafibrate and atorvastatin effects on serum chitotriosidase genotype in, 447-450
ciprofibrate versus gemfibrozil for, 729-733
- Mixed hyperlipoproteinemia (HLP), hemorrhologic abnormalities and risk of atherosclerosis in, 166-170
- MLC-P (myosin light-chain phosphorylation) in resting platelets of diabetic premenopausal women, 151-156
- ML/55 polymorphism of HDL *PON1* gene, relation between carotid artery atherosclerosis and, in smoking and nonsmoking men, 1095-1101
- Mn (manganese)-dependent SOD (superoxide dismutase), effects of overexpression of, on collagen accumulation by mesangial cells, 1043-1048
- MNCs, *see* Mononuclear cells
- Modeling, physiologic, of IVGTT in NIDDM, 512-519
- Moderate exercise
aortopulmonary shunts and metabolic responses to, 399-406
postprandial lipemia, skeletal muscle LPL activity and, 756-762
by women, CHO metabolism during, 481-487
- Moderate glycemic index meals, effects of, on metabolism and exercise performance by men, 849-855
- Monocyte-endothelial cell adhesion, LDL-induced soluble cell adhesion molecules and, and autoantibodies to oxidized LDLs in CRF subjects on HD, 207-215
- N(G)-Monomethyl-L-arginine (L-NMMA), effects of, on insulin-mediated SM blood flow and glucose disposal in elderly subjects, 306-310
- Mononuclear cells (MNCs)
effects of cortisol on ROS generation by, 548-552
proliferation of peripheral blood, in HD subjects, effects of PBMC total Cu^{++} and Zn^{++} on, 270-276
- Monoxygenase system, cytochrome P-450-linked-, rifampicin effects on depressive effects of IL-1 on, 231-236
- Monophosphate, cyclic guanosine 3',5', and NO-induced glucagon secretion from pancreatic alpha cells, 703-707
- Monounsaturated fatty acids (MUFAs)
in IR, 88
in LM, MAF, tofu, and MOS meals, 506
- Monounsaturated fatty acids (MUFAs) (*Continued*)
and physical activity effects on IR association with intake of, 1188
serum, circulating GM-CSF, 1481
in serum PL FAs in NIDDM, 1475
in very-high-fiber vegetable, fruit, nut diet, 496
- Morbidly obese subjects, *see* Nondiabetic morbidly obese subjects, metformin effects in
- Morphology, pancreatic islet, systemic bromocriptine/SKF38393 effects on, in obesity, 1379
- MOS (meat with safflower oil) meal, PP sex hormone concentrations and, in men, 508-509
- mRNA (messenger ribonucleic acid)
CYP2D, IL-1 effects on, 231-236
differentiated adipocyte stromal cell, 411
effects of overexpression of Mn-dependent SOD on collagen accumulation by mesangial cells, 1043-1048
GPI-PLD, regulated by glucose and insulin, 1489-1492
hepatic and skeletal muscle IRS-2, HF diet effects on, 1369-1376
HKII, effects of exercise on increase of, in obese subjects, 602-606
hypothalamic NPY, in cancer cachexia, 1213-1219
lipogenic enzyme, in WAT after starvation-refeeding cycles, 734-738
mitochondrial, in beta cells, 200-206
in NIDDM, *see* mRNA in NIDDM
in obesity, *see* mRNA in obesity
regulation of GPI-PLD, in beta cells, regulated by glucose and insulin, 1489-1492
RXR, in SM of nondiabetic subjects, 830-834
see also Gene expression
- mRNA (messenger ribonucleic acid) in NIDDM
HKII, effects of exercise on increase of, 602-606
RXR, in SM of obese NIDDM subjects, 830-834
- mRNA (messenger ribonucleic acid) in obesity
GLUT2 and GK, systemic bromocriptine/SKF38393 effects on, 1379
HKII, exercise effects on increase of, 602-606
RXR in SM of obese NIDDM subjects, 830-834
- MS (metabolic syndrome; insulin resistance syndrome), urinary, exertion of E and NE related to obesity, insulin and, in Chinese subjects, 135-143
- MTHFR (methylenetetrahydrofolate reductase), and tHcy differences between men and women, 640-645
- Mucosa, small intestinal, effects of suppressed intestinal apoptosis on thickness of, in STZ-DM, 259-264
- MUFAs, *see* Monounsaturated fatty acids
- Muscle
in NIDDM, Mg content in, 1411
STZ-DM, lactate transport in SVs of, 418-424
see also Muscle cells; Muscle glycogen; Skeletal muscle *entries*
beginning with terms: Intramyocellular, Muscular and
element: Myo-
- Muscle cells
skeletal, lipids and O_2 supply in, in women, 380-381
vascular smooth, *see* Vascular smooth muscle cells
- Muscle glycogen, effects high and moderate glycemic index meals on exercise performance and, 852
- Muscular dystrophy, Duchenne, paradoxical weight loss with extra EE at BAT in adolescents with, 1181-1185
- Mutant insulin syndrome (MIS; Insulin Wakayama), renal metabolism of insulin in, 863-867
- Mutation
Gln27Glu, *see:* β_2 -ADR gene Gln27Glu mutation

Mutation (Continued)

- I/D, of ACE gene in Chinese NIDDM women with ACE inhibitor-related cough, 1346-1350
 of thrombophilic 20210 G/A prothrombin gene for atherothrombotic CVD, interaction between ERT and, in hyperlipidemia, 360-365
see also Polymorphism
- Myocardial infarction (MI), 24-35
 CAD and, 186
 endogenous whole blood cardiostrophin-1 in, 237-240
 prior to age 40, IR associated with, 30-35
 risk factors for atherosclerosis in survivors of, and their spouses, 24-29
- Myocardial insulin, effects of cardiac workload changes on substrate fluxes and responsiveness of, 1083-1090
- Myosin light-chain phosphorylation (MLC-P) in resting platelets of diabetic premenopausal women, 151-156
- N (nitrogen), *see* α -Amino nitrogen; Urea nitrogen
- Na (sodium)
 furosemide effects on, 242-244
 insulin sensitivity and urinary excretion of, in hypertensive subjects and their normotensive offspring, 929-935
 NE effects on, 1232
 plasma, *see* Plasma Na
 serum, *see* Serum Na
 and sodium-lithium countertransport in essential hypertension, APOE gene polymorphism effects on, 157-160
see also Na^+/H^+ exchanger isoform-1; Na^+/K^+ adenosine triphosphatase
- NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, suppressive effects of hydrocortisone on $p47^{\text{phox}}$ subunit of, 548-552
- Na^+/H^+ (sodium/hydrogen) exchanger isoform-1 (NHE-1), potassium and, in VSMCs of hypertensive subjects, 778-782
- Na^+/K^+ (sodium/potassium) adenosine triphosphatase (ATPase), platelet, as marker in hyperthyroidism, 1393-1396
- Naloxone, effects of, on preprandial and PP GHRH-induced GH release after BPD-induced weight loss, post-BPD opioid dysregulation and, 382-386
- Natriuretic peptides, atrial, in hypertensive subjects and their normotensive offspring, 932, 934
- NCV (nerve conduction velocity), peripheral, in STZ-DM, ALA or evening primrose oil effects on, 868-875
- NE, *see* Norepinephrine
- NEFAs (nonesterified fatty acids), *see* Free fatty acids
- Neoglucobrassicin, 1124, 1131, 1133, 1134
- Neonatal growth restriction, membrane phospholipid fatty acid composition, insulin sensitivity and, 1070-1077
- Nephrectomy, partial, long-term effects of, on biological parameters, renal histology, and guanidino compounds, 1418-1425
- Nephropathy
 diabetic, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity in, 1014-1018
 IgG and reflux, 208
see also Chronic renal failure; Glomerular pathology
- Nerve conduction velocity (NCV), peripheral, in STZ-DM, ALA or evening primrose oil effects on, 868-875
- Nervous system, autonomic, in hepatic glucose production, 744, 748-749
- Neuropeptide Y (NPY), hypothalamic
 mRNA of, in cancer cachexia, 1213-1219
 vanadium effects on, 667-673
- NHE-1 (Na^+/H^+ exchanger isoform-1) in VSMCs of hypertensive subjects, potassium and, 778-782
- Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, suppressive effects of hydrocortisone on $p47^{\text{phox}}$ subunit of, 548-552
- Nicotine, oral, effects of, on TNF- α levels in obesity, 79-85
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nitric oxide (NO)
 cGMP and glucagon secretion from pancreatic alpha cells induced by, 703-707
 in platelets of diabetic premenopausal women, 153
- Nitric oxide synthase (NOS), ET-1 gene expression and levels of, in fructose-induced hypertension, 74-78
- Nitrogen, *see* α -Amino nitrogen; Urea nitrogen
- L-NMMA [*N*(G)-monomethyl-L-arginine], effects of, on insulin-mediated SM blood flow and glucose disposal in elderly subjects, 194-199, 306-310
- NO, *see* Nitric oxide
- Nondiabetic morbidly obese subjects, metformin effects in adolescents, 1457-1461
 with BMI greater than 30, metformin reducing BW, centripetal obesity, leptin, and LDL-C in, 856-861
- Nondiabetic subjects, 825-834
 correlation between serum VEGF and carotid artery distensibility in, 825-829
 IR effects on serum PON arylesterase activity in, 805-811
 morbidly obese, *see* Nondiabetic morbidly obese subjects, metformin effects in
 with pancreatic cancer, glucose-stimulated amylin secretion in, 1036-1042
 premenopausal, platelet function in, 151-156
 RXR expression in skeletal muscle of, 830-834
 1704G/T and 2184A/G RAGE gene polymorphisms in, 1152-1160
 vascular hemostatic risk factors in, 870
- Nonesterified fatty acids, *see* Free fatty acids
- Nonglucose stimulation, insulin secretion in response to, in NIDDM, 1282-1285
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), 1147-1160
 Abs to pancreatic islet cells and GAD in identification of type 1½ diabetes in patients presenting with, 1008-1013
 acylation-stimulating protein concentration related to C-reactive protein in, 283-287
 autonomic balance of NIDDM subjects' offspring, 1270-1274
 exercise effects in, *see* Non-insulin-dependent diabetes mellitus, exercise effects in
 glucose in, *see* Glucose in NIDDM
 Hirschsprung's disease and susceptibility to development of, 1389-1390
 insulin secretion in, *see* Insulin release and secretion in NIDDM
 inverse relationship between circulating FFAs and insulin time series disorderliness in, circulating insulin levels and, 41-46
 macroalbuminuric, *see* Macroalbuminuric non-insulin-dependent diabetes mellitus
 and metabolic syndrome, 135-143
 mRNA in, *see* mRNA in NIDDM
 normoalbuminuric, *see* Normoalbuminuric non-insulin-dependent diabetes mellitus
 with obesity, *see* Non-insulin-dependent diabetes mellitus with obesity
 PGE₁ and conversion of hepatic α -amino-nitrogen to urea nitrogen in poorly controlled, 253-258
 physiologic modeling of IVGTT in, 512-519
 platelet amino acids in, *see* Platelet amino acids
 prostacyclin-induced skin BF changes in, ABI and plasma TM and, 568-572

- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) (*Continued*)
- by race and ethnicity, *see* Race and ethnicity of NIDDM subjects
 - serum Mg during gemfibrozil or simvastatin therapy of, 1147-1151
 - serum PL FA composition and insulin action in, 1472-1478
 - 1704G/T and 2184A/G *RAGE* gene polymorphisms associated with antioxidant status in, 1152-1160
 - simvastatin effects on PP HTG in, 355-359
 - SM, *see* Skeletal muscle in NIDDM
 - sulfonylureas in, *see* Sulfonylureas in NIDDM
 - urinary excretion in, *see* Urinary excretion in NIDDM
 - vitamin D-binding protein gene and risk of, 366-369
 - see also* Japanese subjects, NIDDM; Streptozotocin-induced diabetes mellitus; Women, NIDDM
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), exercise effects in
- with cardiovascular disease, changes in disease and in $\dot{V}O_{2\max}$ changes in subjects with, 1255-1263
 - on HKII mRNA, 602-606
 - on serum leptin, 1136-1140
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) with obesity
- hyperinsulinemia and, and parasympathetic drive to pancreas, 223-230
 - platelet amino acids in, 739-741
 - see also* Non-insulin-dependent diabetes mellitus with obesity, SM in
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) with obesity, SM in
- RXR expression in, 830-834
 - SM PKC theta content in, 555
- Non-obese (lean) subjects
- diabetic, δ opioid receptors and glucose uptake in SM of, 1402-1408
 - effects of changes in glucose, insulin, and IGF-1 level on serum CBG in, 1248-1252
 - high-fructose diet effects on preservation of beta-cell mass and on prevention of diabetes in, 1369-1376
 - insulin secretion in, *see* Non-obese subjects, insulin release and secretion in
- Non-obese (lean) subjects, insulin release and secretion in
- hyperinsulinemia and short-term fasting, suppression of insulin secretion and, 107-111
 - and insulin sensitivity in Japanese NIDDM subjects, bezafibrate effects on, 477-480
- Nonsmoking men, relation between HDL *PON1* gene M/L55 polymorphism and carotid artery atherosclerosis in smoking and, 1095-1101
- Nonthyroid illness (NTI), thyroid function abnormalities in, 1397-1401
- Noradrenaline, *see* Norepinephrine
- Norepinephrine (NE; noradrenaline)
- and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453, 1455
 - during exercise, *see* Norepinephrine during exercise
 - plasma, *see* Plasma norepinephrine
 - urinary excretion of, related to obesity, insulin, and metabolic syndrome in Chinese subjects, 135-143
- Norepinephrine (NE; noradrenaline) during exercise
- with high/or moderate glycemic meals, 852-854
 - in moderate exercise, 401
- Normal subjects, *see* Healthy subjects and entries beginning with element: Norm-
- Normoalbuminuric non-insulin-dependent diabetes mellitus (NIDDM)
- platelet taurine fluxes and, 61
 - prostacyclin-induced skin BF changes in, 569
- Normoglycemic subjects, obese, PKC theta content in SM of, 555
- Normolipidemia, basal and PP serum-promoted C efflux in, 1330-1335
- Normoponderal subjects, *see* Non-obese subjects
- Normotensive offspring, insulin sensitivity and Na excretion in hypertensive subjects and their, 929-935
- Normotriglyceridemia (NTG), apo E-containing Lp(a) in, 277-282
- NOS (nitric oxide synthase), ET-1 gene expression and levels of, in fructose-induced hypertension, 74-78
- NPY, *see* Neuropeptide Y, hypothalamic
- NTG (normotriglyceridemia), apo E-containing Lp(a) in, 277-282
- NTI (nonthyroid illness), thyroid function abnormalities in, 1397-1401
- Nuts, effects of in very-high-fiber vegetable, fruit, nut diet, on serum lipids and colonic function, 494-503
- O₂ (oxygen)
- PO₂ in moderate exercise, 402
 - see also* O₂ supply; $\dot{V}O_2$ during exercise; $\dot{V}O_{2\max}$ during exercise
- O₂ (oxygen) supply
- skeletal muscle cell lipids and, in women, 380-381
 - systemic, in moderate exercise, 401, 402
- OA (osteoarthritis) of knee, relationship between OPG/OCIF concentrations in synovial fluid and severity of, 1-2
- Obesity
- β_2 -*ADR* gene Gln27Glu mutation and, *see*: β_2 -*ADR* gene Gln27Glu mutation, obesity and
 - in children, *see* Children, obese
 - diet-induced, *see* Obesity, diet-induced
 - DM with, *see* Obesity, DM with
 - ethnicity and, *see* Obesity, race and ethnicity and
 - exercise in, *see* Exercise by obese subjects
 - with or without glucose intolerance, effects of changes in glucose, insulin, and IGF-1 level on serum CBG in, 1248-1252
 - with hyperglycemia, citalopram effects on development of, 144-150
 - insulin in, *see* Insulin in obesity
 - leptin in, *see* Leptin in obesity
 - metabolic risk factors for, *see* Metabolic risk factors for complications of obesity, AT distribution and
 - mRNA in, *see* mRNA in obesity
 - normoglycemic, PKC theta SM content in, 555
 - oral nicotine effects on TNF- α levels in, 79-85
 - plasma CETP activity and, 783-788
 - plasma FFAs in, *see* Plasma free fatty acids in obesity
 - polymorphism of *CRH* gene regulatory region in relation to cortisol secretion, gene-gene interaction and, 1059-1062
 - systemic bromocriptine/SKF38393 effects on GLUT2, beta-cell hyperplasia, GK, and *irl* levels in, 1377-1384
 - see also* Adolescents, obese; Children, obese; Glucose uptake in DM with obesity; Healthy subjects, obese; Insulin sensitivity in obesity; Men, obese hyperinsulinemic; Metabolically normal obesity subtype; Nondiabetic morbidly obese subjects, metformin effects in; Sibutramine, weight loss by obese subjects with; Weight loss by insulin-resistant women; Women, obese; Young adults, obese
- Obesity, diet-induced
- effects of, on *PPAR* α , *PPAR* γ , retinoic acid, and T₃ nuclear receptor gene expression, 1161-1167
 - low-dose leptin and sibutramine in treatment of, 889-893

- Obesity, DM with
 acipimox effects on plasma FFAs mimicking CL-316243 effects in, 945-951
 in Japanese subjects, relationship of Gln27Glu mutation of β_2 -ADR gene to IGT and, 443-446
 δ opioid receptors and glucose uptake in SM of subjects with, 1402-1408
 S_1 of blood glucose versus S_1 of blood FFAs in, 573-582
see also Non-insulin-dependent diabetes mellitus with obesity
- Obesity, race and ethnicity and
 changes in obesity and changes in CVD risk in children, 299-305
 of obese young adults, *see* Race and ethnicity of obese young adults
 serum leptin and BP in obese Peruvian Indian and Caucasian women, 325-329
 urinary excretion of epinephrine and NE related to metabolic syndrome and obesity in Chinese subjects, 135-143
- Obstructive pulmonary disease, *see* Chronic obstructive pulmonary disease
- OC, *see* Oral contraception
- ODC (ornithine decarboxylase), STZ-DM effects on activity of, 261-263
- Offspring
 of CHD parents, Lp variables from childhood to adulthood in, 1441-1446
 of NIDDM subjects, autonomic balance of, 1270-1274
 normotensive, of hypertensive parents, insulin sensitivity and Na excretion in, 929-935
 of South Asian immigrants, leptin, lipid profile, insulin, and anthropometry of, 1197-1202
 3-month-old, effects of restricted maternal Fe on blood pressure, glucose tolerance, and serum lipids in, 562-567
see also Children
- OGTT, *see* Oral glucose tolerance test
- 3-OHB (3-hydroxybutyrate) in fasting MCAD-deficient children, 162-165
- 17-OHCS (17-hydrocorticosteroid), exercise effects on urinary excretion of, in NIDDM, 1138
- Oil
 effects of ALA or evening primrose, on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in STZ-DM, 868-875
 effects of meat and safflower meal on PP sex hormone concentration in men, 505-511
 urinary excretion of phenols of olive, and their metabolites, 1426-1428
- Older insulin-resistant men
 Japanese men, effects of Trp64Arg β_2 -ADR gene polymorphism and FABP2 gene Ala54Thr polymorphism on FPG and IR, 1301
 LDL particle size, and proinsulin in, 120-124
- Older men
 changes in leg blood flow and capillary density in SM mediated by insulin in, 1078-1082
 insulin-resistant, *see* Older insulin-resistant men
 LDL particle size, and proinsulin in older men, 120-124
 smoking and nonsmoking, relation between HDL *PON1* gene polymorphism and carotid artery atherosclerosis in, 1095-1101
- Older subjects, 306-318
 dexamethasone-induced anorexia and long-lasting hyperleptinemia in, 1054-1068
 exercise-induced oxidative stress in, antipyrine oxidation and, 1484-1488
- Older subjects (*Continued*)
 hyperhomocysteinemia in, 1466-1471
 L-NMMA effects on insulin-mediated SM blood flow and glucose disposal in, 194-199, 306-310
 RMR in, effects of FM and AT distribution on, 972-975
 rural and urban Mexican, lipids and apo B as risk factors for CAD in, 311-318
see also Aging; Older men; Women, older
- Oleate, oxidation of, and myocardial insulin responsiveness to cardiac workload, 1084-1086
- Olive oil phenols, urinary excretion of, and their metabolites, 1426-1428
- OPG/OCIF (osteoprotegerin/osteoclastogenesis inhibitory factor), relationship between severity of osteoarthritis of knee and synovial fluid concentrations of, 1-2
- Opioid dysregulation, post-BPD, and naloxone effects on preprandial and postprandial GHRH-induced GH release in BPD-induced weight loss, 382-386
- δ (delta) Opioid receptors, glucose uptake in SM of obese and lean DM subjects, 1402-1408
- Oral contraception (OC)
 and APOE gene polymorphism effects on lipid concentrations, 938
 effects of, on serum DHEA, 488-493
- Oral glucose tolerance test (OGTT)
 of glucose effects on plasma von Willebrand factor concentration, 1453-1454
 effects of interactions between Gln27Glu mutation of β_2 -ADR gene and polymorphism of glucocorticoid receptor gene and LPL gene on, 246-252
 in IR, 86-92
 of lactating women with GDM history, 715
 of morbidly obese adolescents, 1460
 of obese PM women on HRT, 835-840
 serum and urinary insulin response to, in MIS, 864-865
 in STZ-DM, vanadium effects of GLUT4 translocation and, 674-676, 679
see also specific conditions
- Oral nicotine, effects of, on TNF- α levels in obesity, 79-85
- Orexin (OX) mRNA (messenger ribonucleic acid) in cancer cachexia, 1213-1219
- Ornithine decarboxylase (ODC), STZ-DM effects on activity of, 261-263
- Osteoarthritis (OA) of knee, relationship between OPG/OCIF concentrations in synovial fluid and severity of, 1-2
- Osteocalcin
 effects of long-term inhaled beclomethasone dipropionate on levels of, in COPD, 1336-1339
 in idiopathic osteoporotic men, 913
 serum, DR effects on, 440
- Osteoporosis, idiopathic, in men, alendronate effects on BMD in, 912-915
- Osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF), relationship between severity of osteoarthritis of knee and synovial fluid concentration of, 1-2
- Overweight, *see* Obesity
- OX (orexin) mRNA (messenger ribonucleic acid) in cancer cachexia, 1213-1219
- Oxidase, NADPH, suppressive effects of hydrocortisone on *p47^{phox}* subunit of, 548-552
- Oxidation
 antipyrine, exercise-induced oxidative stress in older subjects and, 1484-1488
 CHO, during exercise, 852

Oxidation (*Continued*)

- dietary fat, Ala54Threo polymorphism of *FABP2* gene in Korean men associated with hyperinsulinemia and increased, but not with intestinal FA absorption, 473-476
- glucose, *see* Oxidation, glucose
- lipid, *see* Oxidation, lipid
- protein, in anorexia nervosa, 877
- see also* Antioxidant(s); Oxidative stress; Oxidized low-density lipoproteins
- Oxidation, glucose
 - in anorexia nervosa, 877
 - KSVLPD effects on, in CRF, 337-338
 - myocardial insulin responsiveness to cardiac workload and, 1084-1086
- Oxidation, lipid
 - in anorexia nervosa, 877
 - KSVLPD effects on, in CRF, 337-338
- Oxidative stress
 - exercise-induced, in older subjects, antipyrine oxidation and, 1484-1488
 - in platelets of diabetic premenopausal women, 153
 - in STZ-DM, muscle SV lactate transport and, 420-421
- Oxidized low-density lipoproteins (LDLs)
 - cell-mediated, glitazide effects on dysfunction of VSMCs induced by, 688-695
 - LDL-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to, in CRF subjects on hemodialysis, 207-215
- Oxygen, *see* O₂
- Oxypurinol, urinary excretion of
 - furosemide effects on, 241-245
 - NE effects on, 1230-1233

P, *see* Phosphorus

- PA-Ag (plasminogen activator-antigen), tissue-type, in obese children, 681-687
- PAI, *see* Plasminogen activator inhibitor; Plasminogen activator inhibitor-1
- Palliative resection in glucanoma syndrome, AAs, lipid kinetics, and glucose following, 720-722
- Pancreas
 - in DM, chromium, selenium, zinc, and iron distribution in, 1168-1170
 - hyperinsulinemia, obesity, NIDDM, and parasympathetic drive to, 223-230
 - see also* Pancreatitis and beginning with terms: Biliopancreatic, Pancreatic
- Pancreatic cancer, nondiabetic subjects with, glucose-stimulated amylin secretion in, 1036-1042
- Pancreatic cells
 - Abs to GAD and to, in identification of type 1½ DM in patients presenting with NIDDM, 1008-1013
 - see also* Pancreatic islet cells
- Pancreatic/duodenal homeobox (PDX-1), and FFA effects on beta cell functions, 613-618
- Pancreatic islet(s)
 - HF diet effects on, 1370-1371
 - systemic bromocriptine/SKF38393 effects on, in obesity, 1379-1380
- Pancreatic islet cells
 - antibodies to glutamic acid decarboxylase and, in identification of type 1½ diabetes in subjects presenting with NIDDM, 1008-1013
 - see also* Alpha cells; Beta cells

- Pancreatic polypeptides, secretion of, in Pima Indian subjects, 223-230
- Pancreatitis, chronic, effects of chronic hyperglycemia, inflammation, or dietary fat malabsorption on apo A-IV concentration in DM secondary to, 1019-1024
- Paracrine mediators of hepatic glucose production, 744, 747-749
- Paradoxical weight loss with extra EE at BAT in adolescents with DMD, 1181-1185
- Paraoxonase (PON) arylesterase
 - altered activity of, and free radical formation in cirrhosis, 997-1000
 - see also* *PONI* gene M/L55 polymorphism; Serum paraoxonase arylesterase
- Parasympathetic drive to pancreas, hyperinsulinemia, obesity, NIDDM and, 223-230
- Parathyroid hormone (PTH) in idiopathic osteoporotic men, 913
- Parents, *see* Family history
- Partial nephrectomy, long-term effects of, on biological parameters, renal histology, and guanidino compounds, 1418-1425
- Partial pressure, carbon dioxide and oxygen, in moderate exercise, 402
- Pathology and pathogenesis
 - of diabetic ketoacidosis, effects of fasting and dehydration in, 171-177
 - glomerular, urinary excretion of type IV collagen and development of, in DM, 1435-1440
 - of NIDDM in Korean subjects, insulin secretory dysfunction and IR in, 590-593
 - see also* specific conditions
- Pathophysiological phenotypes in Japanese subjects with varying degrees of glucose tolerance, minimal model analysis and C-peptide secretion rate in characterization of, 812-818
- PBMCs (peripheral blood mononuclear cells), effects of total Cu⁺⁺ and Zn⁺⁺ content of, on PBMC proliferation in hemodialysis subjects, 270-276
- PCO₂ (carbon dioxide partial pressure) in moderate exercise, 402
- PDX-1 (pancreatic/duodenal homeobox), and FFA effects on beta cell functions, 613-618
- PEPCK (phosphoenol carboxykinase) gene, hepatic, PPARα regulation of, 966-967
- Peptides
 - atrial natriuretic, in hypertensive parents and their normotensive offspring, 932, 934
 - glucagon-like peptide-1, insulinotropic actions of, 583-589
 - pancreatic polypeptide secretion in Pima Indian subjects, 223-230
 - see also* C-peptides
- Perilipin, translocation of HSL and, upon lipolysis stimulation during lactation, 1264-1269
- Peripheral blood mononuclear cells (PBMCs), effects of total Cu⁺⁺ and Zn⁺⁺ content of, on PBMC proliferation in hemodialysis subjects, 270-276
- Peripheral gene expression in DM regulated by PPARγ and PPARα, 963-971
- Peripheral nerve conduction velocity (NCV) in STZ-DM, ALA or evening primrose oil effects on, 868-875
- Peripheral tissues, PPARγ activation in, 967-968
- Peroxisome proliferator-activated receptor, *see* Gene expression, PPARγ and PPARα; Gene expression, PPARγ and PPARα effects on; Peroxisome proliferator-activated receptor γ
- Peroxisome proliferator-activated receptor γ (PPARγ)
 - and FFA effects on beta cell functions, 613-618
 - see also* Gene expression, PPARγ, TZDs and; Gene expression, PPARγ and PPARα effects on

- Peruvian women, obese Indian and Caucasian, serum leptin and blood pressure in, 325-329
- p47^{phox}* subunit of NADPH oxidase, suppressive effects of cortisol on, 548-552
- PFK-1 (phosphofructo-1-kinase), effects of high-protein, CHO-free diet on, 1208-1212
- PFTs (pulmonary function tests) in COPD, 1398
- PG(s), *see* Prostacyclin; Prostaglandin(s); Prostaglandin E₁; Prostaglandin E₂
- pH
arterial, *see* Arterial blood gases
extracellular, in KCN- and IAA-exposed hepatocytes, 344-345
- Phe (phenylalanine) in IDDM and NIDDM platelets, 740
- Phenols, olive oil, urinary excretion of, and their metabolites, 1426-1428
- Phenotypes, pathophysiological, in Japanese subjects with varying degrees of glucose tolerance, minimal model analysis and C-peptide secretion rate in characterization of, 812-818
- Phenylalanine (Phe) in IDDM and NIDDM platelets, 740
- Phosphatase
alkaline, *see* Alkaline phosphatase
hepatic *HKP-1* gene regulated by PPAR α , 966-967
- Phosphate, *see* ATP; cGMP; NADPH oxidase; Phosphate dehydrogenase; Pyridoxal-5-phosphate
- Phosphate dehydrogenase, glycerol, and TZD- and glucocorticoid-induced preadipocyte stromal cell differentiation, 411
- Phosphoenol carboxykinase (PEPCK) gene, hepatic, PPAR α regulation of, 966-967
- Phosphofructo-1-kinase (PFK-1), effects of high-protein, CHO-free diet on, 1208-1212
- Phospholipase D (PLD), GPI-specific, glucose and insulin regulating expression of, 1489-1492
- Phospholipid(s) (PL)
high-fat, high-cholesterol diet effects on, 461
in hypertension with *APOE* gene polymorphism, 159
- Phospholipid (PL) fatty acids (FAs)
insulin sensitivity and composition of membrane, early growth restriction and, 1070-1077
relationship of serum CEs and, to markers of IR, glucose tolerance and, 86-92
serum, composition of, and insulin action in NIDDM, 1472-1478
- Phosphorus (P)
in GH-deficient prepubertal children, GH therapy effects on, 544
serum, in COPD, 1337
- Phosphorylation, myosin light-chain, in resting platelets of diabetic premenopausal women, 151-156
- Physical activity, *see* Exercise
- Physiologic modeling of IVGTT in NIDDM, 512-519
- Phytosterol(s)
for apo E deficiency effects on hepatic cholesterol and bile acid synthesis, LDL receptor function, and levels of plasma and fecal sterols, 708-714
see also Phytosterolemia; Plant stanol fatty acid esters
- Phytosterolemia in diabetic stroke-prone subjects, 1361-1368
- Pima Indian subjects, pancreatic polypeptide secretion in, 223-230
- Pioglitazone
effects of, on balloon-injured VSMC proliferation, 955-962
effects of, on urinary excretion of podocyte in macroalbuminuric NIDDM, 1193-1196
- PK (pyruvate kinase), effects of high-protein, CHO-free diet on, 1208-1212
- PKC (protein kinase C), glucose effects on renal interstitial fibroblast hyaluronan production, through TGF- β cascade and, 789-794
- PKC θ theta (protein kinase C theta) in SM of NIDDM subjects, 553-557
- PL, *see* Phospholipid(s)
- Plant stanol fatty acid (FA) esters
effects of, on C absorption and HMG-CoA reductase activity, 1106-1112
effects of, on plasma ubiquinol-10 and fat-soluble antioxidant concentrations, 520-529
see also specific plant stanols fatty acid esters; for example: Campestanol fatty acid esters
- Plasma, viscosity of, in primary dyslipoproteinemias, 167
- Plasma albumin in hyperhomocysteinemic elder subjects, 1467, 1469
- Plasma aldosterone
furosemide effects on, 242, 243
in hypertensive subjects and their normotensive offspring, 934
- Plasma alkaline phosphatase (ALP) in Tg subjects, CETP activity and, 532
- Plasma amylin in pancreatic cancer, 1038
- Plasma angiotensin II (AngII), furosemide effects on, 242, 243
- Plasma apolipoprotein(s) (apo), levels of, as risk factor for atherosclerosis in MI survivors and their spouses, 26-27
- Plasma apolipoprotein A-I (apo A-I) in heterozygous FH, 636
- Plasma atrial natriuretic peptides (ANPs) in hypertensive subjects and their normotensive offspring, 934
- Plasma cholesterol (C)
in Cu deficiency, 559
fasting, in IR with HTN, 1449, 1450
free, in apo E deficiency, probucol and/or phytosterol therapy effects on, 709
and Lp distribution of apo C-III, 113
in Tg subjects, CETP activity and, 532
total, *see* Total plasma cholesterol
- Plasma cholesteryl ester transfer protein (CETP)
insulin sensitivity and activity of, 783-788
thyroid hormone effects on plasma HDL removal rate and activity of, in Tg subjects, 530-536
- Plasma Cl (chloride)
NE effects on urinary excretion of, 1232
total, furosemide effects on, 243, 244
- Plasma coagulation factors in cirrhosis, 1342
- Plasma cobalamin, and differences in, between men and women, 644
- Plasma C-peptides (CPs; connecting peptides)
in glucanoma syndrome, 721
LDL particle size, IR, proinsulin and, 122
- Plasma creatinine in metabolic syndrome, 137-140
- Plasma epinephrine (E; EPI; adrenaline)
alcohol effects on, during acute hypoglycemia in NIDDM, 454-455
in exercising women, 485
- Plasma 17 β (beta) estradiol, and differences in, between men and women, 644
- Plasma ferritin in Cu deficiency, 559
- Plasma flow, hepatic, in cirrhosis, 1342
- Plasma folate, and differences in, between men and women, 641, 642, 644
- Plasma free fatty acids (FFAs; nonesterified fatty acids)
in fasting MCAD-deficient children, ketone production and, 162
in moderate exercise, *see* Plasma free fatty acids in moderate exercise
in obesity, *see* Plasma free fatty acids in obesity
in Tg subjects, HL activity and, 532
- Plasma free fatty acids (FFAs; nonesterified fatty acids) in moderate exercise
effects of reduced exercise on CHO metabolism, 481-487

- Plasma free fatty acids (FFAs; nonesterified fatty acids) in moderate exercise (*Continued*)
- PP lipemia, skeletal muscle LPL activity and, 759
- Plasma free fatty acids (FFAs; nonesterified fatty acids) in obesity with DM, acipimox effects on, mimicking CL-316243 effects in, 945-951
- role of, in insulin resistance of obese women, 819-824
- Plasma glucagon (hyperglycemic-glycogenolytic factor) in exercising women, 485
- Plasma glucose
- BRL-49653 effects on, 1295-1296
 - in CRF, KSVLPD effects on, 337-338
 - and exercise effects on HKII mRNA, 603
 - fasting, in IR with HTN, 1449, 1450
 - in fructose-induced hypertension, 76
 - hepatic glucose production regulation and concentration of, 744, 746
 - in IDDM with DKA, 173
 - in moderate exercise, 759
 - in NIDDM, *see* Plasma glucose in NIDDM
 - in lean DM subjects, 1403
 - obesity, *see* Plasma glucose in obesity
 - steady-state, *see* Steady-state plasma glucose
 - vanadium effects on, 669-671
 - see also* Fasting plasma glucose
- Plasma glucose in NIDDM
- in acute hypoglycemia of NIDDM, alcohol effects on, 453
 - insulin action on, serum PL FA composition and, 1473
 - in Korean subjects, 591
 - see also* Fasting plasma glucose in NIDDM
- Plasma glucose in obesity
- CVD risk and, 300-302
 - with DM, 1403
- Plasma growth hormone (GH)
- alcohol effects on, during acute hypoglycemia in NIDDM, 454-455
 - in cirrhosis, 1342
- Plasma guanidino compounds (GCs), partial nephrectomy and, 1420
- Plasma high-density lipoprotein (HDL), thyroid hormone effects on removal rate of, in Tg subjects, 530-536
- Plasma high-density lipoprotein-cholesterol (HDL-C)
- in HTN with *APOE* gene polymorphism, 159
 - in metabolic syndrome, 141
- Plasma high-density lipoprotein₂-cholesterol (HDL₂-C) in HTN with *APOE* gene polymorphism, 159
- Plasma high-density lipoprotein₃-cholesterol (HDL₃-C) in HTN with *APOE* gene polymorphism, 159
- Plasma insulin
- in cold-acclimated subjects on high-protein, CHO-free diet, 1494
 - in CRF, KSVLPD effects on, 337-338
 - effects of, on regional BF and glucose uptake, 69
 - in exercise, *see* Plasma insulin, exercise and
 - fasting, *see* Fasting plasma insulin in NIDDM
 - in fructose-induced hypertension, 76
 - in glucanoma syndrome, 721
 - LDL particle size, IR, proinsulin and, 122
 - lipid levels and, interaction between polymorphism of LPL and glucocorticoid receptor gene and Gln27Glu mutation of β_2 -*ADR* gene, 246-252
 - in metabolic syndrome, 140, 141
 - in obesity, *see* Plasma insulin in obesity
 - vanadium effects on, 669-671
- Plasma insulin, exercise and
- exercising women, 485
- Plasma insulin, exercise and (*Continued*)
- fasting, exercise effects on, in NIDDM, 1138
- Plasma insulin in obesity
- CVD risk and, 300-302
 - oral nicotine effects on, 80-81
 - systemic bromocriptine/SKF38393 effects on, 1379
- Plasma insulin-like growth factor-1 (IGF-1)
- for acromegaly, serum IGFBP-3 with serum leptin compared to, 1117-1121
 - in cirrhosis, 1342
- Plasma insulin-like growth factor-binding protein-3 (IGFBP-3) in cirrhosis, 1342
- Plasma K (potassium)
- NE effects on urinary excretion of, 1232
 - total, furosemide effects on, 243, 244
- Plasma lactate, alcohol effects on, during acute hypoglycemia in NIDDM, 453
- Plasma leptin
- fasting, in IR with HTN, 1449, 1450
 - vanadium effects on, 669-671
- Plasma lipid(s)
- chitotriosidase activity and, concentrations of, 448-449
 - and CV risk factors in men, 884
 - environmental factors influence on *APOE* gene polymorphism effects on, in Mediterranean Spanish population, 936-944
 - level of, as risk factor for atherosclerosis in MI survivors and their spouses, 26-27
 - plasma insulin levels and, interaction between polymorphism of LPL and glucocorticoid receptor gene and Gln27Glu mutation of β_2 -*ADR* gene, 246-252
 - see also* specific lipids
- Plasma lipoprotein (Lp)
- chitotriosidase activity and concentration of, 448-449
 - in FH, association between TaqIB polymorphism in *CETP* gene locus and, 651-656
 - levels of, as risk factor for atherosclerosis in MI survivors and their spouses, 26-27
 - TG-rich remnant, Lp distribution of apo C-III and its relationship to, 112-119
- Plasma low-density lipoprotein-cholesterol (LDL-C) in HTN, 159
- fasting, with IR, 1449, 1450
- Plasma Na (sodium)
- NE effects on urinary excretion of, 1232
 - total, furosemide effects on, 242-244
- Plasma nicotine, oral nicotine administration and levels of, 81
- Plasma norepinephrine (NE; noradrenaline)
- alcohol effects on, during acute hypoglycemia in NIDDM, 454-455
 - in exercising women, 485
 - NE effects on, 1231-1232
- Plasma oxypurinol, furosemide effects on, 242
- Plasma proinsulin, LDL particle size, IR, 122
- Plasma protein
- and differences in, between men and women, 644
 - in hyperhomocysteinemic elderly subjects, 1467
 - total, furosemide effects on, 243, 244
- Plasma purines, furosemide effects on, 242
- Plasma renin activity (PRA), furosemide effects on, 242, 243
- Plasma renin in hypertensive subjects and their normotensive offspring, 934
- Plasma sterols, effects of apo E deficiency on hepatic cholesterol and bile acid synthesis, LDL receptor function, and levels of fecal and, probucol or phytosterol therapy for, 708-714
- Plasma taurine in NIDDM, fluxes in, 62

- Plasma testosterone (T), differences in, between men and women, 641
- Plasma thrombomodulin (TM), and prostacyclin-induced changes in skin BF in NIDDM, 568-572
- Plasma thyroxine (T_4) in Tg subjects, CETP activity and, 532
- Plasma triacylglycerol (TAG) in Tg subjects, CETP activity and, 532
- Plasma triglycerides (TG)
fasting, in IR with HTN, 1449, 1450
in heterozygous FH, 636
in moderate exercise, 759
total, *see* Total plasma triglycerides
- Plasma ubiquinol-10 (coenzyme Q10), effects of plant stanol ester mixtures on concentrations of fat-soluble antioxidants and, 520-529
- Plasma very-low-density lipoprotein-cholesterol (VLDL-C) in HTN, *APOE* gene polymorphism and, 159
- Plasma von Willebrand factor (vWF), insulin sensitivity and glucose effects on concentration of, 1452-1456
- Plasminogen activator-antigen (PA-Ag), tissue-type, in obese children, 681-687
- Plasminogen activator inhibitor (PAI), metformin effects on, 858-860
- Plasminogen activator inhibitor-1 (PAI-1) in obese children, 681-687
- Platelet(s)
resting, of diabetic premenopausal women, myosin light-chain phosphorylation in, 151-156
see also Platelet amino acids; Platelet count; Platelet Na^+ , K^+ adenosine triphosphatase
- Platelet amino acids (AAs)
in NIDDM, 739-741
see also Taurine, platelet
- Platelet count in diabetic premenopausal women, 153
- Platelet Na^+/K^+ (sodium/potassium) adenosine triphosphatase (ATPase), as marker in hyperthyroidism, 1393-1396
- PLD (phospholipase D), GPI-specific, glucose and insulin regulating expression of, 1489-1492
- PLP (pyridoxal-5-phosphate), differences in, between men and women and, 643
- PM, *see* Postmenopausal women
- PMNLs (polymorphonuclear leukocytes), effects of cortisol on ROS generation by, 548-552
- PO_2 (oxygen partial pressure) in moderate exercise, 402
- Polymorphism
 β_2 -*ADR* gene, *see* β_2 -*ADR* gene polymorphism
APOE gene, *see* *APOE* gene polymorphism
bradykinin B2 receptor gene -58T/C, not associated with to ACE inhibitor-related cough in Chinese NIDDM women, 1346-1350
of *CRH* gene regulatory region in relation to cortisol secretion, obesity, and gene-gene interaction, 1059-1062
FABP2 gene, *see* Ala54Threo polymorphism of *FABP2* gene
HDL *PON1* gene M/L55, relation between carotid artery atherosclerosis and, in smoking and nonsmoking men, 1095-1101
of insulin gene in Japanese NIDDM subjects, 631-634
of LPL gene, *see* Lipoprotein lipase gene polymorphism
1704G/T and 2184A/G *RAGE* gene, associated with antioxidant status, 1152-1160
TaqIB, of *CETP* gene locus, association between plasma Lp levels and, in FH, 651-656
TNF- α -238 and -308, in HTN with IR, 1447-1451
of vitamin D-binding protein gene and risk of NIDDM in French subjects, 366-369
see also Mutation
- Polymorphonuclear leukocytes (PMNLs), effects of cortisol on ROS generation by, 548-552
- Polypeptides, secretion of pancreatic, in Pima Indian subjects, 223-230
- Polyunsaturated fatty acids (PUFAs)
in IR, 88, 1188
in LM, MAF, tofu, and MOS meals, 506
serum, circulating GM-CSF, 1481
in very-high-fiber vegetable, fruit, nut diet, 496
- PON, *see* Paraoxonase arylesterase
- PON1* gene M/L55 polymorphism, HDL, relation between carotid artery atherosclerosis and, in smoking and nonsmoking men, 1095-1101
- Porphyria attacks, acute intermittent, triptorelin with tobolone in prevention of cyclic, 995-996
- Postabsorptive testosterone (T), high-fat diet effects on PP and, 1351-1355
- Postmenopausal (PM) women
age and exercise affecting abdominal AT distribution in, 976-982
hyperlipidemic, PP lipemia and metabolic disturbances in, 330-334
IR, dietary cholesterol, and cholesterol concentrations in, 594-597
see also Hormone replacement therapy, PM women on
- Postprandial growth hormone (PP GH), naloxone effects on GHRH-induced release of, after BPD-induced weight loss, post-BPD opioid dysregulation and, 382-386
- Postprandial hypertriglyceridemia (PP HTG) in NIDDM combined with hyperlipidemia, simvastatin effects on, 355-359
- Postprandial (PP) lipemia
in hyperlipidemic postmenopausal women, metabolic disturbances with, 330-334; *see also* Hyperlipidemia(s)
LPL and, *see* Lipoprotein lipase, PP lipemia and
- Postprandial (PP) serum-promoted cholesterol (C) efflux, basal and, in normolipidemia, 1330-1335
- Postprandial (PP) sex hormone concentration in men after LF, MAF, tofu, and MOS meals, 505-511
- Postprandial testosterone, *see* Testosterone, PP, diet effects on
- Potassium, *see* K
- Potassium cyanide (KCN), glucose effects on viability of hepatocytes exposed to, 342-348
- PP, *see* entries beginning with term: Postprandial
- PPAR, *see* Gene expression, *PPAR* γ and *PPAR* α ; Gene expression, *PPAR* γ and *PPAR* α effects on; Peroxisome proliferator-activated receptor γ
- PRA (plasma renin activity), furosemide effects on, 242, 243
- Pravastatin, effects of ezetimibe with, on hypercholesterolemia, 1234-1241
- Preadipocyte stromal cells, TZDs and glucocorticoids inducing differentiation of, 407-413
- Precocious puberty, central, effects of estrogen and androgen on bone maturation and BMD in children with, 377-379
- Predisposition
to NIDDM development in HD, 1389-1390
see also Risk factors
- Premenopausal women
age, menopausal status, and exercise affecting abdominal AT distribution in, 976-982
APOE gene polymorphism in, 938
diabetic, myosin light-chain phosphorylation in resting platelets of, 151-156
- Preprandial growth hormone (GH), naloxone effects on GHRH-induced release of, after BPD-induced weight loss, post-BPD dysregulation and, 382-386

- Prepubertal children
 with CPP, estrogen and androgen effects on bone maturation and BMD in, 377-379
 GH-deficient, effects of GH therapy on body composition and AT distribution in, 537-547
- Primary dyslipoproteinemia, hemorrhheologic abnormalities and risk of atherosclerosis in, 166-170
- PRL (prolactin) in GH-deficient prepubertal children, GH therapy effects on, 544
- Pro (proline), antidiabetic activities of cyclo (his-pro), zinc, and arachidonic acid in STZ-DM, 53-59
- Probucol therapy of apo E deficiency effects on hepatic cholesterol and bile acid synthesis, LDL receptor function, and plasma and fecal sterol levels, 708-714
- Proinsulin
 effects of insulin, amylin and, on renin release, 763-766
 LDL particle size, IR and, in older men, 120-124
- Prolactin (PRL) in GH-deficient prepubertal children, GH therapy effects on, 544
- Proline (Pro), antidiabetic activities of cyclo (his-pro), zinc, and arachidonic acid in STZ-DM, 53-59
- Prostacyclin (PGI₂), skin BF changes in NIDDM induced by, ABI and plasma TM and, 568-572
- Prostaglandin(s) (PG)
 in hepatic glucose production, 744, 747
see also Prostacyclin; Prostaglandin E₁; Prostaglandin E₂
- Prostaglandin E₁ (PGE₁), and conversion of hepatic α -amino-nitrogen to urea nitrogen in poorly controlled NIDDM, 253-258
- Prostaglandin E₂ (PGE₂), leptin release stimulated by arachidonic acid and, in AT of obese subjects, 921-928
- Protein
 binding, *see* Ala54Threo polymorphism of *FABP2* gene; Insulin-like growth factor-binding protein-1; Growth hormone-binding protein; Insulin-like growth factor-binding protein-3; Vitamin D-binding protein gene
 cholesteryl ester transfer, *see*: *CETP* gene locus; Cholesteryl ester transfer protein
 C-reactive, *see* C-reactive protein
 dietary, *see* Dietary protein
 and differences in, between men and women, 641
 furosemide effects on, 244
 G-, role of, in resistance to vascular insulin/IGF-1 actions, 607-612
 oxidation of, in anorexia nervosa, 877
 plasma, *see* Plasma protein
 stress hormone effects on synthesis of, in T lymphocytes of healthy subjects, 1308-1314
 total, *see* Total protein
see also Glycoprotein; Lipoprotein; Protein kinase C; Protein kinase C theta; Protein wasting and specific proteins
- Protein kinase C (PKC), glucose effects on renal interstitial fibroblast hyaluronan production through TGF- β cascade and, 789-794
- Protein kinase C theta (PKC θ) in SM of NIDDM subjects, 553-557
- Protein wasting, 288-298
 in AIDS, effects of, on protein metabolic response to acute exercise, 288-292
 due to protein restriction and dexamethasone, glutamine effects on, 293-298
- Prothrombin gene mutation, 20210 G/A thrombophilic, for atherothrombotic CVD in hyperlipidemia, interaction between ERT and, 360-365
- PTH (parathyroid hormone) in idiopathic osteoporotic men, 913
- p22^{phox}* message gene expression, effects of PPAR γ and PPAR α on *CuZn-SOD* and, in HUVECs and HAECS, 3-11
- Puberty
 serum leptin relationship to, in adolescents having been SGA neonates, 1141-1146; *see also* Adolescents
see also Prepubertal children
- PUFAs, *see* Polyunsaturated fatty acids
- Pulmonary disease, *see* Chronic obstructive pulmonary disease
- Pulmonary function tests (PFTs) in COPD, 1398
- Pulse rate, *see* Heart rate
- Purine(s), intake of, in gout, VAT accumulation and, 395
- Purine nucleotides, *see* Uric acid; Xanthine and entries beginning with term: Hypoxanthine
- Pycnodysostosis, GH therapy effects on growth in, 905-911
- Pyelonephritis in CRF, 208
- Pyridoxal-5-phosphate (PLP), differences in, between men and women and, 643
- Pyridoxine (vitamin B₆), effects of folic acid, cyanocobalamin and, on fibrinogen, Lp(a), and Hcy in CRF, 131-134
- Pyruvate kinase (PK), effects of high-protein, CHO-free diet on, 1208-1212
- 3R,4S-1,4-S-(methoxyphenyl)-3-(3-phenylpropyl)-2-azetidinone, (ezetimibe; SCH48461), hypocholesterolemic effects of lovastatin with, 1234-1241
- R_{at}, *see* Glucose rate of appearance
- RA (rheumatoid arthritis), serum IL-6 and thyroid hormones in, 463-467
- Race and ethnicity
 of adolescents, *see* Race and ethnicity of adolescents
 of children, *see* Race and ethnicity of children
 and DHEA levels, 1316
 exercise and, *see* Race and ethnicity, exercise and
 influence of environmental factors on effects of *APOE* gene polymorphism on plasma lipid concentrations in Mediterranean Spanish population, 936-944
 lipids and apo B as risk factors for CAD in elderly rural and urban Mexican subjects, 311-318
 of NIDDM subjects, *see* Race and ethnicity of NIDDM subjects
 obesity and, *see* Obesity, race and ethnicity and
 pancreatic polypeptide secretion in Pima Indian subjects, 223-230
 and serum HDL-C variation, 896-898, 900, 901
 variations in vitamin D-binding protein gene expression and risk of NIDDM in French subjects, 366-369
 of young adults, *see* Race and ethnicity of young adults
see also Chinese subjects; Korean subjects entries beginning with term: Japanese and specific conditions
- Race and ethnicity, exercise and
 exercise effects on HKII mRNA, 603
 familial aggregation for DHEAS and its responsiveness to endurance training, 916-920
 of NIDDM subjects with cardiovascular disease, changes in disease and in $\dot{V}O_{2\max}$ and, 1256
- Race and ethnicity of adolescents
 distribution and correlation of HDL-C with, 370-376
 with IDDM and diabetic retinopathy, blood glucose modulation of serum PON arylesterase activity and concentration and, 657-660
- Race and ethnicity of children
 distribution and correlation of HDL-C with, 370-376
 South Asian immigrants' children, lipid profile, leptin, insulin, and anthropometry, 1197-1202
- Race and ethnicity of NIDDM subjects
 with cardiovascular disease, changes in disease and changes in $\dot{V}O_{2\max}$ during exercise and, 1256

- Race and ethnicity of NIDDM subjects (*Continued*)
 insertion/deletion of *ACE* gene in Chinese women associated with
ACE inhibitor-related cough in, 1346-1350
 insulin secretory dysfunction and IR in pathogenesis of NIDDM in
 Korean subjects, 590-593
- Race and ethnicity of obese young adults
 changes in obesity and changes in CVD risk in, 299-305
 dyslipidemic young adults, *APOE* gene polymorphism and, 698
- Race and ethnicity of young adults
 with IDDM and diabetic retinopathy, blood glucose modulation of
 serum PON arylesterase activity and concentration in, 657-
 660
 of young adult men, T, SHBG, body composition and, 1242-1247
see also Race and ethnicity of obese young adults
- Radiologic features of pycnodysostosis, 905-911
- RAGE* gene polymorphism, 2184A/G and 1704G/T, antioxidant
 status and, 1154, 1156-1159
- Rate of appearance, *see* Glucose rate appearance
- RBC(s) (red blood cells), *see entries beginning with term:*
 Erythrocyte
- Reactive oxygen species (ROS), cortisol effects on PMNL and MNC
 generation of, 548-552
- Red blood cells (RBC), *see entries beginning with term:* Erythrocyte
- Reductase, *see* HMG-CoA reductase; Methylenetetrahydrofolate
 reductase
- REE, *see* Resting energy expenditure
- Reflux nephropathy in CRF, IgG and, 208
- Regional blood flow (BF), insulin effects on glucose uptake and,
 65-73
- Regional growth hormone-binding protein (GHBP), circulating and,
 in cirrhosis, 1340-1345
- Remnant-like particles-cholesterol (RLP-C) in DM with CAD, 1462-
 1465
- Renal disease, *see* Nephropathy
- Renal failure, *see* Chronic renal failure, hemodialysis for; Diabetes
 mellitus with CRF; Supplementation in CRF
- Renal histology, long-term effects of partial nephrectomy on
 guanidino compounds, biological parameters and, 1418-1425
- Renal interstitial fibroblasts, glucose effects on hyaluronan
 production by, through PKC and TGF- β cascade, 789-794
- Renal metabolism of insulin in mutant insulin syndrome, 863-867
- Renal vein growth hormone-binding protein (GHBP) in cirrhosis,
 1343
- Renin
 effects of insulin, amylin, and proinsulin on release of, 763-766
 plasma, in hypertensive subjects and their normotensive offspring,
 934
- RER (respiratory exchange ratio), fasting, in athletes, minimal model
 analysis of insulin sensitivity and, 1286-1293
- Resection of palliative glucanoma syndrome, AAs, lipid kinetics, and
 glucose following, 720-722
- Resistance exercise, *see* Endurance exercise
- Resistance to vascular insulin/IGF-1 actions in female subjects, 607-
 612
- Respiratory exchange ratio (RER), fasting, in athletes, minimal
 model analysis of insulin sensitivity and, 1286-1293
- Respiratory quotient (RQ), sibutramine and low-dose leptin effects
 on, in obesity, 891
- Resting energy expenditure (REE)
 by anorectic subjects, 877
 creatine and endurance exercise effects on LBF and, 1429-1434
 by DMD subjects, 1183
 by exercising AIDS subjects, 291
 by postmenopausal women, short-term HRT effects on, 268
- Resting metabolic rate (RMR) of older subjects, AT and FM effects
 on, 972-975
- Resting platelets of premenopausal diabetic women, myosin light-
 chain phosphorylation in, 151-156
- Restricted diet, *see* Dietary restriction
- Retinoic acid gene expression, effects of diet-induced obesity on,
 1161-1167
- 11-*trans*-Retinoic acid (atRA) metabolism, effects of farnesol
 derivatives on, 1356-1360
- Retinoid X receptor (RXR), expression of, in skeletal muscle of
 nondiabetic and obese NIDDM subjects, 830-834
- Retinol, effects of, on concentrations of plasma ubiquinone-10 and
 fat-soluble antioxidants, 525
- Retinopathy, diabetic, in adolescents and young adults, race and
 blood glucose modulation of serum PON arylesterase activity
 and concentration in, 657-660
- Rheumatoid arthritis (RA), serum IL-6 and thyroid hormones in,
 463-467
- Rifampicin, effects of, on depressive action of IL-1 on cytochrome
 P-450-linked-monooxygenase system, 231-236
- Risk factors
 CV, *see* Risk factors, cardiovascular
 for IR in gout, VAT accumulation and, 393-398
 lipid, ALA or evening primrose oil effects on, in STZ-DM, 868-
 875
 for NIDDM in French subjects, variations in vitamin-binding
 protein gene and, 366-369
- Risk factors, cardiovascular
 in borderline hypertensive young men, glucose disposal rate in,
 1175-1180
 vascular hemostatic, ALA on evening primrose oil effects on, in
 STZ-DM, 868-875
see also Risk factors for atherosclerosis; Risk factors for CVD
- Risk factors for atherosclerosis
 in primary dyslipoproteinemias, hemorrheologic abnormalities and,
 166-170
 in survivors of MI and their spouses, 24-29
- Risk factors for CVD
 for atherothrombotic CVD, 362
 for CAD, lipids and apo B as, in older urban and rural Mexican
 subjects, 311-318
 gonadal steroids and SHBG as, in men, 882-888
see also Risk factors for CVD in obesity
- Risk factors for CVD in obesity
 changes in obesity related to changes in, in children and young
 adults, 299-305
 for coronary heart disease, relationship between IR, weight and, in
 obese women, 795-800
- RLP-C (remnant-like particles-cholesterol) in DM with CAD, 1462-
 1465
- RMR (resting metabolic rate) of older subjects, AT and FM effects
 on, 972-975
- RNA (ribonucleic acid), *see* mRNA
- ROS (reactive oxygen species), effects of cortisol on PMNL and
 MNC generation of, 548-552
- Rosiglitazone (BRL-49653), action of, through regulation of GLUT1
 and GLUT4 in skeletal muscle and AT, 1294-1300
- RQ (respiratory quotient), sibutramine and low-dose leptin effects
 on, in obesity, 891
- Rural Mexican subjects, elderly, lipids and apo B as risk factors for
 CAD in, 311-318
- RXR (retinoid X receptor), expression of, in skeletal muscle of
 nondiabetic and obese NIDDM subjects, 830-834

- S (sucrose) in high-fructose diet, 1370
- Safflower oil and meat meal, effects of, on PP sex hormone concentration in men, 505-511
- SA-HRV (spectral analysis of heart rate variability) analysis of NIDDM subjects' offspring autonomic balance, 1270-1274
- Sarcolemmal vesicles (SVs), muscle, STZ-DM effects on lactate transport in, 418-424
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acids (SFAs)
- in IR, 88
 - in LM, MAF, tofu, and MOS meals, 506
 - in NIDDM, serum PL FAs in, 1475
 - and physical activity effects on IR association with intake of, 1188
 - serum, circulating GM-CSF, 1481
 - in very-high-fiber vegetable, fruit, nut diet, 496
- SBP (systolic blood pressure), *see* Blood pressure
- SCD (sickle cell disease), insulin effects on leg blood flow and glucose uptake in, 387-392
- SCH 48461 (ezetimibe), hypocholesterolemic effects of HMG-CoA reductase inhibitors with, 1234-1241
- SCH 58235 (ezetimibe), hypocholesterolemic effects of HMG-CoA reductase inhibitors with, 1234-1241
- Sclerosis, *see* Risk factors for atherosclerosis
- Sedentary men, S_g and S_i in exercising middle-aged and young men and in, 349-354
- Selenium (Se), tissue contents and subcellular distribution of cobalt, iron, zinc, chromium and, in DM, 1168-1174
- Ser₄₄₇-Stop polymorphism of LPL gene associated with variation in serum HDL-C, 894-904
- Serine (Ser) in IDDM and NIDDM platelets, 740
- Serotonin reuptake inhibitor(s) (SSRIs), effects of, on hyperglycemic obesity development, 144-150
- Serum albumin
- in cirrhosis, 1342
 - in CRF, 208
- Serum amyloid amylase in NIDDM, 285
- Serum bilirubin in cirrhosis, 1342
- Serum BUN (blood urea nitrogen) in CRF, 208
- Serum Ca (calcium) in COPD, 1337
- Serum calcitonin, DR effects on, 436-442
- Serum chitotriosidase genotype frequency, atorvastatin and bezafibrate effects on, in combined hyperlipidemia, 447-450
- Serum cholesterol (C)
- in diet-induced obesity, 1163
 - in DM with CRF, systemic 11β -HSD and, 803; *see also* Serum cholesterol in NIDDM
 - LDL particle size, IR, proinsulin and, 122
 - PP and basal serum-promoted efflux of, in normolipidemia, 1330-1335
 - total, *see* Total serum cholesterol
- Serum cholesterol esters (CEs), relationship of PL fatty acids and dietary, to markers of IR in men and women, glucose tolerance and, 86-92
- Serum cholesterol (C) in NIDDM
- insulin action on, serum PL FA composition and, 1473
 - in Korean NIDDM subjects, 591
- Serum Cl (chloride) in DM with CRF, systemic 11β -HSD and, 803
- Serum corticosteroid binding globulin (CBG), effects of changes in glucose, insulin, and IGF-1 level on, in lean and obese subjects, and in obesity with glucose intolerance, 1248-1252
- Serum cortisol in pancreatic cancer, 1037
- Serum cortisone/cortisol ratios, systemic 11β -HSD assessed with, in healthy subjects and in DM with CRF, 801-804
- Serum C-peptides (CPs; connecting peptides)
- fasting, *see* Fasting serum C-peptides
 - in hyperinsulinemia, 108, 109
- Serum creatinine
- in AIDS, 290
 - in cirrhosis, 1342
 - in CRF, *see* Serum creatinine in CRF
 - in gout, 953
 - during HAART, 1278
 - and Mg effects on IMGU and serum lipids in IDDM, 1410
 - in NIDDM, *see* Serum creatinine in NIDDM
 - in pancreatic cancer, 1037
- Serum creatinine in CRF
- in dialyzed patients, 208
 - in DM with CRF, systemic 11β -HSD and, 803
- Serum creatinine in NIDDM
- with macroalbuminuria, 1194
 - prostaticin-induced skin BF changes and, 569
- Serum dehydroepiandrosterone (DHEA) in younger and older women, estrogen effects on, 488-493
- Serum fatty acids (FAs), circulating GM-CSF and composition of, in men and women and, 1479-1483
- Serum folate in hyperhomocysteinemic elder subjects, 1467, 1469
- Serum free fatty acids (FFAs; nonesterified fatty acids)
- in fructose-induced hypertension, 76
 - in hyperinsulinemia, 108, 109
 - in NIDDM, gemfibrozil or simvastatin effects on, 1149
- Serum glucose
- fasting, *see* Fasting serum glucose
 - HF diet effects on, 1372
- Serum HCO₃ (bicarbonate) in IDDM with DKA, 173
- Serum high-density lipoprotein-cholesterol (HDL-C)
- in NIDDM, gemfibrozil or simvastatin effects on, 1149
 - Ser₄₄₇-Stop polymorphism of LPL gene associated with variation in, 894-904
- Serum insulin
- HF diet effects on, 1372
 - in MIS, 864-865
 - in obese children, short-term weight loss effects on, 1324, 1326, 1327
 - see also* Fasting serum insulin; Serum insulin, diet effects on
- Serum insulin, diet effects on
- alcohol intake effects during acute hypoglycemia in NIDDM, 452
 - high-fat, high-cholesterol diet effects, 460
 - in moderate exercise, 759
- Serum insulin-like growth factor-binding protein (IGFBP-3) with serum leptin for acromegaly, plasma IGF-1 compared with, 1117-1121
- Serum interleukin-6 (IL-6), thyroid hormones and, in rheumatoid arthritis, 463-467
- Serum K (potassium) in DM with CRF, systemic 11β -HSD and, 803
- Serum leptin, 1136-1146
- in adolescents having been SGA neonates, relationship of, to gender, puberty, body composition, insulin sensitivity, creatinine, and serum uric acid, 1141-1146
 - blood pressure and, in obese Peruvian Indian and Caucasian women, 325-329
 - high-fat, high-cholesterol diet effects on, 460
 - in NIDDM, exercise effects on, 1136-1140
 - oral nicotine effects on, 81
 - in premenopausal and PM women, abdominal AT distribution and, 978, 980
 - relation of, to lipid profile in children, 1091-1094

- Serum leptin (*Continued*)
 serum IGFBP-3 with, for acromegaly, plasma IGF-1 compared with, 1117-1221
- Serum lipids
 effects of restricted maternal Fe on blood pressure, glucose tolerance and, in 3-month-old offspring, 562-567
 in IDDM, Mg effects on IMGU and, 1409-1417
 in NIDDM, alcohol effects during acute hypoglycemia in, 453
 in STZ-DM, ALA or evening primrose oil effects on, 872
see also Serum lipids, diet effects on
- Serum lipids, diet effects on
 high-fat, high-cholesterol diet, and chromosome 4 segment (*D4Mit6-Npy* ~ 1 cm) effects on serum lipids and composition, 458-462
 plant stanol FA ester mixture effects on, 522
 very-high-fiber vegetable, fruit, nut diet effects, 494-503
- Serum lipoprotein (Lp), diet effects on
 chromosome 4 segment (*D4Mit6-Npy* ~ 1 cm) effects following high-fat, high-cholesterol diet, 458-462
 plant stanol FA ester mixture effects, 522
- Serum lipoprotein(a) [Lp(a); high-density lipoprotein₁], diet effects on
 chromosome 4 segment (*D4Mit6-Npy* ~ 1 cm) effects on, after high-fat, high-cholesterol diet, 461
 very-high-fiber vegetable, fruit, nut diet effects, 497
- Serum low-density lipoprotein-cholesterol (LDL-C) in NIDDM, gemfibrozil or simvastatin effects on, 1149
- Serum methionine (Met) during HAART, 1278
- Serum Mg (magnesium) during gemfibrozil or simvastatin therapy in NIDDM, 1147-1151
- Serum Na (sodium)
 in cirrhosis, 1342
 in DM with CRF, systemic 11β -HSD and, 803
- Serum osteocalcin, DR effects on, 440
- Serum paraoxonase (PON) arylesterase
 activity of, in nondiabetic subjects, IR effects on, 805-811
see also Serum paraoxonase arylesterase in DM
- Serum paraoxonase (PON) arylesterase in DM
 blood glucose level modulated by, in young IDDM subjects, 657-660
 HRT effects on, in diabetic PM women, 319-324
- Serum phospholipid (PL) fatty acids (FAs), composition of, and insulin action in NIDDM, 1472-1478
- Serum phosphorus (P) in COPD, 1337
- Serum triacylglycerol (TAG) in diet-induced obesity, 1163
- Serum triglycerides (TG)
 fasting, HF diet effects on, 1372
 in fructose-induced hypertension, 76
 high-fat, high-cholesterol diet effects on, 461
 LDL particle size, IR, proinsulin and, 122
 in metabolic syndrome, 137-141
 in NIDDM, *see* Serum triglycerides in NIDDM
see also Total serum triglycerides
- Serum triglycerides (TG) in NIDDM
 and insulin action on serum PL FA composition, 1473
 in Korean subjects, 591
- Serum uric acid (UA)
 in gout, VAT accumulation and risk of IR in, 393-398
 serum leptin relationship to, in adolescents having been SGA neonates, 1141-1146
- Serum vascular endothelial growth factor (VEGF) in IDDM and nondiabetic subjects, correlation between carotid artery distensibility and, 825-829
- Serum very-low-density lipoprotein-cholesterol (VLDL-C) in NIDDM, gemfibrozil or simvastatin effects on, 1149
- 1704G/T *RAGE* gene polymorphisms associated with antioxidant status, 1152-1160
- Severe hypercholesterolemia with diabetic dyslipoproteinemia, atorvastatin effects on, 984, 986
- Severe insulin resistance (IR), altered *GLUT1* and *GLUT3* gene expression and subcellular redistribution of GLUT4 in acanthosis nigricans with, 771-777
- Severity
 of COPD, effects of, on thyroid function, 1397-1401
 of osteoarthritis of knee, relationship between OPG/OCIF concentrations in synovial fluid and, 1-2
see also entries beginning with term: Severe and specific conditions
- Sex
 of acromegaly subjects, 1119
 of adolescents, *see* Sex of adolescents
 and *APOE* gene polymorphism effects on plasma lipid concentration, 939
 of CAD subjects, *see* Sex of CAD subjects
 of children, *see* Sex of children
 circulating GM-CSF, serum FA composition and, 1480
 of COPD subjects, 1398
 of CRF subjects, 208, 271, 272
 and CT-1 stability, 238
 of diabetic nephropathy subjects, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity and, 1015
 of DM subjects, *see* Sex of DM subjects
 of exercising subjects, *see* Sex of exercising subjects
 of familial gout subjects, 1206
 and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
 of HIV infection patients, 1278
 of hyperlipidemic subjects, *see* Sex of hyperlipidemic subjects
 of hypertensive subjects, *see* Sex of hypertensive subjects
 of hyperthyroidic subjects, 1394
 and IR, *see* Sex of insulin-resistant subjects
 of NIDDM subjects' offspring, autonomic balance and, 1271
 of nondiabetic subjects, serum PON arylesterase activity and, 806, 808, 809
 of obese subjects, *see* Sex of obese subjects
 of older subjects, *see* Sex of older subjects
 and pancreatic polypeptide secretion, 224
 and protein wasting in AIDS, 290
 serum DHEA relationship to AT and, 488-493
 variation in serum HDL-C and, 896-898, 900, 901
- Sex of adolescents
 distribution and correlates of HDL-C with race and, 370-376
 having been SGA neonates, serum leptin relationship to, 1141-1146
- Sex of CAD subjects
 with β_2 -*ADR* gene mutation and, 186
 RLP-C and, 1463
- Sex of children
 distribution and correlates of HDL-C with race and, 370-376
 of fasting MCAD-deficient children, ketone production and, 162, 163
 relation of serum leptin to lipid profile and, 1093
see also Sex of obese children
- Sex of DM subjects
 with CAD, RLP-C in, 1463
 with CRF, systemic 11β -HSD and, 802, 803
see also Sex of IDDM subjects; Sex of NIDDM subjects

- Sex of exercising subjects
and exercise effects on HKII mRNA, 603
insulin sensitivity, fasting RER and, 1288
- Sex of FH subjects
with heterozygous FH, 636
and TaqIB polymorphism in *CETP* gene locus associated with plasma Lp levels, 653
- Sex hormone(s), *see specific sex hormones*
- Sex hormone-binding globulin (SHBG) in men
and CV risk factors, 882-888
effects of LF, MAF, tofu, and MOS meals on PP concentrations of, 505-511
T, body composition and, in young adult men, race and, 1242-1247
- Sex of hyperlipidemic subjects
with mixed hyperlipidemias, 731
with NIDDM, simvastatin effects on, 356
see also Sex of FH subjects
- Sex of hypertensive subjects
with *APOE* gene polymorphism, 159
and their normotensive offspring, insulin sensitivity and Na excretion and, 931, 932
- Sex of IDDM subjects
with DKA, 172
and Mg effects on IMGU and serum lipids, 1410
- Sex of insulin-resistant subjects
with acanthosis nigricans, 772
and glucose effects on plasma von Willebrand factor, 1453
with HTN, 1449, 1453
and MI prior to age 40, 31
- Sex of NIDDM subjects
with *ACE* gene I/D, 1348
aminophylline effects on insulin secretion and, 1031
hyperlipidemic, simvastatin effects and, 356
platelet taurine fluxes and, 61
and polymorphisms of insulin gene, 631
and troglitazone effects on VAT and sulfonylurea-associated fatty liver, 415
vitamin D-binding protein gene variations and, 367
- Sex of obese children
with metabolic and hemostatic complications, 683, 685
short-term weight loss effects on metabolic complications of obesity and, 1323-1329
- Sex of obese subjects
with CVD risk, 300, 301
and effect of changes in glucose, insulin, and IGF-1 level on serum CBG, 1249
with metabolic syndrome, 141
morbidly obese adolescents, 1458
with upper body obesity, 20
see also Sex of obese children; Sex of obese subjects with metabolic complications
- Sex of obese subjects with metabolic complications
and abdominal SAT contribution to complications, 431-433
obese children with metabolic and hemostatic abnormalities, 683, 685
- Sex of older subjects
dyslipidemic urban and rural Mexican subjects, 313-315
and L-NMMA effects on insulin-mediated SM blood flow and glucose disposal, 195, 307
RMR and, 974
- SFAs, *see* Saturated fatty acids
- S_e , *see* Glucose effectiveness, S_i and
- SGA, *see* Small-for-gestational age neonates
- SHBG, *see* Sex hormone-binding globulin in men
- Short-term antiretroviral therapy, highly active, of HIV infection, N-methylglycine and N,N-dimethylglycine during, 1275-1281
- Short-term fasting, hyperinsulinemia compared with, in suppression of insulin secretion in obese men, 107-111
- Short-term hormone replacement therapy (HRT), effects of, on energy balance and body composition of postmenopausal women, 265-269
- Short-term weight loss by obese children, effects of, on metabolic complications, 1323-1329
- Shunts, aortopulmonary, and metabolic responses to moderate exercise, 399-406
- S_i , *see* Insulin sensitivity
- Sibutramine, weight loss by obese subjects with and low-dose leptin, 889-893
metabolic complications after, 819-824
- Sickle cell disease (SCD), insulin effects on leg blood flow and glucose uptake in, 387-392
- Simvastatin in NIDDM
effects of, on PP hypertriglyceridemia in hyperlipidemic NIDDM, 355-359
serum Mg and, 1147-1151
- Sinigrin, 1124, 1131, 1133, 1134
- Sitostanol fatty acid (FA) esters
effects of, on cholesterol absorption and HMG-CoA reductase activity, 1106-1112
effects of, on ubiquinone-10 and fat-soluble antioxidant concentrations, 523
- Sitosterol
effects of, on apo E deficiency, 709, 710
effects of, on ubiquinone-10 and fat-soluble antioxidant concentrations, 523
in very-high-fiber vegetable, fruit, nut diet, 496
- Sitosterolemia, macrophage HMG-CoA reductase in, 1224-1229
- Skeletal muscle (SM)
action of BRL-49653 through regulation of GLUT1 and GLUT4 in, 1294-1300
capillary density of, and insulin-mediated changes in leg blood flow in older men, 1078-1082
GLUT1 and GLUT3 gene expression and redistribution of GLUT4 in, in acanthosis nigricans with severe IR, 771-777
long-term denervation effects on IRS-1-mediated insulin signaling in, 216-222
L-NMMA effects on glucose disposal and blood flow in, in older subjects, 195-199, 306-310
 δ opioid receptors and glucose uptake in obese and lean diabetic subjects, 1402-1408
see also Skeletal muscle cells; Skeletal muscle insulin receptor substrate-2; Skeletal muscle lipoprotein lipase; Skeletal muscle in NIDDM
- Skeletal muscle (SM) cells, lipids and O_2 supply in, in women, 380-381
- Skeletal muscle (SM) insulin receptor substrate-2 (IRS-2), HF diet effects on expression of, 1369-1376
- Skeletal muscle lipoprotein lipase (LPL), PP lipemia and activity of, in moderate exercise, 756-762
- Skeletal muscle (SM) in NIDDM
with obesity, RXR expression in, 830-834
protein kinase C θ content in, 553-557
- SKF38393/bromocriptine, systemic, effects of, on aberrant beta-cell hyperplasia, GLUT2, glucokinase, and *irl* levels in obesity, 1377-1384
- Skin blood flow (BF), prostacyclin-induced changes in, in NIDDM, ABI and plasma TM and, 568-572

- SLC (sodium-lithium countertransport) in essential hypertension, *APOE* gene polymorphism effects on, 157-160
- SLE (systemic lupus erythematosus) in CRF, 208
- SM, *see* Skeletal muscle
- Small-for-gestational age (SGA) neonates
adolescents having been, serum leptin relationship to gender, puberty, body composition, insulin sensitivity, creatinine, and serum uric acid in, 1141-1146
- Lp profile of, CETP and, 723-728
- Small intestinal mucosa, effects of suppressed intestinal apoptosis on thickness of, in STZ-DM, 259-264
- SMCTs (structured medium- and long-chain triacylglycerols), thermic effect of LCTs versus, in young women, 125-130
- Smoking
and ATCVD in hyperlipidemic women, 362
- CAD and, 186
- circulating GM-CSF, serum FA composition and, 1480
- and COPD, 1337, 1338
- as CV risk factor in men, 885, 886
- by DM subjects with CAD, RLP-C and, 1463
- effects of, on *APOE* gene polymorphism effects on plasma lipid concentration, 938
- in FH, TaqIB polymorphism in *CETP* gene locus and, 653
- by Japanese middle-aged men, hyperuricemia development and, 623, 624
- by lactating women with GDM history and, 716
- maternal, Lp profile, and CETP in neonates and, 724
- and MI, *see* Smoking, MI and
- oral nicotine effects on TNF- α levels in obesity, 79-85
- and physical activity effects on IR association with dietary fat intake, 1188, 1189
- relation between HDL *PON1* gene M/L55 polymorphism and carotid artery atherosclerosis in nonsmoking and smoking men, 1095-1101
- Smoking, MI and
and MI prior to age 40 associated with IR, 31
- as risk factor for atherosclerosis in MI survivors and their spouses, 25
- Smooth muscle cells, *see* Vascular smooth muscle cells
- SOD, *see* Superoxide dismutase
- Sodium, *see* Na; Sodium-lithium countertransport
- Sodium-lithium countertransport (SLC) in essential hypertension, *APOE* gene polymorphism effects on, 157-160
- Soluble cell adhesion molecules, LDL-induced monocyte-endothelial cell adhesion, autoantibodies to oxidized LDLs and, in CRF subjects on hemodialysis, 207-215
- Somatostatin for glucanoma syndrome, 720, 721
- South Asian immigrants, offspring of, lipid profile, leptin, insulin, and anthropometry of, 1197-1202
- Spanish population, Mediterranean, influence of environmental factors on effects of *APOE* gene polymorphism on plasma lipid concentrations in, 936-944
- Spectral analysis of heart rate variability (SA-HRV) analysis of NIDDM subjects' offspring autonomic balance, 1270-1274
- Spouses of MI survivors, risk factors for atherosclerosis in, and in MI survivors, 24-29
- SSPG, *see* Steady-state plasma glucose
- SSRIs (serotonin reuptake inhibitors), effects of, on development of obesity with hyperglycemia, 144-150
- Stanols, *see* Plant stanol fatty acid esters
- Starch in high-fructose diet, 1370
- Starvation-refeeding cycles, lipogenic enzyme mRNA in WAT after, 734-738
- Statins, *see* Atorvastatin; Fluvastatin; Lovastatin; Pravastatin; Simvastatin in NIDDM
- Steady-state plasma glucose (SSPG)
and IR in HTN, 1449, 1450
- in postmenopausal women, dietary cholesterol and, 595, 596
- see also* Steady-state plasma glucose in obese women
- Steady-state plasma glucose (SSPG) in obese women
insulin-resistant women, 820
- and relationship between IR, weight loss, and risk for CAD, 796
- Steroid hormones, *see specific hormones*
- Sterols
plasma and fecal, effects of apo E deficiency on hepatic cholesterol and bile acid synthesis, LDL receptor function, and levels of, probucol or phytosterol therapy for, 708-714;
see also Phytosterol(s); Plant stanol fatty acid esters
- see also* Cholesterol
- Stigmasterol in very-high-fiber vegetable, fruit, nut diet, 496
- Streptozotocin-induced diabetes mellitus (STZ-DM)
ALA or evening primrose oil effects on lipid and vascular hemostatic risk factors, blood flow, and peripheral nerve conduction in, 868-875
- effects of, on muscle sarcolemmal vesicle lactate transport, 418-424
- suppressed intestinal apoptosis effects on small intestinal mucosa thickness in, 259-264
- synergistic antidiabetic activities of zinc, cyclo (his-pro), and arachidonic acid in, 53-59
- and vanadium effects on GLUT4 translocation in WAT, 674-680
- Stress, *see* Oxidative stress; Stress hormones
- Stress hormones
effects of, on protein synthesis in T lymphocytes in healthy subjects, 1308-1314
- see also* Cortisol; Epinephrine; Norepinephrine
- Stroke-prone subjects with diabetes, phytosterolemia in, 1361-1368
- Stromal cells, preadipocyte, TZDs and glucocorticoids inducing differentiation of, 407-413
- Structured medium- and long-chain triacylglycerols (SMCTs), thermic effect of LCTs versus, in young women, 125-130
- STZ-DM, *see* Streptozotocin-induced diabetes mellitus
- Subcellular distribution
of Cr, copper, selenium, Fe, and zinc in DM, 1168-1174
- GLUT4, in acanthosis nigricans with severe IR, 771-777
- Subcutaneous adipose tissue (SAT)
in metabolically normal obese subjects, genetic control of size of, 1501-1502
- see also* Subcutaneous adipose tissue, and metabolic complications of obesity
- Subcutaneous adipose tissue (SAT), and metabolic complications of obesity
abdominal SAT contribution to complications, 425-435
- see also* Subcutaneous adipose tissue in obese children
- Subcutaneous adipose tissue (SAT) in obese children, 682
- short-term weight loss effects on metabolic risk factors and, 1323-1329
- Substrate fluxes, effects of cardiac workload changes on, 1083-1090
- Sucrose (S) in high-fructose diet, 1370
- Sulfate, as mediator of therapeutic effects of glucosamine sulfate, 767-770
- Sulfonylureas in NIDDM
fatty liver associated with, troglitazone effects on VAT and, 414-417
- with hyperlipidemia, 356
- Superoxide dismutase (SOD)
aspirin effects on, in Cu deficiency, 558-561

- Superoxide dismutase (SOD) (*Continued*)
 effects of PPAR γ and PPAR α on *p22^{phox}* message and Cu-Zn SOD gene expression in HUVECs and HAECs, 3-11
 Mn-dependent, effects of overexpression of, on collagen accumulation by mesangial cells, 1043-1048
- Supplementation
 effects of Mg, on IMGU and serum lipids in IDDM, 1409-1417
see also Supplementation in CRF
- Supplementation in CRF
 with vitamin B₆, folic acid, and cyanocobalamin, effects of, on fibrinogen, Lp(a), and Hcy in CRF, 131-134
 VLPD, with ketoacids, glucose load EE of CRF subjects before and after, 335-341
- Survivors of MI and their spouses, risk factors for atherosclerosis in, 24-29
- SVs (sarcolemmal vesicles), muscle, STZ-DM effects on lactate transport in, 418-424
- Sympathoadrenal system, role of insulin and, in obesity, 140-141
- Synovial fluid, relationship between OPG/OCIF concentrations in, and severity of osteoarthritis of knee, 1-2
- Synthase, nitric oxide, in fructose-induced hypertension, ET-1 gene expression and levels of, 74-78
- Systemic bromocriptine/SKF38393, effects of, on aberrant beta-cell hyperplasia, GLUT2, glucokinase, and irl levels in obesity, 1377-1384
- Systemic hemodynamics
 insulin effects on, 389
see also Blood flow; Blood pressure; Heart rate
- Systemic 11 β (beta)-hydroxysteroid dehydrogenase (HSD), serum cortisone/cortisol ratios in assessment of, in healthy subjects and in DM with CRF, 801-804
- Systemic lupus erythematosus (SLE) in CRF, 208
- Systemic O₂ (oxygen) supply in moderate exercise, 401, 402
- Systolic blood pressure, *see* Blood pressure
- T, *see* Testosterone
- T₃, *see* Triiodothyronine; Triiodothyronine nuclear receptor gene expression
- T₄, *see* Thyroxine
- T lymphocytes, stress hormone effects on protein synthesis in, healthy subjects, 1308-1314
- TAG, *see* Triacylglycerols
- TaqIB polymorphism in *CETP* gene locus, association between plasma Lp levels and, in FH, 651-656
- Taurine, platelet
 in IDDM, 740
 in NIDDM, 60-64, 740
- TBG (thyroxine-binding globulin), cleavage of, during CPB, 1113-1116
- TBW (total body water), short-term HRT effects on, in PM women, 267
- TC, *see* Total cholesterol
- Teenagers, *see* Adolescents
- Testes in DM, zinc, iron, selenium, and cobalt distribution in, 1168, 1171
- Testosterone (T)
 and CV risk factors, 882-888
 diet effects on, *see* Testosterone, PP, diet effects on
 differences in, between men and women, 641, 643
 free, *see* Free testosterone
 hydroxylation of, after broccoli intake, 1126
 in obesity, polymorphism of *CRH* gene regulatory region and, 1060
 SHBG, body composition and, in young adult men, race and, 1242-1247
- Testosterone (T), PP, diet effects on
 high-fat diet effects on postabsorptive and PP T, 1351-1355
 of LF, MAF, tofu, and MOS meals on, 505-511
- Tg (transgenic) subjects, thyroid hormone effects on plasma CETP activity and plasma HDL removal rate in, 530-536
- TG, *see* Triglyceride(s)
- TGF- β (transforming growth factor- β) cascade, glucose effects on renal interstitial fibroblast hyaluronan production through PKC and, 789-794
- TGL (triglyceride lipase), hepatic, activity of, in gout, 952-954
- tHcy, *see* Total homocysteine
- Thermic effects of SMLCTs versus LCTs in young women, 125-130
- Thiazolidinediones, *see* Adipocytes, TZDs and; Gene expression, PPAR γ , TZDs and; Pioglitazone; Rosiglitazone; Troglitazone
- 3-month-old offspring, effects of restricted maternal Fe on blood pressure, glucose tolerance, and serum lipids in, 562-567
- 3T3-L1 adipocytes
 ALA effects on glucose-induced IR and on irl during incubation of, 1063-1069
 TZDs and TNF- α downregulating PPAR γ mRNA in, 36-40, 407
- Threonine (Threo)
 in IDDM and NIDDM platelets, 740
see also Ala54Threo polymorphism of *FABP2* gene
- Thrombomodulin (TM), plasma, and prostacyclin-induced skin BF changes in NIDDM, 568-572
- Thrombophilic 20210 G/A prothrombin gene mutation in atherothrombotic CVD interaction between ERT and, in hyperlipidemia, 360-365
- Thromboxane A₂ (TxA₂) in hepatic glucose production, 747
- Thyroid function
 severity of COPD and, 1397-1401
see also Hyperthyroidism; Thyroxine; Triiodothyronine
- Thyroid function tests in COPD, 1398-1399
- Thyroid hormones, *see* Thyroxine; Triiodothyronine
- Thyroid-stimulating hormone, *see* Thyroxine
- Thyroxine (thyroid-stimulating hormone; T₄)
 in COPD, 1397-1400
 effects of, on plasma CETP activity and plasma HDL removal rate in Tg subjects, 530-536
 GH therapy effects on, in pycnodysostosis, 910
 in hyperthyroidism, 1394
 in idiopathic osteoporotic men, 913
 in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731
 in rheumatoid arthritis, 463-467
- Thyroxine-binding globulin (TBG), cleavage of, during CPB, 1113-1116
- Tibial bone mineral density (BMD), DR effects on, 438-439
- Tissue contents of cobalt, iron, copper, selenium, chromium, and zinc in DM, 1168-1174
- Tissue-type plasminogen activator-antigen (tPA-Ag) in obese children, 681-687
- TKA (tyrosine kinase activity), and vascular insulin/IGF-1 actions, 607-612
- TKBs (total ketone bodies) in IDDM with DKA, 174-175
- TM (thrombomodulin), plasma, and prostacyclin-induced skin BF changes in NIDDM, 568-572
- TNF- α , *see* Tumor necrosis factor- α ; Tumor necrosis factor- α -238 and -308 polymorphisms
- Tobacco, *see* Smoking
- Tobolone, triptorelin with, in prevention of cyclic AIP attacks, 995-996
- Tocopherol(s) (vitamin E), effects of, on concentrations of plasma ubiquinone-10 and fat-soluble antioxidants, 525, 526

- α (alpha)-Tocopherol in NIDDM and nondiabetic subjects, antioxidant status and, 1155-1158
- γ (gamma)-Tocopherol (vitamin E) in NIDDM and nondiabetic subjects, antioxidant status and, 1155-1158
- Tofu, PP sex hormone response to meals containing, in men, 508
- Total adipose tissue (AT; body fat)
contributions of, to metabolic complications of obesity, 425-435
LDL particle size, IR, proinsulin and, 122
- Total body water (TBW), short-term HRT effects on, in postmenopausal women, 267
- Total cholesterol (TC)
in adolescents having been SGA neonates, serum leptin relationship to, 1142
blood, and effects of glucose ingestion on plasma von Willebrand factor concentration, 1453
in carotid artery atherosclerosis subjects, 1097
CETP and, *see* Total cholesterol, CETP and
in children, *see* Total cholesterol in children
chitotriosidase activity and concentration of, 449
circulating GM-CSF, serum FA composition and, 1480
in CRF, effects of vitamin B₆, folic acid, and cyanocobalamin on, 132
and CV risk factors in men, 884
diet effects on, *see* Total cholesterol, diet effects on
gene polymorphism, *see* Total cholesterol, gene polymorphism and
in gout, *see* Total cholesterol in gout
in hyperhomocysteinemic elder subjects, 1467
and hyperuricemia development in middle-aged men, 623-625
in IDDM, apo A-IV concentrations and, 1021
IR and, *see* Total cholesterol, and IR
in metabolic syndrome, 137-140
in moderate exercise, 759
mutation and, *see* Total cholesterol, mutation and
in NIDDM, *see* Total cholesterol in NIDDM
in nondiabetic subjects, serum PON arylesterase activity and, 806, 808
in obesity, *see* Total cholesterol in obesity
in PM women, *see* Total cholesterol in PM women
in premenopausal women, *see* Total cholesterol in premenopausal women
in primary dyslipoproteinemias, 167
serum, *see* Serum cholesterol
- Total cholesterol (TC), Ala54Threo polymorphism of *FABP2* gene and effects of, 474
insulin sensitivity and, in older women, 1103
and Trp64Arg β_2 -*ADR* gene polymorphism, 1303-1305
- Total cholesterol (TC), CETP and
in IR, plasma CETP activity and, 785
maternal and neonatal profile of TC, 725, 726
- Total cholesterol (TC), diet effects on
plant stanol FA ester effects, 525
serum, high-fat, high-cholesterol diet effects, 461
very-high-fiber vegetable, fruit, nut diet effects, 497
- Total cholesterol (TC), gene polymorphism and
APOE gene polymorphism effects on plasma lipids and, 938, 939
LPL gene polymorphism and, 887
see also Total cholesterol, Ala54Threo polymorphism of *FABP2* gene and
- Total cholesterol (TC), and IR
LDL particle size, IR, proinsulin and, 122
MI prior to age 40 associated with, 31
plasma CETP activity and, 785
- Total cholesterol (TC), mutation and
Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
see also Total cholesterol, gene polymorphism and
- Total cholesterol (TC) in children
in GH-deficient prepubertal children, GH therapy effects on, 544
in normotensive offspring of hypertensive parents, 931
in South Asian immigrants' offspring, 1199, 1200
- Total cholesterol (TC) in gout
familial gout, 1206
HTLG and LPL activity and, 953
VAT accumulation, IR risk and, 394, 396
- Total cholesterol (TC) in NIDDM
with hyperlipidemia, 356
platelet taurine fluxes and, 61
prostacyclin-induced skin BF changes and, 571
serum, gemfibrozil or simvastatin effects on, 1149
with sulfonylurea-induced fatty liver, troglitazone effects on, 415, 416
- Total cholesterol (TC) in obesity
with and without hyperinsulinemia, 180
polymorphism of *CRH* gene regulatory region and, 1060
- Total cholesterol (TC) in PM women
abdominal AT distribution and, 978, 980
diabetic PM women on HRT, serum PON arylesterase effects on, 321
dietary cholesterol and, 595, 596
hyperlipidemic PM women, PP lipemia and, 331
- Total cholesterol (TC) in premenopausal women
abdominal AT distribution and, 978, 980
and myosin light-chain phosphorylation in resting platelets, 153
- Total Cl (chloride), plasma, furosemide effects on, 243, 244
- Total Cu⁺⁺ (copper) and Zn⁺⁺ (zinc) in PBMCs, effects of, on PBMC proliferation on hemodialysis, 270-276
- Total homocysteine (tHcy)
during HAART, 1278
in men and women, differences between, 640-645
- Total K (potassium), plasma, furosemide effects on, 243, 244
- Total ketone bodies (TKBs) in IDDM with DKA, 174-175
- Total lipids, serum, chromosome 4 segment (*D4Mit6-Npy* ~1 cm) effects on, after high-fat, high-cholesterol diet, 458-462
- Total Na (sodium), plasma, furosemide effects on, 243, 244
- Total plasma cholesterol (C)
in apo E deficiency, probucol and/or phytosterol therapy effects on, 709
in DM with CAD, RLP-C and, 1463, 1464
in heterozygous FH, 636
in HTN, *APOE* gene polymorphism and, 159
- Total plasma triglycerides (TG)
in DM with CAD, RLP-C and, 1463, 1464
in HTN, *APOE* gene polymorphism and, 159
- Total protein
and hyperuricemia development in middle-aged men, 623-625
plasma, furosemide effects on, 243, 244
- Total serum cholesterol (C)
high-fat, high-cholesterol diet effects on, 461
in NIDDM, gemfibrozil or simvastatin effects on, 1149
- Total serum triglycerides (TG)
high-fat, high-cholesterol diet effects on, 461
in NIDDM, gemfibrozil or simvastatin effects on, 1149
- Total thyroxine (T₄) in COPD, 1397-1400
- Total triglycerides (TG)
in NIDDM with hyperlipidemia, 356
plasma, *see* Total plasma triglycerides
in primary dyslipoproteinemias, 167

- Total triglycerides (TG) (*Continued*)
 serum, *see* Total serum triglycerides
- Total triiodothyronine (T_3) in COPD, 1397-1400
- Total urine output, furosemide effects on, 242
- tPA-Ag (tissue-type plasminogen activator-antigen) in obese children, 681-687
- Training, *see* Exercise
- Transfer protein, *see*: CETP gene locus; Cholesteryl ester transfer protein
- Transferase, *see* Alanine aminotransferase; Aspartate aminotransferase; γ -Glutamyl transferase
- Transforming growth factor- β (TGF- β) cascade, glucose effects on renal interstitial fibroblast hyaluronan production through PKC and, 789-794
- Transgenic (Tg) subjects, thyroid hormone effects on plasma CETP activity and plasma HDL removal rate in, 530-536
- Triacylglycerol (TAG)
 in NTG and HTG, 279, 280
 plasma, in Tg subjects, CETP activity and, 532
 serum, in diet-induced obesity, 1163
 structured medium- and long-chain, thermic effect of LCTs versus, in young women, 125-130
- Triglyceride(s) (TG)
 in adolescents having been SGA neonates, serum leptin relationship to, 1142-1144
 in atherosclerosis, *see* Triglyceride(s) in atherosclerosis
 in CAD, 186
 in children, *see* Triglyceride(s) in children
 chitotriosidase activity and concentration of, 449
 circulating GM-CSF, serum FA composition and, 1480
 in CRF, effects of vitamin B_{12} , folic acid, and cyanocobalamin on, 132
 as CV risk factor in men, 884, 886
 in elderly urban and rural Mexican subjects, coronary risk factors and, 313-315
 exercise and, *see* Triglyceride(s), exercise effects on
 glucose effects on plasma von Willebrand factor concentration and, 1453
 and glucose rate of appearance following galactose ingestion, 95
 in gout, *see* Triglyceride(s) in gout
 in hyperhomocysteinemic elder subjects, 1467
 in hyperlipidemia, *see* Triglyceride(s) in hyperlipidemia
 and hyperuricemia development in middle-aged men, 623-625
 in IDDM, apo A-IV concentrations and, 1021, 1022
 in IR, *see* Triglyceride(s) in IR
 in lactating women with GDM history, 717
 maternal and neonatal profile of, CETP and, 725, 726
 mutation and, *see* Triglyceride(s), mutation and
 in NIDDM, *see* Triglyceride(s) in NIDDM
 in nondiabetic subjects, serum PON arylesterase activity and, 806, 808
 in normolipidemia, serum-promoted C efflux and, 1332
 in obesity, *see* Triglyceride(s) in obesity
 plasma, *see* Plasma triglycerides
 in premenopausal and postmenopausal women, abdominal AT distribution and, 978, 980
 serum, *see* Serum triglycerides
 total, *see* Total triglycerides
 very-high-fiber vegetable, fruit, nut diet effects on, 497
see also Hypertriglyceridemia; Normotriglyceridemia; Triglyceride lipase; Triglyceride-rich remnant lipoprotein
- Triglyceride(s) (TG), Ala54Threo polymorphism of *FABP2* gene and effects of polymorphism, 474
 with Trp64Arg β_2 -*ADR* gene polymorphism, 1303-1305
- Triglyceride(s) (TG), exercise effects on
 aerobic exercise effects, 842, 845
 on NIDDM subjects with cardiovascular disease, changes in disease and $\dot{V}O_{2max}$ changes and, 1258, 1260, 1261
- Triglyceride(s) (TG), gene polymorphism and
APOE gene polymorphism effects on TGs and, 938, 939
 in FH, TaqIB polymorphism in *CETP* gene locus, 653
 LPL gene polymorphism and, 887, 900
 in obesity, *CRH* gene regulatory region polymorphism and, 1060
see also Triglyceride(s), Ala54Threo polymorphism of *FABP2* gene and; Triglyceride(s), mutation and
- Triglyceride(s), mutation and
 and *ACE* gene I/D in NIDDM, 1348
 and Gln27Glu mutation of β_2 -*ADR* gene, 444, 445
see also Triglyceride(s), gene polymorphism and
- Triglyceride(s) (TG) in atherosclerosis
 in carotid artery atherosclerosis subjects, 1097
 in MI survivors and their spouses, 27
- Triglyceride(s) (TG) in children
 of CHD parents, childhood-to-adulthood variables in, 1444
 in GH-deficient prepubertal children, GH therapy effects on, 544
 in normotensive offspring of hypertensive parents, 931
 in obese children, short-term weight loss effects on, 1324, 1326, 1327
 serum leptin relationship to, 1093
 in South Asian immigrants' offspring, 1199, 1200
 in 3-month-old offspring, restricted maternal Fe and, 566
- Triglyceride(s) (TG) in gout
 in familial gout, 1206
 HTGL and LPL activity and, 953
 VAT accumulation and IR risk in, 394
- Triglyceride(s) (TG) in hyperlipidemia
 in mixed hyperlipidemias, gemfibrozil and/or ciprofibrate effects on, 731
see also Triglyceride(s) in hyperlipidemic women
- Triglyceride(s) (TG) in hyperlipidemic women
 atherothrombotic CVD and, 362
 in PM women, and PP lipemia, 331
- Triglyceride(s) (TG) in insulin-resistant obese women
 obese Peruvian Indian and Caucasian women, 326
 relationship between IR, weight loss, and risk of coronary heart disease in, 796, 798
- Triglyceride(s) (TG) in IR
 and MI prior to age 40, 31
 in obese women, *see* Triglyceride(s) in insulin-resistant obese women
 plasma CETP activity and, 785
 in PM women, *see* Triglyceride(s) in PM women
- Triglyceride lipase (TGL), hepatic, activity of, in gout, 952-954
- Triglyceride(s) (TG) in NIDDM
 with *ACE* gene I/D, 1348
 acylation-stimulating protein-CRP relation and, 285
 in lean Japanese subjects, bezafibrate effects on, 478
 platelet taurine fluxes and, 61
 prostacyclin-induced skin BF changes and, 571
 with sulfonylurea-induced fatty liver, troglitazone effects on, 415, 416
- Triglyceride(s) (TG) in obese children
 metabolic and hemostatic abnormalities and, 682, 684, 685
 short-term weight loss effects on, 1324, 1326, 1327
- Triglyceride(s) (TG) in obesity
 CVD risk and, 300-302
 in dyslipidemic young adults, 699
 with and without hyperinsulinemia, 180

- Triglyceride(s) (TG) in obesity (*Continued*)
 and metabolic complications of obesity, 430, 431
 polymorphism of *CRH* gene regulatory region and, 1060
see also Triglyceride(s) in insulin-resistant obese women;
 Triglyceride(s) in obese children
- Triglyceride(s) (TG) in PM women
 diabetic women on HRT, serum PON arylesterase effects on, 321
 dietary cholesterol and, 595, 596
 in hyperlipidemic women, PP lipemia and, 331
 obese women, relationship between IR, weight loss, and risk of
 coronary heart disease, 796, 798
- Triglyceride (TG)-rich remnant lipoprotein (Lp), Lp distribution of
 apo C-III and its relationship to plasma, 112-119
- Triiodothyronine (T_3)
 in COPD, 1397-1400
 effects of, on plasma CETP activity and plasma HDL removal rate
 in Tg subjects, 530-536
 in rheumatoid arthritis, 463-467
- Triiodothyronine (T_3) nuclear receptor gene expression, diet-induced
 obesity effects on, 1161-1167
- Triphosphatase, platelet Na^+/K^+ adenosine, as marker in
 hyperthyroidism, 1393-1396
- Triphosphate, adenosine, intracellular, in KCN- and IAA-exposed
 hepatocytes, 344
- Triptorelin, tobolone with, in prevention of cyclic AIP attacks, 995-
 996
- Troglitazone (CS-045), effects of, on visceral adiposity and fatty
 liver associated with sulfonylureas in NIDDM, 414-417
- Trp64Arg polymorphism of β_3 -*ADR* gene
 CAD and, 184-188
 effects of Ala54Threo polymorphism of *FABP2* gene with, on
 insulin resistance and FPG in young and older Japanese men,
 1301-1307
- TSH (thyroid-stimulating hormone), *see* Thyroxine
- Tumor necrosis factor- α (TNF- α)
 in hepatic glucose production, 744, 748
 in obesity, oral nicotine effects on levels of, 79-85
PPAR γ mRNA in 3T3-L1 adipocytes downregulated by TZDs
 and, 36-40, 407
- Tumor necrosis factor- α (TNF- α -238 and -308) polymorphisms
 in IR with HTN, 1447-1451
- 20210 G/A prothrombin gene, mutation of thrombophilic, for
 atherothrombotic CVD, interaction between ERT and, in
 hyperlipidemia, 360-365
- 2184A/G *RAGE* gene polymorphisms associated with antioxidant
 status, 1152-1160
- TxA2 (thromboxane A2) in hepatic glucose production, 747
- Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type 1½ diabetes mellitus (DM), Abs to pancreatic islet cells and
 GAD in identification of, in patients presenting with NIDDM,
 1008-1013
- Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes
 mellitus
- Type III hyperlipoproteinemia (HLP), hemorrhologic abnormalities
 and risk of atherosclerosis, 166-170
- Type IV collagen, urinary excretion of, and glomerular pathology
 development in DM, 1435-1440
- Tyrosine (Tyr) in IDDM and NIDDM platelets, 740
- Tyrosine kinase activity (TKA), and vascular insulin/IGF-1 actions,
 607-612
- TZDs (thiazolidinediones), *see* Adipocytes, TZDs and; Pioglitazone;
 Rosiglitazone; Troglitazone
- UA, *see* Uric acid
- Ubiquinol-10 (coenzyme Q10), plasma, effects of plant stanol FA
 mixtures on concentrations of fat-soluble antioxidants and,
 520-529
- Umbilical vein endothelial cells (UVECs)
 cytokine effects on LDL metabolism by, 99-106
 effects of *PPAR* γ and *PPAR* α on *CuZn-SOD* and *p22^{phox}*
 message gene expression in, 3-11
- Upper body obesity, insulin action activation in, 19-23
- Urban Mexican subjects, elderly, lipids and apo as risk factors for
 CAD in, 311-318
- Urea
 development of hyperuricemia in middle-aged men, 621-626
 and glucose rate of appearance following galactose ingestion, 97
 vitamin B₆, folic acid, and cyanocobalamin effects on fibrinogen,
 Lp(a), Hcy and, in CRF, 132
- Urea nitrogen
 blood, *see* BUN
 and glucose rate of appearance following galactose ingestion, 96
 PGE₁ and conversion of hepatic α -amino-nitrogen to, in poorly
 controlled NIDDM, 253-258
- Uric acid (UA)
 in CRF, effects of vitamin B₆, folic acid, and cyanocobalamin on,
 132
 degradation of, during exercise by HTN subjects, 646-650
 and glucose rate of appearance following galactose ingestion, 96, 97
 in gout, *see* Uric acid in gout
 in NIDDM, with *ACE* gene I/D, 1348
 serum, *see* Serum uric acid
 and Trp64Arg β_3 -*ADR* gene polymorphism and Ala54Threo
 polymorphism of *FABP2* gene, 1303-1305
 urinary excretion of, *see* Uric acid, urinary excretion of
- Uric acid (UA), urinary excretion of
 furosemide effects on, 241-245
 NE effects on, 1230-1233
- Uric acid (UA) in gout
 activity of HTGL and LPL and, 953
 in familial gout, 1206
 serum, VAT accumulation and risk of IR in, 393-398
- Urinary excretion
 albumin and Mg, in IDDM, 1410, 1411
 calcium, in idiopathic osteoporotic men, 913
 creatinine, NE effects on, 1232
 DA, in DMD, 1185
 E, *see* Urinary excretion, E
 GC, 1420-1421
 hypoxanthine, *see* Hypoxanthine, urinary excretion of
 insulin, in MIS, 863-867
 of K, Na, and Cl, NE effects on, 1232
 of mevalonate and C-peptide, very-high-fiber vegetable, fruit, nut
 diet effects on, 496-498
 N, in anorexia nervosa, 877
 Na, in hypertensive subjects and their normotensive offspring,
 929-935
 NE, *see* Urinary excretion, NE
 in NIDDM, *see* Urinary excretion in NIDDM
 of olive oil phenols and their metabolites, 1426-1428
 oxypurinol, *see* Oxypurinol, urinary excretion of
 type IV collagen, and glomerular pathology development in DM,
 1435-1440
 urea, in CRF, KSVLPD effects on, 337
 uric acid, *see* Uric acid, urinary excretion of
 xanthine, *see* Xanthine, urinary excretion of
see also entries ending with suffix: -uria

- Urinary excretion, E
in DMD, 1185
and metabolic syndrome in Chinese subjects, 135-143
- Urinary excretion, NE
in DMD, 1185
in normotensive offspring and their hypertensive parents, 934
related to obesity, insulin, and metabolic syndrome in Chinese subjects, 135-143
- Urinary excretion in NIDDM
of 17-OHCS, exercise effects on, 1138
podocyte, in macroalbuminuric NIDDM, pioglitazone effects on, 1193-1196
- Urine output, furosemide effects on, 242
- UVECs, *see* Umbilical vein endothelial cells
- Valine (Val) in IDDM and NIDDM platelets, 740
- Vanadium, 667-680
effects of, on insulin sensitivity and appetite, 667-673
in STZ-DM, effects of, on GLUT4 translocation in WAT, 674-680
- Vascular endothelial cells
aortic, *see* Aortic endothelial cells
LDL-induced soluble cell adhesion molecules, autoantibodies to oxidized LDLs and adhesion of monocyte-, in CRF, 207-215
umbilical vein, *see* Umbilical vein endothelial cells
- Vascular endothelial growth factor (VEGF), serum, in IDDM and nondiabetic subjects, correlation between carotid artery distensibility and, 825-829
- Vascular endothelin-1 (ET-1) gene expression, NOS levels, fructose-induced hypertension and, 74-78
- Vascular hemostatic risk factors, ALA or evening primrose oil effects on, in STZ-DM, 868-875
- Vascular insulin/insulin-like growth factor-1 (IGF-1), resistance to actions of, 607-612
- Vascular smooth muscle cells (VSMCs)
gliclazide effects on dysfunction of, induced by VSMC-mediated oxidized LDLs, 688-695
potassium and NHE-1 in, in hypertension, 778-782
proliferation of balloon-injured, pioglitazone effects on, 955-962
- VAT, *see* Visceral adipose tissue
- Vegetable(s)
cruciferous, *see* Broccoli, effects of, on cytochrome P-450 activities in liver, kidney, and colon
effects of very-high-fiber vegetable, fruit, nut diet on serum lipids and colonic function, 494-503
- Vegetable oil, effects of, on concentrations of plasma ubiquinone-10 and fat-soluble antioxidants, 525
- VEGF (vascular endothelial growth factor), serum, in IDDM and nondiabetic subjects, correlation between carotid artery distensibility and, 825-829
- Ventricular mass, left, in men, CV risk factors and, 882-888
- Very-high-fiber vegetable, fruit, nut diet, effects of, on serum lipids and colonic function, 494-503
- Very-low-density lipoprotein-cholesterol (VLDL-C)
childhood-to-adulthood, in offspring of CHD parents, variables in, 1444
and CV risk factors in men, 884
in diabetic PM women on HRT, serum PON arylesterase effects on, 321
in FH, TaqIB polymorphism in *CETP* gene locus and, 653
high-fat, high-cholesterol diet effects on, 461
and Lp distribution of apo C-III, 115
plasma, in HTN, *APOE* gene polymorphism and, 159
in primary dyslipoproteinemias, 167
serum, in NIDDM, gemfibrozil or simvastatin effects on, 1149
- Very-low-protein diet (VLPD), ketoacid-supplemented, EE of CRF subjects before and after, following glucose load, 335-341
- Visceral adipose tissue (VAT)
abdominal, GH therapy effects on, in GH-deficient prepubertal children, 543
beta cell function and, in lactating women with GDM history, 715-719
contributions of, to metabolic complications of obesity, 425-435
in metabolically normal obese subjects, genetic control of size of, 1501-1502
and risk of IR in gout, 393-398
troglitazone effects on fatty liver associated with sulfonylureas and, in NIDDM, 414-417
- Viscosity, plasma, in primary dyslipoproteinemias, 167
- Vitamin B₆ (pyridoxine)
effects of folic acid, cyanocobalamin and, on fibrinogen, Lp(a), and Hcy, in CRF, 131-134
during HAART, 1278
in hyperhomocysteinemic elder subjects, 1467
- Vitamin B₁₂ (cyanocobalamin)
in diabetic nephropathy, blood S-adenosylmethionine concentrations and lymphocyte MTHFR activity and, 1015
effects of folic acid, pyridoxine and, on fibrinogen, Lp(a), and Hcy, in CRF, 131-134
in hyperhomocysteinemic elder subjects, 1467
during weight loss by obese children and adolescents, 1221
- Vitamin D-binding protein gene (Gc locus), variations in, and risk of NIDDM in French subjects, 366-369
- Vitamin E, *see* Tocopherol(s); α -Tocopherol; γ -Tocopherol
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- VLPD (very-low-protein diet), ketoacid-supplemented, EE of CRF subjects before and after, following glucose load, 335-341
Vo₂ (aerobic capacity) during exercise
in aerobic exercise, 842, 847
aortopulmonary shunts and, 401
effects of high and moderate glycemic index meals on, 852
exercise effects on, 603, 1485
by HTN subjects, 648
in moderate exercise by women, CHO metabolism and, 482
see also Vo_{2max} during exercise
- Vo_{2max} (maximal aerobic capacity) during exercise
changes in blood lipids and, 841-846
in exercising young and middle-aged men, S_g, S_i and, 350
by NIDDM subjects with cardiovascular disease, changes in disease and changes in, 1255-1263
- Von Willebrand factor (vWF), plasma, glucose and concentration of, insulin sensitivity and, 1452-1456
- VSMCs, *see* Vascular smooth muscle cells
- Waist-to-hip ratio (WHR)
and Ala54Thr polymorphism of *FABP2* gene, 474
of CAD subjects, 186
of children, *see* Waist-to-hip ratio of children
circulating GM-CSF, serum FA composition and, 1480
and Gln27Glu mutation of β_2 -ADR gene, 444, 445
of hyperlipidemic subjects, *see* Waist-to-hip ratio of hyperlipidemic subjects
of lactating women with GDM history, 716
MI and, *see* Waist-to-hip ratio, MI and
of NIDDM subjects, *see* Waist-to-hip ratio of NIDDM subjects
of NIDDM subjects' offspring, autonomic balance and, 1271
of nondiabetic subjects, serum PON arylesterase activity and, 806, 808, 809
of normolipidemic subjects, serum-promoted C efflux and, 1332, 1333

Waist-to-hip ratio (WHR) (*Continued*)

- of obese subjects, *see* Waist-to-hip ratio of obese subjects
- of older subjects, RMR and, 973
- and physical effects on dietary fat intake/IR association, 1188, 1189
- of PM women, *see* Waist-to-hip ratio of PM women
- of premenopausal women, and myosin light-chain phosphorylation in resting platelets, 153
- in young adult men, race and, 1243
- Waist-to-hip ratio (WHR), MI and
 - and MI prior to age 40 associated with IR, 31
 - WHR of MI survivors and their spouses, as risk factor for atherosclerosis, 25
- Waist-to-hip ratio (WHR) of children
 - of NIDDM subjects, autonomic balance and, 1271
 - of normotensive offspring and their hypertensive parents, 931, 932
 - of South Asian immigrants' offspring, 1199
 - see also* Waist-to-hip ratio of obese children
- Waist-to-hip ratio (WHR) of hyperlipidemic subjects
 - older subjects, coronary risk factors and, 314, 315
 - postmenopausal, 330
- Waist-to-hip ratio (WHR) of NIDDM subjects
 - with ACE gene I/D, 1348
 - of exercising NIDDM subjects with cardiovascular disease, changes in disease, $\dot{V}O_{2max}$ and, 1258, 1260, 1261
- Waist-to-hip ratio (WHR) of obese children
 - metabolic and hemostatic abnormalities and, 682
 - and short-term weight loss effects on, 1324, 1326
- Waist-to-hip ratio (WHR) of obese subjects
 - with metabolic syndrome, 137-140
 - of obese children, *see* Waist-to-hip ratio of obese children
 - polymorphism of *CRH* gene regulatory region and, 1060
 - with upper body obesity, 20, 21
- Waist-to-hip ratio (WHR) of PM women
 - hyperlipidemic, 330
 - short-term HRT effects on, 267
- WAT, *see* White adipose tissue
- Weight, *see* Body weight; Weight gain; Weight loss
- Weight gain by lactating women with GDM history, 716
- Weight loss
 - BPD-induced, post-BPD opioid dysregulation and naloxone effects on GHRH-induced PP and preprandial GH release after, 382-386
 - effects of, on metabolic complications, *see* Metabolic complications, weight loss effects on
 - by obese subjects, *see* Adolescents, obese, weight loss by; Children, weight loss by obese; Sibutramine, weight loss by obese subjects with; Weight loss by insulin-resistant obese women
 - Weight loss by insulin-resistant obese women
 - and risk of coronary heart disease in, 795-800
 - with sibutramine, metabolic changes after, 819-824
- White adipose tissue (WAT)
 - lipogenic enzyme mRNA in, after starvation-refeeding cycles, 734-738
 - in STZ-DM, vanadium effects on GLUT4 translocation in, 674-680
- White blood cell (WBC) count
 - and hyperuricemia development in middle-aged men, 623-625
 - see also* specific conditions
- White subjects, *see* Race and ethnicity
- Whole blood, stability of CT-1 in, 237-240
- WHR, *see* Waist-to-hip ratio

Women

- anorectic, *see* Anorexia
- circulating GM-CSF and serum FA composition in, 1479-1483
- lactating, with history of GDM, beta cell function and visceral AT in, 715-719
- O₂ supply and skeletal muscle cell lipids in, 380-381
- total homocysteine differences between men and, 640-645
- see also* Healthy subjects; Hyperlipidemic women; Postmenopausal women; Premenopausal women; Sex; Women, exercising; Women, insulin-resistant; Women, NIDDM; Women, obese; Women, older; Young women and entries beginning with term: Maternal
- Women, exercising
 - CHO metabolism in, 481-487
 - NIDDM women, with cardiovascular disease, changes in disease and changes in $\dot{V}O_{2max}$ of, 1256
 - see also* Exercise
- Women, insulin-resistant
 - glucose tolerance and relationship of dietary fat, serum CEs, and PL FAs to markers of IR in, 86-92
 - obese, *see* Weight loss by insulin-resistant obese women
 - PM women, 595, 596
 - see also* Insulin resistance
- Women, NIDDM
 - with cardiovascular disease, changes in disease and changes in $\dot{V}O_{2max}$ of, 1256
 - Chinese, insertion/deletion of ACE gene associated with ACE inhibitor-related cough in, 1346-1350
 - see also* Non-insulin-dependent diabetes mellitus
- Women, obese
 - Peruvian Indian and Caucasian, correlation between serum leptin and blood pressure in, 325-329
 - PM, relationship between AT distribution, insulin sensitivity, and HRT in, 835-840
 - weight loss by, *see* Weight loss by insulin-resistant obese women
 - see also* Obesity
- Women, older
 - Ala54Threo polymorphism of *FABP2* gene and insulin sensitivity in, 1102-1105
 - estrogen effects on serum DHEA in, 488-493
 - see also* Aging; Older subjects
- Xanthine
 - degradation of, during exercise by HTN subjects, 646-650
 - see also* Xanthine, urinary excretion of
- Xanthine, urinary excretion of
 - furosemide effects on, 241-245
 - norepinephrine effects on, 1230-1233
- Xenobiotic metabolizing monooxygenases, rifampicin effects on, 230-236
- Young adults, 299-310
 - L-NMMA effects on insulin-mediated SM blood flow and glucose disposal in, 306-310
 - obese, *see* Young adults, obese
 - see also* Race and ethnicity of young adults; Young men; Young women
- Young adults, obese
 - APOE gene polymorphism modulating association between dyslipidemia and obesity in, 696-702
 - changes in obesity related to changes in CVD risk in, 299-305

Young men

adult, T, SHBG, and body composition in, race and, 1242-1247
borderline hypertensive, CV risk factors and glucose disposal rate
in, 1175-1180

exercising middle-aged and, S_g and S_i in sedentary men,
compared, 349-354

Japanese, effects of β_2 -*ADR* gene Trp64Arg polymorphism with
FABP2 gene Ala54Threo polymorphism on insulin resistance
and FPG in, 1301-1307

see also Young adults

Young women

estrogen effects on serum DHEA in, 488-493

thermic effect of SMCTs versus LCTs in, 125-130

Young women (*Continued*)

see also Young adults

Zinc (Zn)

antidiabetic activities of cyclo (his-pro), arachidonic acid and, in
STZ-DM, 53-59

effects of PPAR γ and PPAR α on *CuZn-SOD* gene expression and
p22^{phox} message gene expression in HUVECs and HAECs,
3-11

tissue contents and subcellular distribution of cobalt, iron,
selenium, chromium and, in DM, 1168-1174

see also Cu $^{++}$ and Zn $^{++}$; *Cu-Zn SOD* gene expression

Zn, *see* Zinc

EX

d